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 Gastrointestinal microbiome studies have failed to include fungi in total 
community analyses. As a result, their diversity and function in the gut is poorly 
understood. Recent work has begun to uncover the role intestinal fungi play in diet, 
immune system development, interactions with other microorganisms in the gut, and 
pathogenesis of diseases. Advances in sequencing technologies allow for the ability to 
profile the fungal gut microbiome (“mycobiome”) in healthy and diseased states. This 
thesis explores the mycobiome in 1) healthy humans with a vegetarian diet and 2) 
pediatric small bowel transplant recipients that develop fungal bloodstream infections.  
The gut mycobiome from healthy adult humans with a vegetarian diet was 
determined using two sequencing technologies and a commercially available probe-based 
method. The use of three culture-independent methods demonstrated that the gut 
mycobiome is best characterized using a combination of methods, as each method has 
strengths, weakness, and biases. In addition, this study provides insight into the 
allochthonous nature of fungal inhabitants in the gut and demonstrates that fungal 
diversity in the gastrointestinal tract is diet related. It is apparent that a wide variety of 
fungi can be identified from the human gastrointestinal tract.  
  Further, the intestinal mycobiome of seven pediatric small bowel transplant 
recipients was characterized. Transplant patients are subject to multiple risk factors and 
have a correspondingly high incidence of candidemia. Molecular typing methods were 
used to assess whether candidemia in small bowel transplant recipients was acquired 
endogenously (from their own gut microbiota) or exogenously. Our results suggest that 
small bowel transplant patients are infected both by Candida colonizing their 
gastrointestinal tract and from exogenous sources. Ultimately, these results underline the 
importance of Candida surveillance in small bowel transplant institutes. 
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“Never, never, never give up.”  
― Winston Churchill 
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PREFACE 
This thesis is comprised of four chapters characterizing the fungal communities in 
the gastrointestinal tract of healthy and diseased humans. A primary goal of this research 
was to raise awareness of gut fungi and discuss methods to characterize this understudied 
group of microorganisms. Chapter 1 provides a review of the current understanding of 
the mycobiome of the human gastrointestinal tract. Chapter 2 provides a profile of the 
gut mycobiome from healthy adults with a vegetarian diet using two culture-independent 
sequencing methods and a commercially available fungal detection assay. In Chapter 3, 
our efforts were aimed at surveying gut fungi populations in small bowel transplant 
patients over time and determining the source(s) of yeasts causing life-threatening 
bloodstream infections. Finally, Chapter 4 summarizes the impact of this work and 
discusses the continual efforts needed to explore the role of the mycobiome in human 
health and disease.  
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CHAPTER 1 
 
FUNGI OF THE HUMAN GASTROINTESTINAL TRACT: A REVIEW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2 
1.1 THE GASTROINTESTINAL MICROBIOTA 
All surfaces of the human body exposed to the environment are colonized with 
complex and diverse populations of microorganisms from all three domains of life [33]. 
A majority of the microbes colonizing the human host are harbored within the 
gastrointestinal (GI) tract, making the GI tract home to one of the densest microbial 
communities on Earth. Approximately 100 trillion microorganisms inhabit the human gut 
and outnumber human host cells by a factor of 10 to 1 [214]. Sequencing an estimated 3.3 
million human intestinal bacterial genes demonstrated the gut microbial genome is 
approximately 150 times greater than the human genome [163]. This population of 
microbes, collectively termed the gastrointestinal microbiota, has received much attention 
and has been at the forefront of biological research for the last decade. 
The acquisition of - and colonization by - microbes residing in the GI tract of 
newborn infants is an emerging field of study. Traditionally, it was believed that the 
gastrointestinal tract of neonates is sterile in utero and immediately becomes colonized 
by microbes from their surroundings upon birth. However, recent culture-independent 
research shows the placenta harbors a unique collection of nonpathogenic bacterial 
commensals from the phyla Firmicutes, Tenericutes, Proteobacteria, Bacteroidetes, and 
Fusobacteria [1]. Previous analyses also show bacteria and fungi are present in the 
amniotic fluid, placenta, and umbilical cord [46, 91, 168]. In addition, bacteria such as 
Staphylococcus, Streptococcus, Enterococcus, and Lactobacillus have been cultured from 
the meconium, the newborns’ first passed stool [135]. Collectively, support for microbial 
transmission from mother to fetus in utero has led to the ‘early programming hypothesis’ 
  
3 
stating that factors acting in utero program the risks for adverse health conditions later in 
life [62].  
The development of the infant’s intestinal microbiota begins early in life and 
colonization order is greatly influenced by a number of lifestyle factors. Newborns are 
first exposed to their mother’s microbiota, and depending of the mode of delivery, 
vaginal or cesarean, their microbiota resembles the vaginal or skin microbiota of their 
mother [5, 49]. In the subsequent days following birth, newborns are continuously faced 
with a number of environmental factors that become major determinants of the 
composition of the gut microbiota. Feeding mode is claimed to substantially affect the gut 
microbiota. Breastfed infants (as compared to formula-fed infants) develop and establish 
a microbiota rich in beneficial microbes such as Bifidobacterium by the end of the first 
week [16, 76, 156, 226]. In addition, human breast milk contains secretory IgA and free 
oligosaccharides that help develop the immune system and protect infants from 
colonization by pathogens [123, 170]. Other extrinsic factors orchestrating the 
development of the gut microbiota include the use of antimicrobial agents, hygienic 
conditions, family structure, and home environment [4, 44]. Throughout the first year of 
life, the infant intestinal tract evolves from a nearly sterile environment to a diverse 
assemblage of microorganisms, where it will slowly begin to resemble the microbiota of 
an adult and remain relatively stable.   
 
 
  
  
4 
1.2 ROLE OF THE GASTROINTESINAL MICROBIOTA IN HEALTH AND 
DISEASE  
The gastrointestinal microbiota plays a central role in the well-being of the human 
host and is therefore often termed ‘the forgotten organ’ [151]. The microbiota has a 
profound functional role in energy harvest and digestion. Complex polysaccharides and 
proteins that escape human digestion in the small intestine serve as the main substrates to 
resident colonic microbes [39]. The microbiota breaks down these undigested nutrients 
into the short-chain fatty acids (SCFA) acetate, butyrate, and propionate. SCFAs become 
readily available to the human host and provide energy that would otherwise be lost. 
Production of SCFAs has been shown to confer health benefits and decrease the risk of 
colon cancer [73, 218]. In addition, the microbiota synthesizes vitamins essential to the 
host [7].  
The GI tract is the primary site of interaction between the human immune system 
and microbiota and, therefore, is of substantial importance for immunological 
development. Studies show the gut microbiota is responsible for the development of 
immune cells such as secretory IgA and provides signaling molecules that aid in 
maturation of the host immune system [128, 140]. In conjunction with the immune 
system providing critical disease resistance and a line of defense against pathogens, the 
gastrointestinal microbiota aids in limiting colonization by pathogens via a phenomenon 
known as colonization resistance [206]. 
While commensal microbial communities in the gut carry out a series of 
advantageous and essential functions, perturbation of the system creates a dysbiosis. 
Dysbiosis refers to a microbial imbalance in the gut with increased levels of harmful 
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microbes and reduced levels of beneficial microbes. Imbalances in the composition of the 
microbiota have been associated with a number of digestive diseases such as ulcerative 
colitis, Crohn’s disease, inflammatory bowel disease, irritable bowel syndrome, and 
colon cancer [90, 120, 144, 160, 220]. In addition, recent research has indicated that 
disruptions in the gut microbiome and relative abundances of certain members are 
associated with complex, non-digestive diseases such as obesity, type 2 diabetes, chronic 
fatigue syndrome, arthritis, liver disease, and autism [36, 54, 106, 115, 183, 189]. 
Determining what constitutes a healthy microbiota is essential for evaluating deviations 
associated with disease.  
 
1.3 DIVERSITY OF THE GASTROINTESTINAL MICROBIOTA 
The gastrointestinal tract extends from the oral cavity to the anus with well-
defined anatomical sections within. Each individual component of the GI tract has a 
specialized function for the digestion and absorption of food. Microorganisms within the 
digestive tract are not randomly distributed but instead are preferentially localized to 
specific regions in different numbers and taxonomic distributions [117]. Properties of 
each section in the digestive tract such as pH, rapid luminal flow, bile salts, and oxygen 
availability are driving factors that shape microbial diversity by supporting or 
discouraging growth [95, 210]. A majority of the gut microbiota is anaerobic, with a 
lower proportion of facultative anaerobes and aerobes [64, 77].  
Microbial numbers increase in a gradient from the stomach to the colon (Table 
1.1). The upper gastrointestinal tract (stomach, duodenum, jejunum, proximal ileum) 
contains a relatively low number of microorganisms. Very few organisms (<10
2 
  
6 
cells/mL), consisting of acid-tolerant lactobacilli and streptococci, are present in the 
stomach and upper small intestine due to harsh pH conditions [117]. Cell densities in the 
proximal small intestine range from 10
4
-10
5
 cells/mL of intestinal content [210]. The 
lower gastrointestinal tract (distal ileum, colon) contains a much higher population and 
diversity of microorganisms—108 cells/gram in the distal ileum and approaching 1010-
10
12 
cells/gram in the colon. Less acidic pH, low concentration of bile acids, and longer 
retention due to slower peristalsis are several properties that distinguish the colon from 
the rest of the GI tract and allow it to be the primary site of colonization [210]. Fecal 
samples are, therefore, commonly used as a snapshot of the gut microbiome.  
 
Table 1.1 Microorganism groups and counts in different sections of the 
gastrointestinal tract [186]. 
Microorganisms Stomach Jejunum Ileum Colon 
Aerobic and facultatively anaerobic microorganism groups 
Enterobacteria 0-10
2
 0-10
3 
10
2
-10
6 
10
4
-10
10 
Enterococci 0-10
3
 0-10
4
 10
2
-10
6
 10
5
-10
10 
Staphylococci 0-10
2
 0-10
3
 10
2-
10
5 
10
4
-10
7 
Lactobacilli 0-10
3 
0-10
4 
10
2
-10
5
 10
6
-10
10 
Fungi 0-10
2
 0-10
2
 10
2
-10
3 
10
2
-10
6 
Anaerobic microorganism groups 
Bacteroides spp. Rare 0-10
2
 10
3
-10
7 
10
10
-10
12 
Bifidobacteria Rare 0-10
3 
10
3
-10
5 
10
8
-10
12 
Anaerobic streptococci Rare 0-10
3
 10
2
-10
4 
10
8
-10
11 
Clostridia  Rare Rare 10
2
-10
4 
10
6
-10
11 
Eubacteria Rare Rare Rare 10
9
-10
12 
Note: Figures in colony forming units (CFU) per mL or per g intestinal content.  
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Lastly, the diversity of the microbiota is divided into two categories: indigenous 
(autochthonous) and transient (allochthonous) microorganisms. Autochthonous 
microorganisms are ubiquitous in the GI tract, readily colonize available niches, and are 
stable over time, whereas allochthonous microorganisms cannot readily colonize the GI 
tract [53]. Allochthonous species are merely transient members that are unable to 
establish themselves in a foreign community. These species mainly originate from 
consumption or ingestion of air and food or water. The distinction between 
autochthonous and allochthonous microorganisms in the gut is crucial to understand how 
organisms interact with their host in terms of whether they effect colonization and 
succession [117]. 
  
1.4 COMPONENTS OF THE HUMAN GUT MICROBIOME 
Bacteria are the most abundant members in the gut and, therefore, have 
overshadowed the presence of other members of the gut microbiome. In fact, this 
complex community of intestinal microbes spans all three domains of life - Bacteria, 
Archaea, and Eukarya - and includes bacteria, protists, fungi, and viruses. Few studies 
have investigated the contribution of microbial residents other than bacteria to function of 
the human host.  
 
1.4.1 PROKARYOTIC DIVERSITY 
Over 99% of the genes in the human gut microbiome are of bacterial origin and 
the number of bacterial species reported from the gut is generally believed to be between 
500-1,000 [163, 221]. Fifty-five bacterial phyla have been described from the human gut; 
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however, the two most dominant phyla are Bacteroidetes and Firmicutes [12, 55, 184]. 
Five other common phyla, present in lower proportions, are Proteobacteria, Fusobacteria, 
Verrucomicrobia, Cyanobacteria, and Actinobacteria. One study involving fecal samples 
from 124 Europeans showed each individual harbored at least 160 species of bacteria and 
a majority of the species was shared among individuals [163]. 
Prokaryotic, single-celled members of the Kingdom Archaea reside alongside 
bacteria in the gut [163]. The archaea, once considered bacteria, consist of halophiles and 
thermophiles, found in extreme environments; and methanogens, found in a broad range 
of habitats. Only a few methanogens are found in the human gut. Methanobrevibacter 
smithii is considered the predominant archaeon; Methanosphaera stadtmaniae and 
Methanobrevibacter oralis are also present in the gut [51, 131, 133, 181]. The carriage 
rate of methanogens in the human gut ranges from 25-95% [51, 194]. Intestinal 
methanogens play a role in the pathogenesis of obesity [132, 176, 225].  
  
1.4.2 VIRAL DIVERSITY  
One aspect of the human gut microbiome that has received little attention is the 
viral component, referred to as the “human virome.” Human feces contain at least 109 
eukaryotic and prokaryotic viruses per gram [167]. The adult virome consists of DNA 
and RNA viruses, the majority being bacteriophages and plant viruses, respectively [25, 
224]. Bacteriophages influence human health by contributing genes to their host bacteria 
that affect overall community and structure of the microbiota [31]. Bacteriophage 
repertoires vary widely between individuals and are likely the reason for inter-individual 
variation in gut bacterial communities [134]. Eukaryotic viruses also have significant 
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effects on human health, causing gastroenteritis and a host of acute, chronic, and fatal 
diseases [32]. 
 
1.4.3 EUKARYOTIC DIVERSITY 
Eukaryotes in the human gut are less extensively studied than prokaryotes, yet 
remain an important component of the microbiome. The Domain Eukarya encompasses a 
vast diversity of organisms spanning from animals, plants, and fungi to protozoa, slime 
molds, and algae. A bulk of the eukaryotes found in the human gut, as expected, are 
microeukaryotes and ignorance of these organisms becomes a major limitation of gut 
microbiome studies.  
Protista (now split into several kingdoms) comprises a collection of single-celled, 
eukaryotic organisms including protozoa, unicellular algae, slime molds, and water 
molds. Several protists are known to cause disease, however, few have been described as 
asymptomatic commensals in the gut [22, 162]. Studies show that the protist Blastocystis 
and fungi are the dominant eukaryotes in the gut [142, 180]. Also, the protists 
Blastocystis and Dientamoeba have been observed in 50% of some Danish cohorts, and 
are nearly absent in those with inflammatory bowel disease [8]. Although protists make 
up a small component of the microbiome, further research is necessary to understand 
their role in health and disease. 
Fungi are eukaryotic organisms that can occur as single-celled yeasts, 
multicellular filamentous molds, or macroscopic organisms such as mushrooms, and 
range from pathogens to commensals and parasites to mutualists. Populations of fungi 
colonize the human host at multiple different body sites—gastrointestinal tract, oral 
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cavity, skin, vaginal tract, and lungs (Figure 1.1) [50, 58, 63, 80, 207]. Most human-
associated fungi are opportunistic pathogens in that disease is caused when the host 
immune system becomes weakened or natural barriers are disrupted. Well-known fungal 
infections range from skin mycoses such as athlete’s foot, ringworm, and yeast 
infections, to more life-threatening systemic mycoses caused by Cryptococcus, Candida, 
and Aspergillus. An estimated 75% of women will encounter a yeast infection during 
their lifetime and roughly 20-25% of the world's population has skin mycoses [79, 190]. 
Fungi represent the majority of eukaryotes in the human gut microbiome and the 
remaining sections of this review detail and depict what is currently known about the 
relatively new field of human gut mycology.  
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Figure 1.1 The human mycobiota [204]. 
 
1.5 THE HUMAN GASTROINTESTINAL MYCOBIOME: A NEW FRONTIER  
Gut bacteria are the most abundant microorganisms in the gastrointestinal tract, and 
therefore, have been the focus of much human microbiome research over the past decade. 
The extent of biodiversity of the “mycobiome” (fungal biota) in the human 
gastrointestinal tract remains to be defined. The term mycobiome was coined in 2010 to 
differentiate the fungal biota from the bacterial biota, as the word “microbiota” is 
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frequently treated as synonymous with bacteria [63]. On July 6, 2013, using a PubMed 
search, the word “mycobiome” appeared in the literature 10 times [38]. As of March 6, 
2015 a PubMed search showed at least 32 publications using the word “mycobiome.” The 
field is clearly advancing and increasing awareness allows gut microbiologists to address 
the same questions to gut fungi as have been studied in bacteria. 
 
1.5.1 HISTORY  
Yeasts were first identified in the human GI tract in the early nineteenth century 
[104]. However, at the time no effort was made to identify and characterize these yeasts. 
In the early 1900s, the presence of yeasts in feces was sporadically documented in the 
medical literature and studies tried to link their presence to gastrointestinal diseases, such 
as sprue (a digestive disease characterized by malabsorption and commonly reported in 
tropical regions) [13, 23, 109]. Years later, just before World War II, isolates from human 
clinical samples were identified as yeasts of the genus Monilia, which were later 
reclassified into the genus Candida [105, 121, 122]. Culturing Candida from the 
intestines of healthy humans and those with gastrointestinal disturbances became a 
popular area of research during the mid-1900s. Candida was the most commonly isolated 
yeast from fecal samples, yet its significance and occurrence in stools had yet to be 
elucidated due to the fact that heavy loads of Candida species were collected from 
healthy humans [23].  
 The long known history of yeasts in the gastrointestinal tract and their peculiar 
presence led physicians in the late 1980s to propose hypotheses linking unhealthy 
lifestyles to Candida overgrowth in the intestine [186, 202]. Mycophobia was also 
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spreading due to falsely interpreting yeasts isolated from the mouth or stool as fungal 
infections [187]. Gut mycology has therefore become a field in need of attention and 
advancement. 
 
1.5.2 GASTROINTESTINAL COLONIZATION BY FUNGI  
As stated previously, microbial colonization starts at birth. The vaginal tract is 
home to a large number of yeasts and, not surprisingly, neonates born vaginally are 
colonized by yeasts from their mother’s vaginal microbiota [21]. Infant colonization by 
Candida spp. is therefore transmitted vertically from the maternal microbiota and also 
horizontally from the environment and hands of health care workers [21, 116]. The 
prevalence of Candida spp. gut colonization in newborns on the day of birth is roughly 
23%, increasing to 50% by four months [56, 174]. Yeast carriage rates in infants are 
approximately 10
3
-10
5
 CFU/g feces [16, 56]. Additionally, 96% of neonates have 
detectable Candida species in the oral cavity by the first month of life [171]. 
Every human being is colonized with fungi [85]. Fungi are detectable in all 
sections of the GI tract of about 70% of healthy adults, normally at 0-10
3
 fungal cells per 
ml or g of intestinal contents [186]. Table 1.1 (above) shows the relative abundance of 
fungi in each section of the gut and outlines the disparity that exists between fungal and 
bacterial residents of the GI tract. Culture-independent analyses show fungal genes 
constitute less than 0.1% of the human gut microbiome [163]. The low abundance of 
fungi in the gut microbiome undoubtedly relegates them to part of the ‘rare biosphere’ 
[191]. The rare biosphere is of significance as it potentially serves as a reservoir for 
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pathogens or keystone species that have a critical role in maintaining the structure and 
function of the human gut microbiome [85].  
 The oral cavity is asymptomatically colonized by Candida and harbors a wide 
diversity of fungi, likely from food and airborne spores [11, 63]. The rapid luminal flow 
and low pH of gastric acid allows few microorganisms to colonize the stomach and 
functions as a barrier to prevent ingested pathogens from reaching the intestine [124]. A 
number of acid-resistant bacteria exist in the stomach as well as a few acid-tolerant fungi 
such as Candida and Phialemonium [19, 208]. The diversity of fungi in the small 
intestine is largely unexplored due to the difficulty in collecting samples [211]. Ileal 
effluent collected from intestinal transplant recipients showed colonization by 
Saccharomyces cerevisiae, Candida spp., Cryptococcus neoformans, and Aspergillus 
clavatus [112]. The properties of the large intestine facilitate extensive microbial 
colonization and proliferation, and a wide diversity of fungal genes is detected in the 
lower gastrointestinal tract.  
 
1.5.3 FUNGAL DIVERSITY OF THE INTESTINAL MYCOBIOME 
 Two large-scale projects, the Human Microbiome Project and MetaHit, provide 
an initial compilation of the gut microbiome ecosystem from 242 and 124 humans, 
respectively [86, 158, 163]. As revealing as the results have been, publications to date 
from these projects focused exclusively on the bacterial component and the fungal 
diversity was not considered. Smaller-scaled, fungal-specific studies using culture-
dependent and/or culture-independent methods have thus been conducted but are limited. 
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 Previous culture-dependent studies identified Candida spp. as the most common 
fungi in the GI tract. With the development of advanced culturing methodologies and 
PCR, the modern era of mycobiome studies has exposed a more in-depth survey of both 
culturable and unculturable fungi in the gut. At present only a handful of mycobiome 
characterization studies exist. To the best of our knowledge, we compiled a 
comprehensive list of fungal species reported from the GI tract of humans by culture-
dependent and culture-independent studies (Table 1.2; includes: healthy and diseased 
adults and infants, fungi from stomach, small intestine, large intestine, differing diets and 
varying geographic locations). Data was compiled December 2014 from articles spanning 
1917-2014. Also, included in the list are fungi detected in our lab from healthy humans 
on a vegetarian diet reported in Chapter 2 of this thesis (denoted S in Table 1.2). If a 
more current name for a fungus exists than that used in the initial publication, the current 
name is also listed. Fungi reported from the literature but not specified to the species 
level are excluded from the list if a species from that genus, family or class is listed. Taxa 
reported in the literature that are indistinguishable from one another at the level of the 
target gene used are listed in the same row.  
 
Table 1.2 Comprehensive catalog of fungi reported in the gastrointestinal tract of 
humans by culture-dependent and -independent methods. 
Phylum Fungal Taxa 
Ascomycota Ajellomyces capsulatus [112], Current name: Histoplasma capsulatum 
 Ajellomyces dermatitidis [112] 
 
Alternaria alternata [68, S], A. brassicicola [113], A. arborescens, A. citri, 
A. mali, A. tenuissima [S] 
 Amphisphaeriaceae sp. [48] 
 Arxiozyma telluris [75], Current name: Kazachstania telluris  
  
16 
 Ascocoryne cylichnium [S] 
 Ascocoryne sarcoides [S] 
 Aspergillus clavatus [112, 113] 
 Aspergillus flavipes
1
 [66] 
 Aspergillus flavus
1
 [67], Aspergillus oryzae [S] 
 Aspergillus fumigatus [203, S]  
 Aspergillus microviridicitrinus
1
 [34]  
 Aspergillus niger
2
 [34, 74, 199, S] 
 Aspergillus penicillioides [30]  
 Aspergillus restrictus [68] 
 Aspergillus sydowii
1
 [199], Aspergillus versicolor
2
 [30, 34, 66, 180, 199] 
 Aureobasidium pullulans2 [30, 152, 198] 
 Beauveria bassiana1 [66] 
 Bispora christiansenii [68], Current name: Intralichen christiansenii  
 Blastoschizomyces capitatus
1
 [97] (also reported as Dipodascus capitatus, 
[203]) Current name: Geotrichum capitatum 
 Botryotinia fuckeliana [112, 152], Current name: Botrytis cinerea  
 Candida albicans
2
 [6, 10, 18, 30, 34, 46, 59, 60, 68, 74, 92, 97, 108, 112, 
113, 118, 152, 153, 180, 192, 195, 198, 208, S] (also reported as 
Endomyces albicans
1
 [9], Oidium albicans
1
 [9], Parasaccharomyces 
ashfordii
1
 [9]) 
 Candida colliculosa1 [10, 18] 
 Candida diddensiae [108] 
 Candida dubliniensis [68, 112, 113, 152] 
 Candida glabrata
2
 [6, 18, 30, 68, 92, 97, 108, 118, 152, 195] (also reported 
as Cryptococcus glabratus
1
 [9], Torulopsis glabrata
1
 [34]) 
 Candida guilliermondii
1
 [6, 10, 34, 97], Current name: Blastodendrion 
artzii 
 Candida inconspicua1 [10] 
 Candida intermedia [10, 30] 
 Candida kefyr
1 
[6, 18, 92], Current name: Atelosaccharomyces 
pseudotropicalis  
 Candida krusei
1
 [6, 10, 18, 30, 34, 75, 97, 118, 198] (also reported as 
Mycoderma monosa
1
 [9]), Current name: Candida acidothermophilum  
 Candida lambica1 [97], Current name: Candida fimentaria  
 Candida lusitaniae
2
 [6, 10, 18, 28, 97] (also reported as Clavispora 
lusitaniae
2
 [68]) 
 Candida metapsilosis [74] 
 Candida milleri [30], Current name: Candida humilis  
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 Candida norvegensis
1
 [6], Current name: Candida mycoderma var. 
annulata  
 Candida quercitrusa [108] 
 Candida orthopsilosis2 [10, 28] 
 Candida parapsilosis
2
 [10, 18, 28, 34, 74, 97, 108, 112, 118, 180, 198, 199, 
208] 
 Candida pelliculosa1 [10], Current name: Candida beverwijkiae 
 Candida rugosa2 [74, 75, 97) (also reported as Mycoderma rugosa1 [9]) 
 Candida sake [74, 203] (also reported as Candida austromarina [30, 152]) 
 Candida solani [30] 
 Candida sphaerica1 [6, 10] 
 Candida stellata1 (reported as Torulopsis stellata [34]) 
 Candida temnochilae1 [10] 
 Candida tropicalis
2
 [6, 10, 18, 28, 30, 34, 66, 74, 97, 108, 112, 113, 198, 
203, S] (also reported as Monilia candida Bon. [9, 208]) 
 Candida utilis
1
 [6, 10], Current name: Candida guilliermondi var. 
niratophila  
 Candida valida1 [10], Current name: Candida krusei var. vanlaeriana 
 Candida vinaria [142], Current name: Trigonopsis vinaria  
 Candida zeynaloides1 [6] (also reported as Candida krissii [30]) 
 Ceratocystis sp. [80] 
 Chaetomium globosum [30, 42, 152] 
 Cladosporium cladosporioides
2
 [28, 34, 108, 152, S], C. bruhnei [67], C. 
herbarum
1
 (= Davidiella tassiana [68, 74, 198]), C. macrocarpum
1
 [198], 
C. sphaerospermum
2 
[108, 198, 199], C. tenuissimum [108] 
 Claviceps purpurea [48] 
 Coccidioides immitis [112] 
 Coccidioides posadasii [112] 
 Cochliobolus sp. [80] 
 Colletotrichum sp. [80] 
 Coniosporium sp. [80] 
 Cryptococcus aggregatus1 [9], Current name: Candida pararugosa 
 Curvularia lunata1 [34] 
 Cyberlindnera jadinii [S] (also reported as Pichia jadinii [74]) 
 Debaryomyces carsonii1 [10], Current name: Priceomyces carsonii 
 Debaryomyces fabryi [28] 
 Debaryomyces hansenii
2
 [28, 48, 68, 74, S] (also reported as Candida 
famata
1
 [6, 92] 
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 Dendrostilbella sp.1 [110] 
 Diaporthales sp. [108] 
 Didymella exitialis [74] 
 Diplodia mutila [S] 
 Doratomyces stemonitis [30] 
 Epicoccum nigrum [S] 
 Eurotium niveoglaucum [S] 
 Eurotium rubrum [S] (also reported as Aspergillus ruber1 [67]) 
 Eutypella sp. [80] 
 Exophiala equina [68] 
 Exophiala heteromorpha [S] 
 Fusarium graminearum [S], F. culmorum [74] 
 Fusarium oxysporum [112, 152]  
 Fusarium sambucinum [74] 
 Galactomyces geotrichum2 [30, 66, 68, 74, 75, 152, 180] 
 Geosmithia flava [74] 
 Geosmithia microcorthyli [74] 
 Geotrichum candidum
2
 [75, 97] (also reported as Galactomyces candidum 
[68]) 
 Geotrichum gigas [74], Current name: Saprochaete gigas  
 Gibberella moniliformis [113] 
 Gloeotinia temulenta/Paecilomyces fumosoroseus [180]  
 Glomerella sp. [74, 80] 
 Hanseniaspora sp. [80] 
 Hortaea werneckii [28] 
 Hyphozyma variabilis var. odora [30] 
 Iodophanus carneus [30] 
 Isaria farinosa1 [66] 
 Kluyveromyces hubeiensis [75, 153] 
 Kluyveromyces lactis [42] 
 Kluyveromyces waltii [112], Current name: Lachancea waltii  
 Lasiodiplodia sp. [80]  
 Lecythophora sp. [S] 
 Leptosphaerulina chartarum [S] 
 Lodderomyces elongisporus1 [10] 
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 Madurella mycetomatis [152] 
 Magnaporthe grisea [42] 
 Metschnikowia sp. [74, 80] 
 Meyerozyma sp. [80] 
 Microdochium sp. [80] 
 Millerozyma sp. [80] 
 Mycocentrospora sp. [80] 
 Nectria haematococca [42], Current name: Haematonectria haematococca 
 Neofusicoccum sp. [80] 
 Neosartorya fischeri [42, S] 
 Neotyphodium gansuense [113] 
 Neurospora tetrasperma [113] 
 Nigrospora sp. [80] 
 Ochrocladosporium elatum1 (reported as Cladosporium elatum [198]) 
 Ophiocordyceps caloceroides [30], Current name: Cordyceps caloceroides 
 Ophiocordyceps sinensis [S] 
 Ophiostoma sp. [80] 
 Orbiliales sp. [108] 
 Paecilomyces variotii1 [34] 
 Paraphaeosphaeria filamentosa [152], Current name: Neophaeosphaeria 
filamentosa  
 Parasaccharomyces thomasii1 [9] 
 Penicillium allii
1
 [66], P. camemberti
2
 [66, S], P. chrysogenum
2
 (= 
Penicillium notatum) [34, 68, 113, 152, 199, S], P. commune [203], P. 
dipodomyicola
1
 [66], P. freii [30], P. italicum [152], P. solitum [67] 
 Penicillium brevicompactum1 [66] 
 Penicillium chermesinum1 [34] 
 Penicillium citrinum1 [199] 
 Penicillium decumbens1 [199] 
 Penicillium glabrum [152] 
 Penicillium marneffei [112] 
 Penicillium ochrochloron1 [34] 
 Penicillium roqueforti [74, 180, 203, S] 
 Penicillium sacculum [152] 
 Penicillium steckii1 [199] 
 Penicillium turbatum [S] 
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 Penicillium verruculosum [152] 
 Phaeococcomyces sp. [80] 
 Phaeosphaeria nodorum [113] 
 Phaeosphaeria pontiformis [74] 
 Phialemonium sp. [208] 
 Phialocephala lagerbergii [S] 
 Phoma sp.1 [110] 
 Pichia kudriavzevii [S] 
 Pichia manshurica1 [10] 
 Plenozythia sp.1 [110] 
 Pleospora herbarum [152] 
 Podosphaera xanthii [S] 
 Pseudosaccharomyces stevensii1 [9] 
 Raciborskiomyces longisetosus [152], Current name: Epipolaeum 
longisetosum  
 Ramularia sp. [74] 
 Saccharomyces bayanus [28, 152] 
 Saccharomyces cariocanus [152] 
 Saccharomyces castellii [112, 113], Current name: Naumovia castellii  
 Saccharomyces cerevisiae
2
 [6, 10, 28, 30, 42, 67, 68, 74, 75, 92, 108, 112, 
113, 118, 142, 152, 180, 203, S] 
 Saccharomyces paradoxus [30] 
 Saccharomyces servazzii [142], Current name: Kazachstania servazzii  
 Scedosporium apiospermum [74] 
 Scheffersomyces stipites [42] 
 Sclerotinia sclerotiorum [68, 112, 113, 152] 
 Sclerotium sp. [67, 152] 
 Scopulariopsis sp. [42] 
 Scytalidium thermophilum [74] 
 Septoria epambrosiae [152] 
 Simplicillium lanosoniveum [30] 
 Simplicillium obclavatum [30] 
 Sirococcus conigenus [152] 
 Stemphylium sp. [80] 
 Sterigmatomyces elviae [75] 
 Strelitziana sp. [80] 
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 Talaromyces stipitatus [42] 
 Teratosphaeria sp. [80] 
 Torula nigra1 [110] 
 Torulaspora pretoriensis [75] 
 Toxicocladosporium sp. [80] 
 Trichocladium asperum [74] 
 Trichoderma lignorum
1
 [34], Current name: Trichoderma viride  
 Trichoderma longibrachiatum [S] 
 Trichophyton verrucosum [112] 
 Verticillium leptobactrum/Verticillium insectorum [180] 
 Westerdykella cylindrical [68] 
 Xeromyces sp. [80] 
 Xylariales sp. [108] 
 Yarrowia lipolytica2 [42, 68, 97, 152] 
 Zygosaccharomyces bisporus [9] 
 Zygosaccharomyces rouxii [28] 
Basidiomycota Agaricus bisporus [48, S] 
 Armillaria sp. [80] 
  Asterophora parasitica [75] 
 Asterotremella albida (nom. inval.) [30], Current name: Sporobolomyces 
albidus  
 Auricularia sp. [80] 
 Bjerkandera adusta [75] 
 Bullera crocea [152], Current name: Dioszegia crocea 
 Ceriporia lacerate [74] 
 Chondrostereum sp. [80] 
 Cinereomyces sp. [80] 
 Climacocystis sp.1 [66] 
 Clitopilus prunulus [68] 
 Cryptococcus albidosimilis [108] 
 Cryptococcus albidus1 [97] 
 Cryptococcus amylolyticus [S] 
 Cryptococcus carnescens [152] 
 Cryptococcus fragicola [30] 
 Cryptococcus humicola (reported as Candida humicola [28]) 
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 Cryptococcus laurentii1 [34] 
 Cryptococcus luteolus1 [97], Current name: Hannaella luteola  
 Cryptococcus neoformans [112, 113] 
 Cryptococcus ovoidea1 [9] 
 Cryptococcus podzolicus [108] 
 Cryptococcus tephrensis [74, S] 
 Cystofilobasidium capitatum2 [67, 152] 
 Dacrymyces sp. [152] 
 Erythrobasidiaceae sp. [74] 
 Exidiopsis calcea [152] 
 Exobasidiomycetes sp. [80] 
 Filobasidium capsuligenum [68] 
 Filobasidium globisporum [68, 152] 
 Flammulina velutipes [152] 
 Fomes fomentarius [68] 
 Fomitopsis pinicola [68, 152] 
 Fuscoporia gilva [74] 
 Graphiola phoenicis [152] 
 Hymenochaete sp. [80] 
  Hypholoma sp. [80] 
 Laccaria bicolor [113] 
 Lentinus sp. [80] 
 Malassezia globosa2 [28, 42, 66, 67, 68, 75, 112, S] 
 Malassezia pachydermatis2 [30, 66, 67, 68, 75, S] 
 Malassezia restricta2 [28, 66, 67, 68, 74, 75, S] 
 Malassezia slooffiae [S] 
 Malassezia sympodialis [74, S] 
 Moniliophthora perniciosa [42, 113], Current name: Crinipellis perniciosa  
 Mrakia sp. [74, S] 
 Oidium lactis1 [9], Current name: Oospora lactis  
 Phanerochaete stereoides [75] 
 Phlebia nitidula [74] 
 Phlebia uda [74], Current name: Mycoacia uda  
 Pholiota sp. [S] 
 Piptoporus sp. [80] 
  
23 
 Postia placenta [42], Current name: Rhodonia placenta 
 Psathyrella candolleana [180] 
 Puccinia poarum [68] 
 Rhodosporidium babjevae [68] 
 Rhodotorula aurantiaca [152] 
 Rhodotorula glutinis1 [97] (also reported as Saccharomyces glutinous1 [9])  
 Rhodotorula minuta1 [34] 
 Rhodotorula mucilaginosa2 [34, 68, 152] 
 Sporobolomyces ogasawarensis [153] 
 Sporobolomyces yunnanensis [152] 
 Thanatephorus sp. [80] 
 Tilletiopsis washingtonensis [74] 
 Torula rubra1 [9], Current name: Rhodotorula rubra  
 Trametes versicolor [152] 
 Trichaptum sp. [80] 
 Tricholoma saponaceum [152] 
 Trichosporon asahii
2
 [10, 68, 75] 
 Trichosporon caseorum [75] 
 Trichosporon cutaneum [75] 
 Trichosporon dermatis [28, 152] 
 Trichosporon faecale [68] 
 Trichosporon guehoae [74] 
 Tyromyces sp. [80] 
 Ustilago maydis [42, 152] 
 Wallemia muriae [30, S] 
 Wallemia sebi [30, 48] 
Chytridiomycota Spizellomyces punctatus [113] 
Microsporidia Enterocytozoon bieneusi [42] 
Zygomycota Entomophthora sp. [48] 
 Mucor racemosus [153] 
 Rhizopus microsporus [28] 
 Syncephalastrum racemosum
1
 [34] 
Note: No superscript indicates fungi were detected by culture-independent method. 
              1
Fungi were detected by culture-dependent method. 
              2
Fungi were detected by both culture-dependent and -independent methods. 
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The most commonly detected fungi in the GI tract of humans among the 36 
studies listed in Table 1.2 are C. albicans (25 studies), Saccharomyces cerevisiae (19), C. 
tropicalis (17), C. parapsilosis (13), C. glabrata (12), C. krusei (10), Malassezia globosa 
(8), M. restricta (7), and Debaryomyces hansenii (7). Candida species are known to 
dominate the GI tract of humans and their presence is not surprising. To the best of our 
knowledge, at least 268 fungal taxa have been reported in gut, which is considerably 
lower than the estimated 500-1,000 bacteria residing in the gut [163, 221]. Additionally, a 
majority of the fungi were only reported in one study. 
 
1.5.4 STABILITY OF THE MYCOBIOME  
Fungi residing in the gastrointestinal tract can originate from a number of sources. 
Fungi are ubiquitous in the environment and are used as food and in food production, 
making their presence in the gut a reflection of the individual’s diet and environmental 
encounters [180]. DNA extracted from food and fecal samples show that foodborne fungi 
from the diet transiently colonize the gut [42]. Species of fungi found in the gut known to 
colonize the skin and respiratory tract are also thought to be transient members [98]. Due 
to the transient and allochthonous nature of numerous fungal members in the gut, stability 
of the gut mycobiome over time is low [74]. Table 1.2 also illustrates the dynamic and 
variable nature of the mycobiome in the number of fungi identified in a single study. 
Fungal populations in the murine gut vary substantially over time and are influenced by 
the environment, while bacterial populations remain relatively stable [47]. There are both 
more bacterial species and more individual bacteria in the gut than fungi and thus, 
bacterial communities may be more robust [204].   
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1.6 MEDICALLY RELEVANT FUNGI: PATHOGENIC YEASTS  
Fungal diseases, especially those caused by opportunistic pathogens, have become 
increasingly important over the past few decades. The success of modern medicine and 
the explosion of new antibacterial agents have led to greater survival of 
immunocompromised patients while creating populations highly susceptible to fungal 
infections. The most common yeasts found associated with disease are Candida, 
Histoplasma, Blastomyces, and Cryptococcus and to a lesser extent species of 
Geotrichum, Malassezia, Pichia, Rhodotorula, Saccharomyces, and Trichosporon. With 
the exception of Blastomyces, each of these fungal genera has been reported in the GI 
tract. The most common filamentous fungi associated with disease found in the gut are 
Aspergillus spp. Additionally; other fungi found in the gut and causing infections include 
Alternaria, Scedosporium, Paecilomyces, and Trichoderma.  
 
1.6.1 CANDIDA SPECIES 
Candida species are normal, harmless commensals on many human body sites 
and have been consistently reported in gut fungi studies. C. albicans is the predominant 
commensal yeast of humans. Candida spp. are also opportunistic pathogens of humans 
and cause disease when mucosal barriers are disrupted and defects in the immune system 
occur. They can invade and cause infections ranging from superficial infections of the 
skin to life-threatening systemic infections. At least 17 Candida species, out of the 
approximately 150 known species, cause disease in humans, the most common being 
Candida albicans, C. dubliniensis, C. glabrata, C. guilliermondii, C. krusei, C. 
lusitaniae, C. parapsilosis, and C. tropicalis [139]. Recent studies show that Candida 
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spp. are the fourth most-common cause of nosocomial bloodstream infections [216, 217]. 
An estimated 60,000 cases of disseminated candidiasis occur each year in the U.S, with 
an estimated cost of 2-4 billion dollars [157, 215].  
In the years prior to 1990, the predominant species causing invasive Candida 
infections was C. albicans [157]. C. albicans lacks an environmental reservoir and is 
almost exclusively associated with humans and possibly other warm-blooded animals and 
avian species [26, 89, 119, 169]. C. albicans is considered the most virulent species of the 
genus Candida because it contains an arsenal of virulence factors and fitness attributes 
that contribute to pathogenesis. The most widely studied virulence factors include 
adhesins, secreted hydrolytic enzymes, and morphogenesis. 
Adherence to the host cell is an essential first step of pathogenesis. C. albicans 
expresses adhesins on the surface of the cell that allow it interact will host cells and 
ultimately colonize host tissues. The agglutinin-like sequence (ALS) protein family 
contains the most recognized C. albicans adhesins and consists of eight large cell-surface 
glycoproteins for adherence to mammalian cells [83]. In addition to host cell adherence, 
Candida species produce three-dimensional structured microbial community biofilms 
surrounded by a matrix of exopolymeric material on biotic and abiotic surfaces [102, 
165]. The formation of Candida biofilms becomes important clinically because of 
biofilms’ increased resistance to antifungals and protection from host immune defenses 
[14]. Biofilms forming on implanted medical devices such as catheters, shunts, prosthetic 
devices, and dentures serve as a reservoir for infection and direct access to the body 
[164]. 
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 Extracellular proteolytic activity is another C. albicans pathogenicity mechanism. 
The best-characterized Candida proteases are the secreted aspartyl proteinases (Sap) 
[136, 137]. Sap proteins help digest molecules for nutrient uptake, distort host cells to 
enable adhesion and tissue invasion, and digest components of the host immune system to 
evade attack [141]. In vitro models using sap deletion mutants show attenuated virulence 
and demonstrate Sap proteins contribute to the overall virulence and are required for 
disseminated infection [84, 177, 182]. 
Morphological switching is a virulence strategy used by C. albicans to aid in its 
pathogenic potential. When C. albicans comes into contact with a surface, yeast cells 
transition into hyphal forms [103]. Both morphological forms are important for 
pathogenicity; the hyphal form aids in cellular invasion and the yeast form is primarily 
involved in dissemination [17, 179]. Quorum sensing regulates the yeast-to-filamentous 
transition in C. albicans by molecules by farnesol [82]. C. albicans also has a range of 
fitness attributes that allow the yeast to adapt to pH changes, stress, and nutrient 
starvation [127].  
 In recent years, there has been an increased prevalence of infections caused by 
species of Candida other than C. albicans. The introduction and widespread use of 
antifungals has led to an increased number of infections caused by C. glabrata, due to its 
resistance to fluconazole, itraconazole, and moderate (dose-dependent) resistance to other 
antifungal agents [201]. Distribution of Candida infections varies among countries and 
institutions; C. glabrata is considered the second most common cause of Candida 
infections in the U.S. and Europe, yet ranks behind C. parapsilosis and C. tropicalis in 
South America and Asia, respectively [35, 107, 159, 197]. Reasons for geographical 
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differences are of interest and outline the complexity of epidemiology. Multiple risk 
factors including clinical practice, antifungal therapies, and colonization of health care 
workers likely support the emergence of non-albicans species as predominant pathogens 
[150].  
 
1.6.2 ASPERGILLUS SPECIES  
Invasive aspergillosis (IA) has increased significantly in recent decades and is the 
most common filamentous fungal lung infection in immunocompromised patients [69, 
130]. Aspergillus species have a worldwide distribution and their ubiquity in the 
environment exposes humans to Aspergillus spores daily. Aspergillus fumigatus is the 
most prevalent species of the 200 aspergilli described and is the main cause of human IA 
[40]. A. flavus, A. glaucus, A. niger, A. nidulans, A. parasiticus, and A. terreus are also 
commonly associated with aspergillosis [138]. Aspergillus species are also well known 
for their ability to produce carcinogenic mycotoxins, aflatoxin, and ochratoxin, and show 
resistance to some antifungals [45, 94]. Numerous species of Aspergillus have been 
reported in the GI tract of humans (Table 1.2).  
  
1.7 CHARACTERIZATION OF THE GASTROINTESTINAL FUNGAL 
COMMUNITY  
The correct identification of fungi is of great importance in clinical settings, and 
especially in novel studies attempting to characterize microbial communities from 
different ecological niches, such as the gastrointestinal tract. Methods for exploring and 
characterizing the microbiota from the GI tract have greatly evolved over time. Wide 
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ranges of techniques are available to identify fungi, all differing in specificity, 
reproducibility, time, and cost. While each method has its own advantages and 
limitations, advances over the years have improved our understanding of the human GI 
tract ecosystem. 
 
 
1.7.1 Culture-dependent methods 
The first studies identifying the fungi of the gastrointestinal tract date back to the 
early 1900s [9, 99]. The ability to culture fungi was critical for discovering and 
identifying their presence. At the time it was known that feces contain a large number of 
bacteria compared to fungi and ordinary culture medium and plating methods would not 
be sufficient for the isolation of fungi from the gut. Therefore media inhibiting bacterial 
growth, such as Sabouraud’s agar, were commonly used [9, 13]. Historically, 
identification and classification of yeasts was based on readily observable gross colony 
features (color, size, shape), microscopic examination, and biochemical properties. Over 
time, culture-dependent methods including selective media, nutrient utilization and 
fermentation, susceptibilities to yeast killer toxins, susceptibilities to chemicals and 
antifungal drugs, secondary metabolites, fatty acid composition, cell wall composition, 
and protein composition have been indispensable for increasing our understanding and 
classifying fungi [70].  
Although advancements have been made in culture-dependent methods, these 
methods present several disadvantages and study limitations that restrict the ability for 
mycologists to accurately characterize fungi in fecal samples. In culture-based studies, 
dominant populations (e.g. Candida spp.) can mask the detection and diversity of low-
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abundance organisms. In addition, current fungal culture techniques may be inadequate to 
optimally cultivate organisms that require microbe–microbe interactions, since culture 
fails to reproduce ecological niches and symbiotic relationships encountered in the 
natural environment [15, 29]. The culturable fraction is also distorted because replication 
times vary among microorganisms and fast-growing species efficiently outcompete 
others [143].  
 
1.7.2 Culture-independent methods 
Considering the above limitations of culture-dependent methods, the advent of 
culture-independent methods has allowed researchers to more efficiently characterize the 
mycobiome. In particular, the development of polymerase chain reaction (PCR) in the 
1980s revolutionized culture-independent fungal detection methods [173]. In the ensuing 
years, the introduction of multiple culture-independent DNA-based methods for 
characterizing the gut microbiota became available—denaturing gel gradient 
electrophoresis (DGGE), oligonucleotide fingerprinting of ribosomal RNA genes 
(OFRG) and restriction fragment length polymorphism (RFLP). While these methods 
have improved the ability to study the mycobiota, they still have a reduced ability to 
identify fungi at the species level and quantify taxa [38].  
The advent of high-throughput DNA sequencing technologies has become the 
preferred method for mycobiome studies [48, 185]. Sanger sequencing and, more 
recently, next-generation amplicon sequencing are capable of distinguishing species 
using genes within the fungal ribosomal RNA gene cluster—18S small subunit rDNA, 
28S large subunit rDNA, and the internal transcribed spacer (ITS1 or ITS2) (Figure 1.2). 
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rRNA genes are appealing targets for fungal identification because they are highly 
multicopy in each genome. Fungal rRNA genes have highly conserved regions serving as 
primer binding sites to determine the sequences of adjacent variable regions by PCR 
amplification. In fungi, 28S provides much greater resolution than 18S, and continues to 
be used for within-genus (i.e., species-level) identification and phylogenetic studies, 
while 18S is rarely adequate to distinguish species [41] (in contrast with the analogous 
bacterial 16S gene, which is widely used for identification). ITS genes are less conserved 
and, therefore, are considered the best target for fungal species and subspecies 
identification [161]. Also, researchers must select which ITS gene (ITS1, ITS2 or ITS1-
5.8s-ITS2) to amplify for identification (Figure 1.2). Next-generation sequencing of these 
genes has provided the most accurate account of the fungal composition of the human gut 
microbiome.  
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B) 
 
 
 
Figure 1.2 Schematic representation of the A) fungal ribosomal gene cluster and B) 
28s nuclear large rDNA with binding locations of PCR primers 
(http://nature.berkeley.edu/brunslab/; accessed February 2015). 
 
 
 
1.7.3 Culture-dependent vs. culture-independent methods 
Few studies have used a combination of culture-dependent and -independent 
methods for the identification of gut fungi and compared the results. One study exploring 
the diversity of gut eukaryotes in a Senegalese man identified 16 fungal species by 
molecular methods targeting the ITS, 18s, and 28s genes and only four fungal species by 
culturing, using three culture media [75]. Three of the four fungi isolated by culture were 
also detected by sequencing; the exception was C. krusei. An earlier gut fungi study using 
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culture-dependent and -independent methods also highlighted a culturing bias. Candida 
spp. were identified as the predominant species by cultivation methods and 
Gloeotinia/Paecilomyces and Galactomyces were found to be the predominant species 
using clone libraries [180]. Chen and colleagues found 37 fungal OTUs using clone 
libraries while only five species, from two genera (Candida and Saccharomyces), were 
isolated by two culture media [30]. The culture-independent method in this study failed to 
detect C. krusei and C. glabrata.  
 
1.8 THE GUT MYCOBIOME IN HEALTHY AND DISEASED STATES  
1.8.1 Benefits of intestinal fungi 
Compared to the vast amount of literature on the benefits of bacteria in the human 
gut, the beneficial role of gut fungi – if any – remains largely unexplored. No strong 
evidence exists for a mutualistic or beneficial relationship with the gut mycobiome [85]. 
The only fungus studied in any detail with indications of treating gastroenteritis is the 
probiotic yeast Saccharomyces cerevisiae var. boulardii  (“S. boulardii”) [222]. Clinical 
trials using S. boulardii as a therapeutic strategy have shown significant efficacy in 
treatment and prevention for various types of diarrhea including traveler’s diarrhea, 
antibiotic associated diarrhea, and inflammatory bowel disease [24, 71, 72, 129]. In 
addition to the presumed health benefits, it is proposed that probiotic yeasts may 
positively interact with probiotic bacteria by enhancing their survival, and overall display 
a synergistic effect [20, 196]. Another potential medical application of probiotic yeasts 
involves their ability to express disease-fighting proteins known as killer toxins, or 
mycocins, against pathogenic yeasts, such as Candida spp. [212].  
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1.8.2 Mycobiome and disease 
Since the renowned Greek physician Hippocrates first described oral candidiasis 
in 400 BC, researchers and clinicians have aimed to explore the roles of commensal and 
pathogenic fungi in human health and disease [3]. In particular, cataloging the gut 
mycobiome in health and disease has been a biological hot spot in recent years. Defining 
fungi present and/or absent as well as alterations in the fungal community in the gut 
during different disease states may inform knowledge of cause and effect. Do these fungi 
contribute to or protect from disease? Do they cause disease directly or indirectly?  
Gastrointestinal colonization by fungi such as C. albicans is suggested as the 
major reservoir and source of invasive fungal infections such as invasive candidiasis 
[148]. C. albicans, the predominant gut fungus, colonizes the GI tract but has the ability 
to invade tissues and disseminate in the body when the gut microbiome is disrupted, 
intestinal mucosal permeability is increased, or the host is immune-suppressed. Candida 
gut colonization has been associated with a number of diseases such as diabetes, 
hematologic malignancies, Crohn’s disease, and graft-versus-host disease; and patient 
populations such as hospital inpatients and extremely low birth weight infants (Table 
1.3). Patients with gastrointestinal disorders such as ulcerative colitis and Crohn’s disease 
are more frequently and heavily colonized by C. albicans than are control groups [100, 
193]. 
In the gut, the disease states studied thus far exhibit associations between fungal 
diversity and disease. This has been demonstrated in patients with Crohn’s disease, 
hepatitis B, and pouchitis [30, 101, 113, 152]. In many of these cases, fungal diversity is 
positively correlated with disease progression and severity. However, this is not the case 
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for the mycobiome at other diseased body sites. The human lung, previously thought to 
be sterile, harbors a lower diversity of fungi in patients with cystic fibrosis than healthy 
controls [78]. This is also true in the nasal mycobiome of allergic patients [188]. Drawing 
broad conclusions about fungal diversity, colonization, and disease is difficult due to the 
low number of studies, sample numbers, and uncertainty across body sites. Gut fungi data 
indicates a role for the mycobiome in the pathogenesis of a number of diseases and 
suggests that altering the mycobiome may aid in preventing or ameliorating disease. The 
question yet remains whether or not disease causes changes in the mycobiome or vice 
versa. As the field advances, mycobiome composition and alterations may be a predictor 
of disease and more research will continue to define the association between fungi and 
disease. 
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 Table 1.3 Changes in the gut mycobiota associated with disease. 
 
Disease status Sample type and size Methodology Primers Findings Reference 
Type 1 diabetes Feces, n=35 Culture n/a 
C. albicans identified in 40% of 
subjects; significant difference 
from 35 controls 
[192] 
Inflammatory 
bowel disease 
Colonic biopsies,  
Crohn’s disease n=31 
Ulcerative colitis n=26 
18s rDNA, DGGE, 
cloning, Sanger 
sequencing 
NS0/EF3 
NS1/FR1 
BF2/TR1 
Higher mean fungal diversity in 
patients with CD; significant 
difference from 47 controls 
[152] 
Crohn’s disease 
Ileal mucosa & feces, 
n=19 
18s rRNA, DGGE, 
cloning, Sanger 
sequencing 
NS1/FR1, 
EF390/GC-FR-1 
Fungal richness and diversity 
significantly increased in patients, 
C. albicans & C. tropicalis 
abundant in patients and absent in 7 
controls 
[113] 
Familial 
Crohn’s disease 
Feces & mouth swabs, 
n= 129 CD patients 
n=113 healthy 
relatives 
Culture, biochemical tests, 
latex agglutination 
n/a 
C. albicans significantly more 
frequent in CD patients and their 
healthy relatives than from 14 
control families 
[193] 
Preterm infants 
(<32 weeks) 
Feces, n=32,  
(7 NEC, 13 sepsis) 
28s rDNA, DGGE, 
cloning, Sanger 
sequencing 
U1/U2-GC 
Fungal colonization in half of 
infants; No fungal species were 
observed in infants who developed 
necrotizing enterocolitis 
[195] 
Intestinal 
transplant 
Ileal effluent & feces, 
n=2 
18s rDNA, DGGE, 
cloning, Sanger 
sequencing 
NS1/FR1 
EF390/GC-FR1 
High fungal diversity soon after 
transplant; less diversity >16-20 
weeks post-transplant  
[112] 
Hepatitis B  
Feces, cirrhosis n=38, 
chronic hepatitis B 
n=35 
Culture  
18s, cloning, RFLP, 
Sanger sequencing 
Unspecified 
Diversity of enteric fungi positively 
correlated with disease progression 
[30] 
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 Table 1.3 Continued. 
 
Disease status Sample type and size Methodology Primers Findings Reference 
Hematologic 
malignancy or 
disorder 
Feces, n=80 
Culture, germ tube test, 
biochemical test 
n/a 
Non-albicans Candida spp. 
significantly higher in patients, C. 
glabrata more prevalent in patients 
than 61 controls 
[6] 
Hospital 
inpatients 
Feces, n=34 
Culture, germ tube test, 
biochemical test 
n/a 
Inpatients higher prevalence of 
yeast, C. glabrata more prevalent in 
inpatients 
[97] 
Extremely low 
birth weight 
infants 
Feces, n=11 
ITS, 454 pyrosequencing, 
metagenomic shotgun 
sequencing 
ITS3/ITS4 
Candida spp. and Clavispora sp. 
dominated, Candida quercitrusa 
most abundant  
[108] 
Diabetes 
Feces,  
type 1 n=27, type 2=17 
Quantitative real-time PCR 
18s, FAM 
Candida probe 
Candida spp. significantly greater 
in type 1 & type 2 patients than 17 
controls  
[65] 
Graft-versus-
host disease 
Feces & oral, 
GVHD n=59 
GI-GVHD n=37 
Culture n/a 
Patients colonized with Candida 
spp. had a significantly higher rate 
of grade II-IV acute GVHD  
[205] 
Pouchitis 
Biopsy & feces,  
n=36 
18s, DGGE NS1/FR1-GC 
Patients who develop pouchitis have 
higher fungal diversity and lower 
bacterial diversity  
[101] 
Varying 
symptoms & 
complaints 
Feces, n=308 Culture n/a 
Smoking habits highly associated to 
Candida colonization; also 
associated with Candida-vaginitis  
[92] 
Gastric ulcers Gastric juice, n=293 Culture, biochemical test n/a 
Significant fungal colonization >10
4
 
CFU/ml in patients with gastric 
ulcers 
[227] 
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1.9 DIET AND THE GASTROINTESTINAL MYCOBIOME 
 Diet is an environmental factor that influences the structure and diversity of 
microorganisms in the gut [42]. Resident bacterial populations are associated with diet 
and long-term dietary patterns [42]. However, few studies have investigated the 
relationship between diet and the human intestinal mycobiome. One recent human study 
demonstrated that consumption of high amounts of carbohydrates was positively 
associated with Candida spp. colonization, while a diet high in amino acids, fatty acids, 
and protein was negatively associated with Candida spp. [80]. Fungal abundance in the 
gastrointestinal tract was also strongly associated with the composition of short-term diet.  
Animal-based diets significantly increase Penicillium spp. [42], while Ukhanova et al. 
showed pistachio and almond consumption does not significantly increase gut fungal 
OTUs [203].  
 Intestinal populations of microorganisms are suspected of contributing to obesity 
by way of diet [111]. The role of gut fungi in obesity is unknown. Only one study has 
addressed this, focusing on the fungal communities in the human gut of a single obese 
person and detecting 18 fungal species [66]. Conversely, a study identifying the fungal 
community of a single anorexic human reported a “restricted” diversity of 10 fungal 
species [67]. However, this number is not unusual for healthy individuals on a 
conventional diet [74].  
 
1.10 THE INTESTINAL MYCOBIOTA AND THE HOST IMMUE SYSTEM 
The GI tract is home to the majority of both the human body’s commensal 
microorganisms and immune cells. Little is known about the interaction between 
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commensal intestinal fungi and the host immune system. Several players of the immune 
system have been reported to play a critical role in fungal recognition and host defense 
against disseminated fungal infections. These include Dectin-1, IL-17, and IL-22 [88]. 
Dectin-1 is a C-type lectin that plays a role in the innate immune response by functioning 
as a pattern-recognition receptor and recognizing beta-glucans found in the cell walls of 
fungi. In mice, Dectin-1 is of critical importance to defend against pathogenic fungi such 
as Pneumocystis carinii and C. albicans [172, 200]. Humans deficient in Dectin-1 suffer 
recurrent mucocutaneous candidiasis infections [57]. Genetic polymorphisms of Dectin-1 
have also been associated with increased severity of ulcerative colitis [87, 204].  
The cytokines IL-17 and IL-22 have been implicated in mucosal and antifungal 
immunity. Mice deficient in components of the IL-17 pathway show increased 
susceptibility to oral candidiasis and skin infections [37, 93]. Furthermore, IL-22 serves 
as a first-line of defense against candidiasis in mice because IL-22 deficient mice are 
more susceptible to GI candidiasis [43]. Mucosal immune responses to fungi are different 
across human body sites. A complete understanding of the interaction between 
commensal fungi and the immune system has yet to be unveiled.  
 
1.11 CROSS-KINGDOM INTERACTIONS; POST-ANTIBIOTIC INTESTINAL 
COMMUNITY REASSEMBLY  
 Interactions among microorganisms within the GI tract have long been recognized 
as important determinants of community function [178]. Inhabitants are unlikely act in 
isolation in the gut and, therefore, live in complex associations with one another. 
Residents of the gastrointestinal microbiota are constantly interacting with one another, 
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competing for nutrients and space and producing compounds that directly inhibit growth 
or kill potential competitors [114]. Microbes in the gut may also form mutualistic and/or 
commensal interactions with one another cooperating via syntrophy - using metabolic 
waste products of another organism as nutrients - and constructing interspecies antibiotic-
resistant biofilms [166, 219]. Hoffman et al. has best described the correlations between 
fungi-bacteria and fungi-archaea [80]. The fungal phyla, Ascomycota and Basidiomycota, 
significantly correlate with bacterial lineages. Candida and Saccharomyces commonly 
co-occur with bacterial taxa Faecalibacterium, Bacteroides, Lachnospiraceae, and 
Ruminococcaceae and these fungal genera are also positively associated with the 
archaeon Methanobrevibacter and negatively associated with the archaeon 
Nitrososphaera. Further analysis showed that Candida was negatively associated with 
Bacteroides.  
Bacteria and fungi interact with one another within an ecosystem physically and 
chemically [154]. These interactions influence overall survival, colonization, and 
virulence. Perhaps the most important bacterial-fungal interaction led to the discovery of 
penicillin [61]. Physical interactions between fungi and bacteria include forming mixed 
biofilms with one another and the ability of bacteria to attach to fungal hyphae, inhibiting 
filamentation and biofilm formation [2, 155]. Bacteria also produce antifungal molecules 
that affect morphology and virulence of Candida [81]. Bacteria have the ability to modify 
the environment by lowering the pH and preventing hyphae formation by C. albicans 
[27].  
Bacteria and fungi are known to inhabit, and interact with one another at, multiple 
human body sites. The species composition of the two may become beneficial or 
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detrimental to the human host. Within the gastrointestinal microbiota, colonization 
resistance is a known interaction that prevents overgrowth by endogenous organisms. The 
bacterial microbiota reduces C. albicans colonization by excluding and out-competing 
Candida for adhesion sites and producing inhibitory molecules [96]. Controlling fungal 
colonization, especially by opportunists, with the use of probiotic bacteria is appealing. 
One study showed the probiotic bacteria, Lactobacillus acidophilus and Lactobacillus 
casei, induce protection against systemic candidiasis in mice [209]. Short chain fatty 
acids (butyric acid) produced by lactic acid bacteria also inhibit filamentation and may 
prevent C. albicans from causing disease [146].  
 
1.11.1 Post-antibiotic recolonization 
The ecological balance in the human gastrointestinal tract is important and 
modulated, in part, by intestinal bacteria preventing fungal colonization and overgrowth. 
However, when broad-spectrum antibiotics are administered they have the potential to 
wipe out the entire bacterial community in the GI tract, perturb the equilibrium and allow 
the host to become susceptible to infections by normally benign, commensal fungi such 
as C. albicans [175]. Antibiotics are, therefore, a major risk factor for candidemia in 
hospitalized patients [149, 213, 223].  
Conversely, post-antibiotic recolonization of the bacterial gut microbiota is 
shaped and altered by the presence of Candida. In the stomach of microbiome-disturbed 
mice, C. albicans prevents Lactobacillus regrowth after antibiotic treatment and promotes 
colonization of Enterococcus [125]. Presence of C. albicans in the murine cecum after 
antibiotic treatment promotes Bacteroidetes populations, Enterococcus faecalis 
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persistence, and inhibits Lactobacillus johnsonii [126]. Another recent study 
demonstrated that the exogenous addition of C. albicans during treatment with the 
cefoperazone in mice led to yeast overgrowth and substantially altered reassembly of the 
bacterial community after treatment [52]. The combination of antibiotics and fungal 
microbiota has been shown to promote the development of allergic airway disease [145, 
147]. 
 
 
  
43 
 
1.12 REFERENCES 
 
1. Aagaard, K., Ma, J., Antony, K.M., Ganu, R., Petrosino, J., et al. (2014). The placenta 
harbors a unique microbiome. Science Translational Medicine, 6, 237ra65. 
  
2. Adam, B., Baillie, G.S., Douglas, L.J. (2002). Mixed species biofilms of Candida 
albicans and Staphylococcus epidermidis. Journal of Medical Microbiology, 51, 
344-349. 
 
3. Adams, F. (1939). The genuine works of Hippocrates, Francis Adams translations. 
Epidemics, Book 3 Circa 460-377 BC. Baltimore, MD: Williams and Wilkins. 
 
4. Adlerberth, I., Strachan, D.P., Matricardi, P.M., Ahrné, S., Orfei, L., et al. (2007). Gut 
microbiota and development of atopic eczema in 3 European birth cohorts. 
Journal of Allergy Clinical Immunology, 120, 343-350. 
  
5. Adlerberth, I., Wold, A.E. (2009). Establishment of the gut microbiota in Western 
infants. Acta Paediatrica, 98, 229-238. 
 
6. Agirbasli, H., Ozcan, S.A., Gedikoğlu, G. (2005). Fecal fungal flora of pediatric 
healthy volunteers and immunosuppressed patients. Mycopathologia, 159, 515-
520. 
 
7. Albert, M.J., Mathan, V.I., Baker, S.J. (1980). Vitamin B12 synthesis by human small 
intestinal bacteria. Nature, 283, 781-782. 
  
8. Andersen, L.O., Nielsen, H.V., Stensvold, C.R. (2013). Waiting for the human 
intestinal Eukaryotome. ISME Journal, 7, 1253-1255. 
 
9. Anderson, H.W. (1917). Yeast-like fungi of the human intestinal tract. The Journal of 
Infectious Diseases, 21, 341-338. 
  
10. Angebault, C., Djossou, F., Abélanet, S., Permal, E., Soltana, M.B., et al. (2013). 
Candida albicans is not always the preferential yeast colonizing humans: a study 
in Wayampi Amerindians. Journal of Infectious Diseases, 208, 1705-1716. 
 
11. Arendorf, T.M., Walker, D.M. (1979). Oral candidal populations in health and 
disease. British Dental Journal, 147, 267-272. 
 
12. Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., et al. (2011). 
Enterotypes of the human gut microbiome. Nature, 473, 174-180. 
 
13. Ashford, B.K. (1915). Relation of the genus “Monila” to certain fermentative 
conditions of the intestinal tract in Porto Rico. Journal of the American Medical 
Association, 64, 1893-1896. 
  
44 
 
 
14. Baillie, G.S., Douglas, L.J. (2000). Matrix polymers of Candida biofilms and their 
possible role in biofilm resistance to antifungal agents. Journal of Antimicrobial 
Chemotherapy, 46, 397-403.  
 
15. Beck, J.M., Young, V.B., Huffnagle, G.B. (2012). The microbiome of the lung. 
Translational Research, 160, 258-266. 
 
16. Benno Y., Sawada K., Mitsuoka, T. (1984). The intestinal microflora of infants: 
composition of fecal flora in breast-fed and bottle-fed infants. Microbiology and 
Immunology, 28, 975-986. 
 
17. Berman, J., Sudbery, P.E. (2002). Candida albicans: a molecular revolution built on 
lessons from budding yeast. National Reviews Genetics, 3, 918-930. 
 
18. Biasoli, M.S., Tosello, M.E., Magaró, H.M. (2002). Adherence of Candida strains 
isolated from the human gastrointestinal tract. Mycoses, 45, 465-469. 
  
19. Bik, E.M., Eckburg, P.B., Gill, S.R., Nelson, K.E., Purdom, E.A., et al. (2006). 
Molecular analysis of the bacterial microbiota in the human stomach. Proceedings 
of the National Academy of Sciences USA, 103, 732-737.  
 
20. Bisson, J.F., Hidalgo, S., Rozan, P., Messaoudi, M. (2010). Preventive effects of 
different probiotic formulations on travelers' diarrhea model in wistar rats: 
preventive effects of probiotics on TD. Digestive Diseases and Sciences, 55, 911-
919.  
 
21. Bliss, J.M., Basavegowda, K.P., Watson, W.J., Sheikh, A.U., Ryan, R.M. (2008). 
Vertical and horizontal transmission of Candida albicans in very low birth weight 
infants using DNA fingerprinting techniques. Pediatric Infectious Disease 
Journal, 27, 231-235.  
 
22. Boorom, K.F., Smith, H., Nimri, L., Viscogliosi, E., Spanakos, G., et al. (2008). Oh 
my aching gut: irritable bowel syndrome, Blastocystis, and asymptomatic 
infection. Parasites & Vectors, 1, 40. 
 
23. Brabander, J.O.W., Blank, F., Butas, C.A. (1957). Intestinal moniliasis in adults. 
Canadian Medical Association Journal, 77, 478-483. 
  
24. Bravo, M.V., Bunout, D., Leiva, L., De La Maza, M.P., Barrera, G., et al. (2008). 
Effect of probiotic Saccharomyces boulardii on prevention of antibiotic-
associated diarrhea in adult outpatients with amoxicillin treatment. Revista 
Medíca de Chile, 136, 981-988. 
 
  
45 
 
25. Breitbart, M., Hewson, I., Felts, B., Mahaffy, J., Nulton, J., et al. (2003). 
Metagenomic analyses of an uncultured viral community from human feces. 
Journal of Bacteriology, 85, 6220-6223. 
 
26. Brito, E.H., Fontenelle, R.O., Brilhante, R.S., Cordeiro, R.A., Monteiro, A.J., et al. 
(2009). The anatomical distribution and antimicrobial susceptibility of yeast 
species isolated from healthy dogs. Veterinary Journal, 182, 320-326. 
 
27. Buffo, J., Herman, M.A., Soll, D.R. (1984). A characterization of pH-regulated 
dimorphism in Candida albicans. Mycopathologia, 85, 21-30. 
 
28. Cano, R.J., Rivera-Perez, J., Toranzos, G.A., Santiago-Rodriguez, T.M., Narganes-
Storde, Y.M., et al. (2014). Paleomicrobiology: revealing fecal microbiomes of 
ancient indigenous cultures. PLoS ONE, 9, e106833. 
 
29. Carraroa, L., Maifrenib, M., Bartolomeolib, I., Martinoa, M.E., Novellia, E., et al. 
(2011). Comparison of culture-dependent and -independent methods for bacterial 
community monitoring during Montasio cheese manufacturing. Research in 
Microbiology, 162, 231-239. 
 
30. Chen, Y., Chen, Z., Guo, R., Chen, N., Lu, H., et al. (2011). Correlation between 
gastrointestinal fungi and varying degrees of chronic hepatitis B virus infection. 
Diagnostic Microbiology and Infectious Disease, 70, 492-498.  
 
31. Chibani-Chennoufi, S., Bruttin, A., Dillmann, M.L., Brussow, H. (2004). Phage-host 
interaction: an ecological perspective. Journal of Bacteriology, 186, 3677-3686. 
 
32. Clark, B., McKendrick, M. (2004). A review of viral gastroenteritis. Current Opinion 
in Infectious Diseases, 17, 461-469. 
  
33. Clemente, J.C., Ursell, L.K., Parfrey, L.W., Knight, R. (2012). The impact of the gut  
microbiota on human health: an integrative review. Cell, 148, 1258-1270.  
 
34. Cohen, R., Roth, F.J., Delgado, E., Ahearn, D.G., Kalser, M.H. (1969). Fungal flora 
of the normal human small and large intestine. The New England Journal of 
Medicine, 280, 638-641. 
  
35. Colombo, A.L., Nucci, M., Salomão, R., Branchini, M.L., Richtmann, R., et al. 
(1999). High rate of non-albicans candidemia in Brazilian tertiary care hospitals. 
Diagnostic Microbiology and Infectious Disease, 34, 281-286. 
 
36. Compare, D., Coccoli, P., Rocco, A., Nardone, O.M., De Maria, S., et al. (2012). Gut-
liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. 
Nutrition, Metabolism and Cardiovascular Diseases, 22, 471-476.  
 
  
46 
 
37. Conti, H.R., Shen, F., Nayyar, N., Stocum, E., Sun, J.N., et al. (2009). Th17 cells and 
IL-17 recpetor signaling are essential for mucosal host defense against oral 
candidiasis. Journal of Experimental Medicine, 206, 299-311. 
 
38. Cui, L., Morris, A., Ghedin, E. (2013). The human mycobiome in health and disease. 
Genome Medicine, 5, 63. 
 
39. Cummings, J.H., Macfarlane, G.T. (1997). Colonic microflora: nutrition and health. 
Nutrition, 13, 476-478. 
  
40. Dagenais, T.R.T., Keller, N.P. (2009). Pathogenesis of Aspergillus fumigatus in 
invasive aspergillosis. Clinical Microbiology Reviews, 22, 447-465. 
 
41. Das, S., Dash, H.R., Mangwani, N., Chakraborty, J., Kumari, S. (2014). 
Understanding molecular identification and polyphasic taxonomic approaches for 
genetic relatedness and phylogenetic relationships of microorganisms. Journal of 
Microbiological Methods, 103, 80-100. 
 
42. David, L.A., Maurice, C.F., Carmody, R.N., Gootenberg, D.B., Button, J.E., et al. 
(2014). Diet rapidly and reproducibly alters the human gut microbiome. Nature, 
505, 559-563. 
 
43. De Luca, A., Zelante, T., D'Angelo, C., Zagarella, S., Fallarino, F., et al. (2010). IL-
22 defines a novel immune pathway of antifungal resistance. Mucosal 
Immunology, 3, 361-373.  
  
44. Dicksved, J., Floistrup, H., Bergstrom, A., Rosenquist, M., Pershagen, G., et al. 
(2007). Molecular fingerprinting of the fecal microbiota of children raised 
according to different lifestyles. Applied and Environmental Microbiology, 73, 
2284-2289. 
 
45. Diekema, D.J., Messer, S.A., Hollis, R.J., Jones, R.N., Pfaller, M.A. (2003). 
Activities of caspofungin, itraconazole, posaconazole, ravuconazole, 
voriconazole, and amphotericin B against 448 recent clinical isolates of 
filamentous fungi. Journal of Clinical Microbiology, 41, 3623-3626. 
 
46. DiGiulio, D.B., Romero, R., Amogan, H.P., Kusanovic, J.P., Bik, E.M., et al. (2008). 
Microbial prevalence, diversity and abundance in amniotic fluid during preterm 
labor: a molecular and culture-based investigation. PLoS ONE, 3, e3056. 
  
47. Dollive, S., Chen, Y.Y., Grunberg, S., Bittinger, K., Hoffmann, C., et al. (2013). 
Fungi of the murine gut: episodic variation and proliferation during antibiotic 
treatment. PLoS ONE, 8, e71806. 
 
  
47 
 
48. Dollive, S., Peterfreund, G.L., Sherrill-Mix, S., Bittinger, K., Sinha, R., et al. (2012). 
A tool kit for quantifying eukaryotic rRNA gene sequences from human 
microbiome samples. Genome Biology, 13, R60. 
  
49. Dominguez-Bello, M.G, Costello, E.K., Contreras, M., Magris, M., Hidalgo, G., et al. 
(2010). Delivery mode shapes the acquisition and structure of the initial 
microbiota across multiple body habitats in newborns. Proceedings of the 
National Academy of Sciences USA, 107, 11971-11975. 
 
50. Drell, T., Lillsaar, T., Tummeleht, L., Simm, J., Aaspõllu, A., et al. (2013). 
Characterization of the vaginal micro- and mycobiome in asymptomatic 
reproductive-age Estonian women. PLoS ONE, 8, e54379. 
 
51. Dridi, B., Henry, M., El Khéchine, A., Raoult, D., Drancourt, M. (2009). High 
prevalence of Methanobrevibacter smithii and Methanosphaera stadtmanae 
detected in the human gut using an improved DNA detection protocol. PLoS 
ONE, 4, e7063. 
 
52. Downward, J.R.E., Falkowski, N.R., Mason, K.L., Muraglia, R., Huffnagle, G.B. 
(2013). Modulation of post-antibiotic bacterial community reassembly and host 
response by Candida albicans. Scientific Reports, 3, 2191. 
 
53. Dubos, R., Schaedler, R.W., Costello, R., Hoet, P. (1965). Indigenous, normal and 
autochthonous flora of the gastrointestinal tract. The Journal of Experimental 
Medicine, 122, 67-76. 
 
54. Duncan, S.H., Lobley, G.E., Holtrop, G., Ince, J., Johnstone, A.M., et al. (2008). 
Human colonic microbiota associated with diet, obesity and weight loss. 
International Journal of Obesity, 32, 1720-1724.  
 
55. Eckburg, P.B., Bik, E.M., Bernstein, C.N., Purdom, E., Dethlefsen, L., et al. (2005). 
Diversity of the human intestinal microbial flora. Science, 308, 1635-1638. 
 
56. Ellis-Pegler, R.B., Crabtree, C., Lambert, H.P. (1975). The faecal flora of children in 
the United Kingdom. Journal of Hygiene, 75, 135-142. 
 
57. Ferwerda, B., Ferwerda, G., Plantinga, T.S., Willment, J.A., van Spriel, A.B., et al. 
(2009). Human dectin-1 deficiency and mucocutaneous fungal infections. New 
England Journal of Medicine, 361, 1760-1767.  
 
58. Findley, K., Oh, J., Yang, J., Conlan, S., Deming, C., et al. (2013). Topographic 
diversity of fungal and bacterial communities in human skin. Nature, 498, 367-
370.  
 
  
48 
 
59. Finegold, S.M., Attebery, H.R., Sutter, V.L. (1974). Effect of diet on human fecal 
flora: comparison of Japanese and American diets. The American Journal of 
Clinical Nutrition, 27, 1456-1469. 
 
60. Finegold, S.M., Sutter, V.L., Sugihara, P.T., Elder, H.A., Lehmann, S.M., et al. 
(1977). Fecal microbial flora in Seventh Day Adventist populations and control 
subjects. The American Journal of Clinical Nutrition, 30, 1781-1792.  
 
61. Fleming, A. (1929). On the antibacterial action of cultures of a Penicillium, with 
special reference to their use in the isolation of B. influenzae. British Journal of 
Experimental Pathology, 10, 226-236.  
 
62. Francino, M.F. (2014). Early development of the gut microbiota and immune health. 
Pathogens, 4, 769-790. 
 
63. Ghannoum, M.A., Jurevic, R.J., Mukherjee, P.K., Cui, F., Sikaroodi, M., et al. (2010). 
Characterization of the oral fungal microbiome (mycobiome) in healthy 
individuals. PLoS Pathogens, 6, e1000713. 
 
64. Gordon, J.H., Dubos, R. (1970). The anaerobic bacterial flora of the mouse cecum. 
Journal of Experimental Medicine, 132, 251-260. 
 
65. Gosiewski, T., Salamon, D., Szopa, M., Sroka, A., Malecki, M.T., et al. (2014). 
Quantitative evaluation of fungi of the genus Candida in feces of adult patients 
with type 1 and 2 diabetes – a pilot study. Gut Pathogens, 6, 43. 
 
66. Gouba, N., Raoult, D., Drancourt, M. (2013). Plant and fungal diversity in gut 
microbiota as revealed by molecular and culture investigations. PLoS ONE, 8, 
e59474. 
 
67. Gouba, N., Raoult, D., Drancourt, M. (2014). Gut microeukaryotes during anorexia 
nervosa: a case report. BMC Research Notes, 7, 33. 
 
68. Gouba, N., Raoult, D., Drancourt, M. (2014). Eukaryote culturomics of the gut 
reveals new species. PLoS ONE, 9, e106994. 
 
69. Groll, A.H., Shah, P.M., Mentzel, C., Schneider, M., Just-Nuebling, G., et al. (1996). 
Trends in postmortem epidemiology of invasive fungal infections at a university 
hospital. Journal of Infection, 33, 23-32. 
 
70. Guarro, J., Gené, J., Stchigel, A.M. (1999). Developments in fungal taxonomy. 
Clinical Microbiology Reviews, 12, 454-500.  
 
  
49 
 
71. Guslandi, M., Giollo, P., Testoni, P.A. (2003). A pilot trial of Saccharomyces 
boulardii in ulcerative colitis. European Journal of Gastroenterology and 
Hepatology, 15, 697-698. 
 
72. Guslandi, M., Mezzi, G., Sorghi, M., Testoni, P.A. (2000). Saccharomyces boulardii 
in maintenance treatment of Crohn’s disease. Digestive Diseases and Sciences, 
45, 1462-1464. 
 
73. Hague, A., Manning, A.M., Hanlon, K.A., Huschtscha, L.I., Hart, D., et al. (1993). 
Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-
independent pathway: implications for the possible role of dietary fibre in the 
prevention of large-bowel cancer. International Journal of Cancer, 55, 498-505. 
 
74. Hallen-Adams, H.E., Kachman, S.D., Kim, J., Legge, R.M., Martínez, I. (In press). 
Fungi inhabiting the healthy human gastrointestinal tract: a diverse and dynamic 
community. Fungal Ecology. 
 
75. Hamad, I., Sokhna, C., Raoult, D., Bittar, F. (2012). Molecular detection of 
eukaryotes in a single human stool sample from Senegal. PLoS ONE, 7, e40888. 
 
76. Harmsen, H.J.M., Wildeboer-Veloo, A.C.M., Raangs, G.C., Wagendorp, A.A., Klijn, 
N., et al. (2000). Analysis of intestinal flora development in breast-fed and 
formula-fed infants by using molecular identification and detection methods. 
Journal of Pediatric Gastroenterology & Nutrition, 30, 61-67. 
 
77. Harris, M.A., Reddy, C.A., Carter, G.R. (1976). Anaerobic bacteria from the large 
intestine of mice. Applied and Environmental Microbiology, 31, 907-912. 
 
78. Harrison, M.J., Twomey, K.B., McCarthy, Y., O’Connell, O.J., Alston, M., et al. 
(2012). Fungal microbiota in the adult cystic fibrosis (CF) airway: 
characterization by second-generation sequencing and correlation with standard 
culture-based methods and clinical phenotype. Irish Journal of Medical Science, 
181, S369-S437. 
 
79. Havlickova, B., Czaika, V.A., Friedrich, M. (2008). Epidemiological trends in skin 
mycoses worldwide. Mycoses, 51(Suppl. 4), 2-15. 
 
80. Hoffmann, C., Dollive, S., Grunberg, S., Chen, J., Li, H., et al. (2013). Archaea and 
fungi of the human gut microbiome: correlations with diet and bacterial residents. 
PLoS ONE, 8, e66019. 
 
81. Hogan, D.A., Vik, A., Kolter, R.A. (2004). A Pseudomonas aeruginosa quorum-
sensing molecule influences Candida albicans morphology. Molecular 
Microbiology, 54, 1212-1223. 
 
  
50 
 
82. Hornby, J.M., Jensen, E.C., Lisec, A.D., Tasto, J.J., Jahnke, B., et al. (2001). Quorum 
sensing in the dimorphic fungus Candida albicans is mediated by farnesol. 
Applied and Environmental Microbiology, 67, 2982-2992.  
 
83. Hoyer, L.L. (2001). The ALS gene family of Candida albicans. Trends in 
Microbiology, 9, 176-180. 
 
84. Hube, B., Sanglard, D., Odds, F.C., Hess, D., Monod, M., et al. (1997). Disruption of 
each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of Candida 
albicans attenuates virulence. Infection and Immunity, 65, 3529-3538. 
 
85. Huffnagle, G.H., Noverr, M.C. (2013). The emerging world of the fungal 
microbiome. Trends in Microbiology, 21, 334-341. 
 
86. Human Microbiome Project Consortium. (2012). Structure, function and diversity of 
the healthy human microbiome. Nature, 486, 207-214. 
 
87. Iliev, I.D., Funari, V.A., Taylor, K.D., Nguyen, Q., Reyes, C.N., et al. (2012). 
Interactions between commensal fungi and the C-type lectin receptor Dectin-1 
influence colitis. Science, 8, 1314-1317. 
 
88. Iliev, I.D., Underhill, D.M. (2013). Striking a balance: fungal commensalism versus 
pathogenesis. Current Opinion in Microbiology, 16, 1-8. 
 
89. Jacobsen, M.D., Bougnoux, M-E., d’ Enfert, C., Odds, F.C. (2008). Multilocus 
sequence typing of Candida albicans isolates from animals. Research in 
Microbiology, 159, 436-440. 
 
90. Jeffery, I.B., O'Toole, P.W., Öhman, L., Claesson, M.J., Deane, J., et al. (2012). An 
irritable bowel syndrome subtype defined by species-specific alterations in faecal 
microbiota. Gut, 61, 997-1006. 
 
91. Jimenez, E., Fernandez, L., Marin, M.L., Martin, R., Odriozola, J.M., et al. (2005). 
Isolation of commensal bacteria from umbilical cord blood of healthy neonates 
born by cesarean section. Current Microbiology, 51, 270-274. 
 
92. Jobst, D., Kraft, K. (2006). Candida species in stool, symptoms and complaints in 
general practice-a cross-sectional study of 308 outpatients. Mycoses, 49, 415-420. 
 
93. Kagami, S., Rizzo, H.L., Kurtz, S.E., Miller, L.S., Blauvelt, A. (2010). IL-23 and IL-
17a, but not IL-12 and IL-22, are required for optimal skin host defense against 
Candia albicans. Journal of Immunology, 185, 5453-5462.  
 
94. Kamei, K., Watanabe, A. (2005). Aspergillus mycotoxins and their effect on the host. 
Medical Mycology, 43(Suppl. 1), S95-S99. 
  
51 
 
 
95. Kanno, T., Matsuki, T., Oka, M., Utsunomiya, H., Inada, K., et al. (2009). Gastric 
acid reduction leads to an alteration in lower intestinal microflora. Biochemical 
and Biophysical Research Communications, 381, 666-670. 
 
96. Kennedy, M.J., Volz, P.A. (1985). Ecology of Candida albicans gut colonization: 
inhibition of Candida adhesion, colonization, and dissemination from the 
gastrointestinal tract by bacterial antagonism. Infection and Immunity, 49, 654-
663. 
 
97. Khatib, R., Riederer, K.M., Ramanathan, J., Baran Jr., J. (2001). Faecal fungal flora 
in healthy volunteers and inpatients. Mycoses, 44, 151-156. 
 
98. Koh, A.Y. (2013). Gastrointestinal colonization of fungi. Current Fungal Infection 
Reports, 7, 144-151.  
 
99. Kohlbrugge, J.H.F. (1901). Die Ätiologie der Aphthae tropicae. Archiv fuer schiffs-
und tropen-hygiene, 5, 394. 
 
100. Ksiadzyna, D., Semianow-Wejchert, J., Nawrot, U., Wlodarczyk, K., Paradowski, L. 
(2009). Serum concentration of interleukin 10, anti-mannan Candida antibodies 
and the fungal colonization of the gastrointestinal tract in patients with ulcerative 
colitis. Advances in Medical Sciences, 54, 170-176. 
 
101. Kühbacher, T., Ott, S.J., Helwig, U., Mimura, T., Rizzello, F., et al. (2006). 
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in 
pouchitis. Gut, 55, 833-841.  
 
102. Kumamoto, C.A. (2002). Candida biofilms. Current Opinion in Microbiology, 5, 
608-611. 
 
103. Kumamoto, C.A. (2008). Molecular mechanisms of mechanosensing and their roles 
in fungal contact sensing. Nature Reviews Microbiology, 6, 667-673. 
 
104. Langenbeck, B. (1842) Froriep's Neue Notizen, 12, 145.  
 
105. Langeron, M., Guerra, P. (1938). Nouvelles recherches de zymologie médicale. 
Annales de Parasitologie Humaine et Comparée, 16, 481-525. 
 
106. Larsen, N., Vogensen, F.K., van den Berg, F.W.J., Nielsen, D.S., Andreasen, A.S., 
et al. (2010). Gut microbiota in human adults with type 2 diabetes differs from 
non-diabetic adults. PLoS ONE, 5, e0009085. 
 
107. Lass-Flörl, C. (2009). The changing face of epidemiology of invasive fungal disease 
in Europe. Mycoses, 52, 197-205. 
  
52 
 
 
108. LaTuga, M.S., Ellis, J.C., Cotton, C.M., Goldberg, R.N., Wynn, J.L., et al. (2011). 
Beyond bacteria: a study of the enteric microbial consortium in extremely low 
birth weight infants. PLoS ONE, 6, e27858. 
 
109. Le Dantec, A. (1908). Présence d’une levure dans le sprue. Comptes rendus des 
séances de la Société de biologie, 64, 1066-1068. 
 
110. Levine, H.B., Cobet, A.B. (1970). The tektite-I dive. Mycological aspects. Archives 
of Environmental Health, 20, 500-505.  
 
111. Ley, R.E., Turnbaugh, P.J., Klein, S., Gordon, J.I. (2006). Microbial ecology: human 
gut microbes associated with obesity. Nature, 444, 1022-1023. 
 
112. Li, Q., Wang, C., Zhang, Q., Tang, C., Li, N., et al. (2012). Use of 18S ribosomal 
DNA polymerase chain reaction-denaturing gradient gel electrophoresis to study 
composition of fungal community in 2 patients with intestinal transplants. Human 
Pathology, 43, 1273-1281.  
 
113. Li, Q., Wang, C., Tang, C., He, Q., Li, N., et al. (2014). Dysbiosis of gut fungal 
microbiota is associated with mucosal inflammation in Crohn's disease. Journal of 
Clinical Gastroenterology, 48, 513-523. 
 
114. Little, A.E.F., Robinson, C.J., Peterson, S.B., Raffa, K.F., Handelsman, J. (2008). 
Rules of engagement: interspecies interactions that regulate microbial 
communities. Annual Review of Microbiology, 62, 375-401. 
 
115. Louis, P. (2012). Does the human gut microbiota contribute to the etiology of autism 
spectrum disorders? Digestive Diseases and Sciences, 57, 1987-1989. 
 
116. Lupetti, A., Tavanti, A., Davini, P., Ghelardi, E., Corsini, V., et al. (2002). 
Horizontal transmission of Candida parapsilosis candidemia in a neonatal 
intensive care unit. Journal of Clinical Microbiology, 40, 2362-2369. 
 
117. Mackie, R.I., Sghir, A., Gaskins, H.R. (1999). Developmental microbial ecology of 
the neonatal gastrointestinal tract. American Journal of Clinical Nutrition, 69, 
1035s-1045s. 
 
118. Macura, A.B., Witalis, J. (2010). Fungi isolated from the stool in patients with 
gastrointestinal disorders in 2005-2009. Przeglad epidemiologiczny, 64, 313-317. 
 
119. Mancianti, F., Nardoni, S., Ceccherelli, R. (2002). Occurrence of yeasts in 
psittacines droppings from captive birds in Italy. Mycopathologia, 153, 121-124. 
 
  
53 
 
120. Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., et al. 
(2006). Reduced diversity of faecal microbiota in Crohn’s disease revealed by a 
metagenomic approach. Gut, 55, 205-211. 
 
121. Martin, D.S., Jones, C.P. (1940). Further studies on the practical classification of the 
Monilias. Journal of Bacteriology, 39, 609-630. 
 
122. Martin, D.S., Jones, C.P., Yao, K.F., Lee, L.E. (1937). A practical classification of 
the Monilias. Journal of Bacteriology, 34, 99-129. 
 
123. Martín-Sosa, S., Martín, M.J., García-Pardo, L.A., Hueso, P. (2003). 
Sialyloligosaccharides in human and bovine milk and in infant formulas: 
variations with the progression of lactation. Journal of Dairy Science, 86, 52-59. 
 
124. Martinsen, T.C., Bergh, K., Waldum, H.L. (2005). Gastric juice: a barrier against 
infectious diseases. Basic & Clinical Pharmacology & Toxicology, 96, 94-102. 
 
125. Mason, K.L., Downward, J.R.E., Falkowski, N.R., Young, V.B., Kao, J.Y., et al. 
(2012). Interplay between the gastric bacterial microbiota and Candida albicans 
during postantibiotic recolonization and gastritis. Infection and Immunity, 80, 
150-158. 
 
126. Mason, K.L., Downward, J.R.E., Mason, K.D., Falkowski, N.R., Eaton, K.A. 
(2012). Candida albicans and bacterial microbiota interactions in the cecum 
during recolonization following broad-spectrum antibiotic therapy. Infection and 
Immunity, 80, 3371-3380. 
 
127. Mayer, F.L., Wilson, D., Hube, B. (2013). Candida albicans pathogenicity 
mechanisms. Virulence, 4, 119-128. 
 
128. Mazmanian, S.K., Liu, C.H., Tzianabos, A.O., Kaspe, D.L. (2005). An 
immunomodulatory molecule of symbiotic bacteria directs maturation of the host 
immune system. Cell, 122, 107-118. 
 
129. McFarland, L.V. (2007). Meta-analysis of probiotics for the prevention of traveler’s 
diarrhea. Travel Medicine and Infectious Disease, 5, 97-105. 
 
130. McNeil, M.M., Nash, S.L., Hajjeh, R.A., Phelan, M.A., Conn, L.A., et al. (2001). 
Trends in mortality due to invasive mycotic diseases in the United States, 1980–
1997. Clinical Infectious Diseases, 33, 641-647. 
 
131. Miller, T.L., Wolin, M.J. (1985). Methanosphaera stadtmaniae gen. nov., sp. nov.: a 
species that forms methane by reducing methanol with hydrogen. Archives of 
Microbiology, 141, 116-122. 
 
  
54 
 
132. Miller, T.L., Wolin, M.J. (1986). Methanogens in human and animal intestinal 
tracts. Systematic and Applied Microbiology, 7, 23-29. 
 
133. Miller, T.L., Wolin, M.J., De Macario, E.C., Macario, A.J. (1982). Isolation of 
Methanobrevibacter smithii from human feces. Applied and Environmental 
Microbiology, 43, 227-232.  
 
134. Minot, S., Sinha, R., Chen, J., Li, H., Keilbaugh, S.A., et al. (2011). The human gut 
virome: inter-individual variation and dynamic response to diet. Genome 
Research, 21, 1616-1625. 
 
135. Moles, L., Gomez, M., Heilig, H., Bustos, G., Fuentes, S., et al. (2013). Bacterial 
diversity in meconium of preterm neonates and evolution of their fecal microbiota 
during the first month of life. PLoS ONE, 8, e66986. 
 
136. Monod, M., Hube, B., Hess, D., Sanglard, D. (1998). Differential regulation of 
SAP8 and SAP9, which encode two new members of the secreted aspartic 
proteinase family in Candida albicans. Microbiology, 144, 2731-2737.  
 
137. Monod, M., Togni, G., Hube, B., Sanglard, D. (1994). Multiplicity of genes 
encoding secreted aspartic proteinases in Candida species. Molecular 
Microbiology, 13, 357-368. 
 
138. Moore, D., Robson, G.D., Trinci, A.P.J. (2011). Fungi as pathogens of animals. In 
21
st
 century guidebook to fungi (pp. 411-448). New York, NY: Cambridge 
University Press. 
 
139. Moran, G., Coleman, D., Sullivan, D. (2012). An introduction to the medically 
important Candida species. In R.A. Calderon & C.J. Clancy (Eds.), Candida and 
Candidiasis, 2
nd
 Edition (pp. 11-25). Washington, DC: ASM Press.  
 
140. Moreau, M.C., Raibaud, P., Muller, M.C. (1982). Relationship between the 
development of the intestinal IgA immune system and the establishment of 
microbial flora in the digestive tract of young holoxenic mice. Annales 
d’Immunologie, 133D, 29-39. 
 
141. Naglik, J.R., Challacombe, S.J., Hube, B. (2003). Candida albicans secreted 
aspartyl proteinases in virulence and pathogenesis. Microbiology and Molecular 
Biology Reviews, 67, 400-428. 
 
142. Nam, Y.D., Chang, H.W., Kim, K.H., Roh, S.W., Kim, M.S., et al. (2008). Bacterial, 
archaeal, and eukaryal diversity in the intestines of Korean people. Journal of 
Microbiology, 46, 491-501. 
 
  
55 
 
143. Nocker, A., Burr, M., Camper, A.K. (2007). Genotypic microbial community 
profiling: a critical technical review. Microbial Ecology, 54, 276-289.  
 
144. Noor, S.O., Ridgway, K., Scovell, L., Kemsley, E.K., Lund, E.K., et al. (2010). 
Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the 
gut microbiota. BMC Gastroenterology, 10, 134.  
 
145. Noverr, M.C., Falkowski, N.R., McDonald, R.A., McKenzie, A.N., Huffnagle, G.B. 
(2005). Development of allergic airway disease in mice following antibiotic 
therapy and fungal microbiota increase: role of host genetics, antigen, and 
interleukin-13. Infection and Immunity, 73, 30-38.  
 
146. Noverr, M.C., Huffnagle, G.B. (2004). Regulation of Candida albicans 
morphogenesis by fatty acid metabolites. Infection and Immunity, 72, 6206-6210. 
 
147. Noverr, M.C., Noggle, R.M., Toews, G.B., Huffnagle, G.B. (2004). Role of 
antibiotics and fungal microbiota in driving pulmonary allergic responses. 
Infection and Immunity, 72, 4996-5003. 
 
148. Nucci, M., Anaissie, E. (2001). Revisiting the source of candidemia: skin or gut? 
Clinical Infectious Diseases, 33, 1959-1967. 
 
149. Nucci, M., Colombo, A. (2002). Risk factors for breakthrough candidemia. 
European Journal of Clinical Microbiology and Infectious Diseases, 21, 209-211. 
 
150. Nucci, M., Marr, K.A. (2005). Emerging fungal diseases. Clinical Infectious 
Diseases, 41, 521-526. 
 
151. O'Hara, A.M., Shanahan, F. (2006). The gut flora as a forgotten organ. EMBO 
Reports, 7, 688-693. 
 
152. Ott, S.J., Kühbacher, T., Musfeldt, M., Rosenstiel, P., Hellmig, S., et al. (2008). 
Fungi and inflammatory bowel diseases: alterations of composition and diversity. 
Scandinavian Journal of Gastroenterology, 43, 831-841. 
 
153. Pandey, P.K., Siddharth, J., Verma, P., Bavdekar, A., Patole, M.S., et al. (2012). 
Molecular typing of fecal eukaryotic microbiota of human infants and their 
respective mothers. Journal of Biosciences, 37, 221-226. 
 
154. Peleg, A.Y., Hogan, D.A., Mylonakis, E. (2010). Medically important bacterial-
fungal interactions. Nature Reviews, 8, 340-349.  
 
155. Peleg, A.Y., Tampakakis, E., Fuchs, B.B., Eliopoulos, G.M., Moellering Jr, R.C., et 
al. (2008). Prokaryote–eukaryote interactions identified by using Caenorhabditis 
  
56 
 
elegans. Proceedings of the National Academy of Sciences USA, 105, 14585-
14590. 
 
156. Penders, J., Thijs, C., Vink, C., Stelma, F.F., Snijders, B., et al. (2006). Factors 
influencing the composition of the intestinal microbiota in early infancy. 
Pediatrics, 118, 511-521. 
 
157. Perlroth, J., Choi, B., Spellberg, B. (2007). Nosocomial fungal infections: 
epidemiology, diagnosis, and treatment. Medical Mycology, 45, 321-346.  
 
158. Peterson, J., Garges, S., Giovanni, M., McInnes, P., Wang, L., et al. (2009). The 
NIH human microbiome project. Genome Research, 19, 2317-2323.  
 
159. Pfaller, M.A., Diekema, D.J. (2004). Twelve years of fluconazole in clinical 
practice: global trends in species distribution and fluconazole susceptibility of 
bloodstream isolates of Candida. Clinical Microbiology and Infection, 10(Suppl. 
1), 11-23. 
 
160. Plottel, C.S., Blaser, M.J. (2011). Microbiome and malignancy. Cell Host Microbe, 
10, 324-335. 
 
161. Porter, T.M., Golding, G.B. (2012). Factors that affect large subunit ribosomal DNA 
amplicon sequencing studies of fungal communities: classification method, 
primer choice, and error. PLoS ONE, 7. e35749.  
 
162. Prado, M., Cairncross, S., Strina, A., Barreto, M., Oliveira-Assis, A., et al. (2005). 
Asymptomatic giardiasis and growth in young children; a longitudinal study in 
Salvador, Brazil. Parasitology, 131, 51-56. 
 
163. Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K.S., et al. (2010). A human gut 
microbial gene catalogue established by metagenomic sequencing. Nature, 464, 
59-65. 
 
164. Ramage, G., Martínez, J.P., López-Ribot, J.L. (2006). Candida biofilms on 
implanted biomaterials: a clinically significant problem. FEMS Yeast Research, 6, 
979-986. 
 
165. Ramage, G., Saville, S.P., Thomas, D.P., López-Ribot, J.L. (2005). Candida 
biofilms: an update. Eukaryotic Cell, 4, 633-638. 
 
166. Rodríguez-Martínez, J.M., Pascual, A. (2006). Antimicrobial resistance in bacterial 
biofilms. Reviews in Medical Microbiology, 17, 65-75. 
 
167. Rohwer, F. (2003). Global phage diversity, Cell, 113, 141. 
 
  
57 
 
168. Roos, P.J., Malan, A.F., Woods, D.L., Botha, P., Hyland, J., et al. (1980). The 
bacteriological environment of preterm infants. South African Medical Journal, 
57, 347-350. 
 
169. Rosenbach, A., Dignard, D., Pierce, J.V., Whiteway, M., Kumamoto, C.A. (2010). 
Adaptations of Candida albicans for growth in the mammalian intestinal tract. 
Eukaryotic Cell, 9, 1075-1086. 
 
170. Ruiz-Palacios, G.M., Calva, J.J., Pickering, L.K., Lopez-Vidal, Y., Volkow, P., et al. 
(1990). Protection of breast-fed infants against Campylobacter diarrhea by 
antibodies in human milk. Journal of Pediatrics, 116, 707-713. 
 
171. Russell, C., Lay, K.M. (1973). Natural history of Candida species and yeasts in the 
oral cavities of infants. Archives of Oral Biology, 18, 957-962. 
 
172. Saijo, S., Fujikado, N., Furuta, T., Chung, S.H., Kotaki, H., et al. (2007). Dectin-1 is 
required for host defense against Pneumocystis carinii but not against Candida 
albicans. Nature Immunology, 8, 39-46. 
 
173. Saiki, R.K., Scharf, S., Faloona, F., Mullis, K.B., Horn, G.T., et al. (1985). 
Enzymatic amplification of β-globin genomic sequences and restriction site 
analysis for diagnosis of sickle cell anemia. Science, 230, 1350-1354.  
 
174. Saiman, L., Ludington, E., Dawson, J.D., Patterson, J.E., Rangel-Fraustro, S., et al. 
(2001). Risk factors for Candida species colonization of neonatal intensive care 
unit patients. Pediatric Infectious Diseases Journal, 20, 1119-1124.  
 
175. Samonis, G., Gikas, A., Anaissie, E.J., Vrenzos, G., Maraki, S., et al. (1993). 
Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal 
yeast colonization of humans. Antimicrobial Agents and Chemotherapy, 37, 51-
53. 
 
176. Samuel, B.S., Gordon, J.I. (2006). A humanized gnotobiotic mouse model of host-
archaeal-bacterial mutualism. Proceedings of the National Academy of Sciences 
USA, 103, 10011-10016. 
 
177. Sanglard, D., Hube, B., Monod, M., Odds, F.C., Gow, N.A. (1997). A triple deletion 
of the secreted aspartyl proteinase genes SAP4, SAP5, and SAP6 of Candida 
albicans causes attenuated virulence. Infection and Immunity, 65, 3539-3546.  
 
178. Savage, D.C. (1977). Microbial ecology of the gastrointestinal tract. Annual Review 
of Microbiology, 3, 107-133. 
 
  
58 
 
179. Saville, S.P., Lazzell, A.L., Monteagudo, C., Lopez-Ribot, J.L. (2003). Engineered 
control of cell morphology in vivo reveals distinct roles for yeast and filamentous 
forms of Candida albicans during infection. Eukaryotic Cell, 2, 1053-1060. 
 
180. Scanlan, P.D., Marchesi, J.R. (2008). Micro-eukaryotic diversity of the human distal 
gut microbiota: qualitative assessment using culture-dependent and -independent 
analysis of faeces. ISME Journal, 2, 1183-1193.  
 
181. Scanlan, P.D., Shanahan, F., Marchesi, J.R. (2008). Human methanogen diversity 
and incidence in healthy and diseased colonic groups using mcrA gene analysis. 
BMC Microbiology, 8, 79. 
 
182. Schaller, M., Korting, H.C., Schäfer, W., Bastert, J., Chen, W., et al. (1999). 
Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model 
of human oral candidosis. Molecular Microbiology, 34, 169-180. 
 
183. Scher, J.U., Abramson, S.B. (2011). The microbiome and rheumatoid arthritis. 
Nature Reviews Rheumatology, 7, 569-578.  
 
184. Schloss, P.D., Handelsman, J. (2004). Status of the microbial census. Microbiology 
and Molecular Biology Reviews, 68, 686-691. 
 
185. Schoch, C.L., Seifertb, K.A., Huhndorfc, S., Robert, V., Spougea, J.L., et al. (2012). 
Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA 
barcode marker for fungi. Proceedings of the National Academy of Sciences USA, 
109, 6241-6246. 
 
186. Schulze, J., Sonnenborn, U. (2009). Yeasts in the gut: from commensals to 
infectious agents. Deutsches Ärzteblatt International, 106, 837-842.  
 
187. Seebacher, C. (1996). Mycophobia-a new disease? Mycoses, 39(Suppl. 1), 30-32.  
 
188. Sellart-Altisent, M., Torres-Rodrígues, J.M., Gómez de Ana, S., Alvarado-Ramírez, 
E. (2007). Nasal fungal microbiota in allergic and healthy subjects. Revista 
Iberoamericana Micología, 24, 125-130. 
 
189. Sheedy, J.R., Wettenhall, R.E., Scanlon, D., Gooley, P.R., Lewis, D.P., et al. (2009). 
Increased d-lactic acid intestinal bacteria in patients with chronic fatigue 
syndrome. In Vivo, 23, 621-628. 
 
190. Sobel, J.D. (2007). Vulvovaginal candidosis. Lancet, 369, 1961-1971. 
 
 
  
59 
 
191. Sogin, M.L., Morrison, H.G., Huber, J.A., Welch, D.M., Huse, S.M., et al. (2006). 
Microbial diversity in the deep sea and the underexplored “rare biosphere”. 
Proceedings of the National Academy of Sciences USA, 103, 12115-12120.  
 
192. Soyucen, E., Gulcan, A., Aktuglu-Zeybek, A.C., Onal, H., Kiykim, E., et al. (2014). 
Differences in the gut microbiota of healthy children and those with type 1 
diabetes. Pediatrics International, 56, 336-343. 
 
193. Standaert-Vitse, A., Sendid, B., Joossens, M., François, N., Vandewalle-El Khoury, 
P., et al. (2009). Candida albicans colonization and ASCA in familial Crohn’s 
disease. American Journal of Gastroenterology, 104, 1745-1753. 
 
194. Stewart, J.A., Chadwick, V.S., Murray, A. (2006). Carriage, quantification, and 
predominance of methanogens and sulfate-reducing bacteria in faecal samples. 
Letters in Applied Microbiology, 43, 58-63. 
 
195. Stewart, C.J., Nelson, A., Scribbins, D., Marrs, E.C.L., Lanyon, C., et al. (2013). 
Bacterial and fungal viability in the preterm gut: NEC and sepsis. Archives of 
Disease and Childhood, 98, F298-F303.  
 
196. Suharja, A.A.S., Henriksson, A., Liu, S.Q. (2014). Impact of Saccharomyces 
cerevisiae on viability of probiotic Lactobacillus rhamnosus in fermented milk 
under ambient conditions. Journal of Food Processing and Preservation, 38, 326-
337. 
 
197. Tan, T.Y., Tan, A.L., Tee, N.W., Ng, L.S., Chee, C.W. (2010). The increased role of 
non-albicans species in candidaemia: results from a 3-year surveillance study. 
Mycoses, 53, 515-521. 
 
198. Taylor, G.R., Henney, M.R., Ellis, W.L. (1973). Changes in the fungal autoflora of 
Apollo astronauts. Applied Microbiology, 26, 804-813. 
 
199. Taylor, G.R., Kropp, K.D., Molina, T.C. (1985). Nine-year microflora study of an 
isolator-maintained immunodeficient child. Applied and Environmental 
Microbiology, 50, 1349-1356. 
 
200. Taylor, P.R., Tsoni, S.V., Willment, J.A., Dennehy, K.M., Rosas, M., et al. (2007). 
Dectin-1 is required for beta-glucan recognition and control of fungal infection. 
Nature Immunology, 8, 31-38. 
 
201. Trick, W.E., Fridkin, S.K., Edwards, J.R., Hajjeh, R.A., Gaynes, R.P. (2002). 
Secular trend of hospital-acquired candidemia among intensive care unit patients 
in the United States during 1989-1999. Clinical Infectious Diseases, 35, 627-630. 
 
  
60 
 
202. Truss, C.O. (1981). The role of Candida albicans in human illness. Orthomolecular 
Psychiatry, 10, 228-238. 
 
203. Ukhanova, M., Wang, X., Baer, D.J., Novotny, J.A., Fredborg, M., et al. (2014). 
Effects of almond and pistachio consumption on gut microbiota composition in a 
randomised cross-over human feeding study. The British Journal of Nutrition, 
111, 2146-2152.  
 
204. Underhill, D.M., Iliev, I.D. (2014). The mycobiota: interactions between commensal 
fungi and the host immune system. Nature Reviews Immunology, 14, 405-416. 
 
205. van der Velden, W.J., Netea, M.G., de Haan, A.F., Huls, G.A., Donnelly, J.P., et al. 
(2013). Role of the mycobiome in human acute graft-versus-host disease. Biology 
of Blood and Marrow Transplantation, 19, 329-332. 
 
206. van der Waaij, D. (1979). The colonization resistance of the digestive tract in man 
and animals. Zentralblatt für Bakteriologie, 7(Suppl. 7), 155-161. 
 
207. van Woerden, H.C., Gregory, C., Brown, R., Marchesi, J.R., Hoogendoorn, B., et al. 
(2013). Differences in fungi present in induced sputum samples from asthma 
patients and non-atopic controls: a community based case control study. BMC 
Infectious Diseases, 13, 69.  
 
208. von Rosenvinge, E.C., Song, Y., White, J.R., Maddox, C., Blanchard, T., et al. 
(2013). Immune status, antibiotic medication and pH are associated with changes 
in the stomach fluid microbiota. ISME Journal, 7, 1354-1366. 
 
209. Wagner, R.D., Pierson, C., Warner, T., Dohnalek, M., Hilty, M., et al. (2000). 
Probiotic effects of feeding heat-killed Lactobacillus acidophilus and 
Lactobacillus casei to Candida albicans-colonized immunodeficient mice. 
Journal of Food Protection, 63, 638-644. 
 
210. Walter, J., Ley, R. (2011). The human gut microbiome: ecology and recent 
evolutionary changes. Annual Review of Microbiology, 65, 411-429. 
 
211. Wang, Z.K., Yang, Y.S., Stefka, A.T., Sun, G., Peng, L.H. (2014). Review article: 
fungal microbiota and digestive diseases. Alimentary Pharmacology and 
Therapeutics, 39, 751-766. 
 
212. Weiler, F., Schmitt, M.J. (2003). Zygocin, a secreted antifungal toxin of the yeast 
Zygosaccharomyces bailii, and its effect on sensitive fungal cells. FEMS Yeast 
Research, 3, 69-76. 
 
  
61 
 
213. Wey, S.B., Mori, M., Pfaller, M.A., Woolson, R.F., Wenzel, R.P. (1989). Risk 
factors for hospital-acquired candidemia. A matched case-control study. Archives 
of Internal Medicine, 149, 2349-2353. 
 
214. Whitman, W.B., Coleman, D.C., Wiebe, W.J. (1998). Prokaryotes: the unseen 
majority. Proceedings of the National Academy of Sciences USA, 95, 6578-6583.  
 
215. Wilson, L.S., Reyes, C.M., Stolpman, M., Speckman, J., Allen, K., et al. (2002). The 
direct cost and incidence of systemic fungal infections. Value Health, 5, 26-34.  
 
216. Wisplinghoff, H., Bischoff, T., Tallent, S.M., Seifert, H., Wenzel, R.P., et al. (2004). 
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from 
a prospective nationwide surveillance study. Clinical Infectious Diseases, 39, 
309-317.  
 
217. Wisplinghoff, H., Seifert, H., Tallent, S.M., Bischoff, T., Wenzel, R.P., et al. (2003). 
Nosocomial bloodstream infections in pediatric patients in United States 
hospitals: epidemiology, clinical features and susceptibilities. Pediatric Infectious 
Disease Journal, 22, 686-691. 
 
218. Wollowski, I., Rechkemmer, G., Pool-Zobel, B.L. (2001). Protective role of 
probiotics and prebiotics in colon cancer. American Journal of Clinical Nutrition, 
73, 451s-455s.  
 
219. Woyke, T., Teeling, H., Ivanova, N.N., Huntemann, M., Richter, M., et al. (2006). 
Symbiotic insights through metagenomic analysis of a microbial consortium. 
Nature, 443, 950-955. 
 
220. Wu, G.D., Bushmanc, F.D., Lewis, J.D. (2013). Diet, the human gut microbiota, and 
IBD. Anaerobe, 24, 117-120. 
 
221. Xu, J., Gordon, J.I. (2003). Honor thy symbionts. Proceedings of the National 
Academy of Sciences USA, 100, 10452-10459. 
 
222. Zanello, G., Meurens, F., Berri, M., Salmon, H. (2009). Saccharomyces boulardii 
effects on gastrointestinal diseases. Current Issues in Molecular Biology, 11, 47-
58. 
223. Zaoutis, T.E., Prasad, P.A., Localio, A.R., Coffin, S.E. Bell, L.M., et al. (2010). Risk 
factors and predictors for candidemia in pediatric intensive care unit patients: 
implications for prevention. Clinical Infectious Diseases, 51, e38-e45. 
 
224. Zhang, T., Breitbart, M., Lee, W.H., Run, J.Q., Wei, C.L. et al. (2006). RNA viral 
community in human feces: prevalence of plant pathogenic viruses. PLoS 
Biology, 4, e3. 
 
  
62 
 
225. Zhang, H., DiBaise, J.K., Zuccolo, A., Kudrna, D., Braidotti, M., et al. (2009). 
Human gut microbiota in obesity and after gastric bypass. Proceedings of the 
National Academy of Sciences USA, 106, 2365-2370. 
 
226. Zivkovic, A.M., German, J.B., Lebrilla, C.B., Mills, D.A. (2011). Human milk 
glycobiome and its impact on the infant gastrointestinal microbiota. Proceedings 
of the National Academy of Sciences USA, 108(Suppl. 1), 4653-4658. 
  
227. Zwolińska-Wcisło, M., Brzozowski, T., Mach, T., Budak, A., Trojanowska, D., et 
al. (2006). Are probiotics effective in the treatment of fungal colonization of the 
gastrointestinal tract? Experimental and clinical studies. Journal of Physiology 
and Pharmacology, 57(Suppl. 9), 35-49. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
CHARACTERIZATION OF THE HUMAN GUT MYCOBIOME: VEGETARIAN 
DIET AS AN ILLUSTRATION  
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2.1 ABSTRACT 
 
The fungal inhabitants of the gastrointestinal tract have been previously 
overlooked in human microbiome studies. Here we present a survey of the fungal 
microbiota in 16 fecal samples from healthy humans with a vegetarian diet. Fungi were 
identified using molecular cloning and 454/Roche amplicon pyrosequencing of ITS gene 
tags; additionally, samples were queried with a Luminex xTAG analyte specific reagent 
(ASR) assay for fungal pathogens. Two fungal phyla were detected, with Ascomycota 
present in all samples and Basidiomycota present in 81% of samples. Both sequencing 
methodologies detected fungi in each fecal sample and in combination identified at least 
57 fungal OTUs. The number of OTUs in each sample ranged from 2-25. A total of 31 
fungal genera were found overall; 14 genera were present in only one sample and four 
genera were present in only two samples. Malassezia was the most abundant genus, 
followed by Aspergillus and Fusarium. Other abundant genera included Penicillium, 
Alternaria, and Candida. Commonly detected fungi such as Aspergillus and Penicillium, 
as well as known dietary fungi Agaricus bisporus and Ophiocordyceps sinensis, are 
presumed to be transient, allochthonous members due to their abundance in the 
environment or dietary associations. We also detected 17 fungal species not previously 
reported from the gut. It is apparent that a wide variety of fungi can be identified from the 
human gastrointestinal tract.  
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2.2 INTRODUCTION 
Over the last few decades, the composition and role of the bacterial gut 
microbiota in humans has been studied extensively. The bacterial microbiota play an 
integral part in the digestion of food, colonization resistance to invading pathogens, and 
development of the immune system [8, 14, 25]. Until recently, microbiome studies have 
failed to include eukaryotes in total community analyses, and eukaryotic diversity and 
function in the gut is poorly understood. However, fungi are consistently identified as the 
dominant human gut eukaryotes [44]. Knowledge of fungi in the gut opens a novel area 
of research, where the same questions once asked about the role of gut bacteria in health 
and disease are now being directed at the fungal microbiota (“mycobiota”). 
Fungi are ubiquitous in the environment, and it is not surprising that humans have 
co-evolved with fungi on many surfaces of the body [27]. Fungi are successful 
commensals and pathogens of humans, despite the relative paucity of specialized 
mammalian fungal pathogens [39]. Yeasts were first recognized to inhabit the 
gastrointestinal (GI) tract in the early 1800s [5, 30]. However, only recently have we 
started to appreciate and question their role. Cultivation studies show fungi to be 
detectable in all sections of the GI tract of 70% of healthy adults, while the abundance – 
10
6
 fungal cells per gram of feces – is orders of magnitude smaller than that of gut 
bacteria [4, 48, 49]. Alterations of the gut mycobiome have been associated with hepatitis 
B and inflammatory bowel disease and increased fungal colonization has been shown to 
impair mucosal barrier defense allowing translocation of gram-negative bacteria [7, 11, 
41]. Mycobiome research also represents an important field of study due to the increasing 
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number of invasive fungal infections in immunocompromised populations such as AIDS, 
cancer, and organ transplant patients [35].  
Culture-dependent methods used to characterize the intestinal mycobiome are 
unable to optimally cultivate organisms of low abundance or those that require microbe–
microbe interactions [3]; additionally, many gut microbes require a modified atmosphere 
for optimal growth. Thus, culture-independent methods, such as PCR-based cloning and 
high-throughput DNA sequencing of fungal rRNA and ITS genes have become the 
preferred method for mycobiome studies [12, 47]. No method has been unanimously used 
and difficulties in defining the complete mycobiome are attributed to low sample 
numbers, individual variation, limited attention, and a lack of consistent identification 
methods and gene targets. In addition, several recent intestinal fungi investigations 
described the diversity of the mycobiome based on a single fecal sample [18, 19, 22].  
Factors such as diet, genetics, and environment play an influential role in 
composition of the gut microbiota and help explain why differences in microbial 
communities exist between human hosts [36]. Few studies have attempted to explore the 
association between enteric fungi and diet [9, 23]. One previous study examining the 
association between diet and intestinal fungi showed fungal abundance of Candida spp. 
were positively correlated with recent consumption of a high carbohydrate diet, while 
Candida spp. were negatively associated with diets high in amino acids, fatty acids, and 
protein [23]. In an effort to deepen the understanding of dietary factors, we investigated 
the intestinal mycobiome of healthy adults with a vegetarian diet. 
It is evident that the present view of the intestinal mycobiome is incomplete. In 
this study, we used molecular cloning and high-throughput ITS gene pyrosequencing to 
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obtain a comprehensive survey of the human gastrointestinal mycobiome. We 
additionally used a commercially available assay using multiplex-PCR with labeled 
primers and subsequent sample hybridization to fluorescent microspheres (Luminex 
xTAG analyte specific reagents [ASRs], Luminex Corporation, Austin, TX). This assay 
was developed to target clinically relevant fungi [2], which include species of Candida 
and Aspergillus that may be detected in the gut. Here we provide preliminary 
characterization of the fungal communities in 16 fecal samples from the gastrointestinal 
tract of healthy adult humans with a vegetarian diet. Furthermore, we compare three 
culture-independent methods, and provide the first evaluation of Luminex fungal ASRs 
on fecal DNA from healthy humans. 
 
2.3 MATERIALS AND METHODS 
Collection of fecal samples 
The Institutional Review Board of the University of Nebraska approved all study 
protocols (IRB Approval Number: 20111112037EP). Written informed consent was 
obtained from all subjects to participate in this study. Fecal samples were obtained from 
15 healthy human adults (6 male, 9 female; one male subject provided two fecal samples 
two months apart, n=16). Study subjects were self-identified vegetarians (may or may not 
eat eggs and/or dairy; no meat, fish or poultry consumption) and the participant ages 
ranged from 19 to 48, with a mean of 23 and a median of 20. All participants were from 
the Midwestern United States. After collection, each fecal sample was immediately 
preserved at -80°C until the time of processing.  
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DNA isolation 
DNA was extracted using a modified method of the QIAamp® DNA stool mini 
kit (QIAGEN) [38]. Briefly, feces were thawed on ice, and approximately 200 mg of 
sample was diluted ten-fold in ice-cold phosphate buffered saline (PBS). Fecal 
homogenates were transferred into a 2-ml sterile bead-beating tube containing 300 mg of 
0.1-mm zirconium beads, and fungal cells were collected by centrifugation at room 
temperature at 8,000 x g for 5 minutes. The cell pellets were washed three times with ice-
cold PBS. The pellets were then resuspended in 100 μl lysis buffer (200 mM NaCl, 100 
mM Tris pH 8.0, 20 mM EDTA) containing 20 mg/ml of lysing enzymes and incubated 
at 37°C for 30 minutes. Using the kit reagents, 1.7 ml of Buffer ASL was added to each 
tube and vortexed until the stool sample was thoroughly homogenized. Mechanical cell 
lysis was performed by bead-beating each sample for two minutes at maximum speed 
(MiniBeadbeater-8, BioSpec Products, USA). Isolation and purification of DNA from 
fecal samples was continued following the manufacturer’s recommendations.  
  
PCR amplification 
PCR was performed using primers targeting the ITS1-5.8S-ITS2 region. Semi-
nested PCR was used to detect fungal DNA amongst the predominant non-fungal DNA 
present in fecal samples. The first round of amplification utilized the fungal-specific 
ITS1-F forward primer [15] and the universal eukaryotic reverse primer TW13 [54] (see 
Table 2.1 for primer sequences). Each PCR reaction mixture included 12.5 μl of REDTaq 
ready mix (Sigma-Aldrich, St. Louis, MO), 2 μl (10 μM) of each oligonucleotide primer, 
7.5 μl molecular biology-grade water, and 1 μl DNA template for a final volume of 25 μl. 
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PCR reactions were performed on an Eppendorf Mastercycler and cycling conditions 
were as follows: initial denaturation for 94°C for 4 min and 30 cycles at 94°C for 30 sec, 
52°C for 1 min, 72°C for 1.5 min, followed by a final extension step of 72°C for 10 min. 
After the initial reaction, a second reaction was performed using the primers ITS1-F and 
ITS4 [54] and 1 μl of the template DNA from the first reaction. PCR amplicons were 
separated using a 0.7% agarose gel in 1 x TAE buffer, stained with 0.5 μg/ml ethidium 
bromide and visualized. PCR products were confirmed with bands around 500-600 bp. 
Negative controls were used throughout the reactions to ensure contamination did not 
occur. 
Fusarium-specific PCR was performed with the following primer combinations: 
GOFW and GORV, which specifically amplify a 435 bp fragment from the galactose 
oxidase gene of F. graminearum [10] (see Table 2.1 for primer sequences); OPT18F470 
and OPT18R470, which specifically amplify a 470 bp fragment from F. culmorum [46]; 
and 3CON, 3D3A, 3D15A, and 3NA, used in a multiplexing reaction to specifically 
amplify 243, 610 and 840 fragments from the Tri3 gene in Fusarium producing 3-
acetyldeoxynivalenol, 15-acetyldeoxynivalenol, and nivalenol, respectively [50]. F. 
graminearum PH-1 was included as a positive control, and 25 μl reactions followed the 
protocols from the respective papers. Additionally, nested reactions were prepared using 
the same primers and protocols as above, with 1 μl of the initial PCR reaction as 
template, to account for the potentially low copy number in DNA extracted from fecal 
samples. 
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Table 2.1 PCR primers used in this study.  
Primer Sequence Reference 
ITS1-F 5’-CTTGGTCATTTAGAGGAAGTAA-3’ [15] 
TW13 5’-GGTCCGTGTTTCAAGACG-3’ [54] 
ITS4 5’-TCCTCCGCTTATTGATATGC-3’ [54] 
GOFW 5’-ACCTCTGTTGTTCTTCCAGACGG-3’ [10] 
GORV 5’-CTGGTCAGTATTAACCGTGTGTG-3’ [10] 
OPT18F470 5’-GATGCCAGACCAAGACGAAG-3’ [46] 
OPT18R470 5’-GATGCCAGACGCACTAAGAT-3’ [46] 
3CON 5’-TGGCAAAGACTGGTTCAC-3’ [50] 
3D3A 5’-CGCATTGGCTAACACATG-3’ [50] 
3D15A 5’-ACTGACCCAAGCTGCCATC-3’ [50] 
3NA 5’-GTGCACAGAATATACGAGC-3’ [50] 
 
Molecular cloning 
PCR products were purified using the Wizard Genomic DNA purification kit 
(Promega, Madison, WI). Purified products were ligated into pGEM
®
-T Easy vectors and 
transformed into JM109 High Efficiency Competent cells (Promega, Lyon, France) 
following the manufacturer’s instructions. Subsequently, 10 colonies negative for β-
galactosidase activity were chosen and sequenced by dideoxy (Sanger) sequencing at 
Michigan State University’s Research Technology Support Facility (East Lansing, MI). 
Samples were identified by sequence homology using nucleotide BLAST against the 
UNITE curated fungal ITS sequence database [29] and the curated FUNCBS database, as 
accessed through the Centraalbureau voor Schimmelcultures 
(www.cbs.knaw.nl/Collections/BioloMICSSequences.aspx?file=all; accessed July 2014). 
Sequences have been deposited in GenBank as accession # KP196567-KP196602. 
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Pyrosequencing of the fungal ITS genes  
Extracted DNA from fecal samples was selectively amplified by PCR using 
primers targeting the ITS1-5.8S-ITS2 genes. PCR reaction mixtures consisted of 25 μl 
REDTaq ready mix (Sigma-Aldrich, St. Louis, MO), 4 μl ITS1-F (10 pmol), 4 μl TW13 
(10 pmol), 15 μl molecular biology-grade water, and 2 μl DNA template. PCR was 
performed on an Eppendorf Mastercycler using the following conditions: 95°C for 15 
min and 30 cycles of 94°C for 30 sec, 52°C for 30 sec and 72°C for 1 min, followed by a 
final elongation for 72°C for 10 min. PCR products were purified using the Wizard SV 
Gel and PCR Clean-up Kit (Promega, Madison, WI). Following cleanup, amplicon 
products from all samples were mixed in equal concentrations and purified using 
Agencourt Ampure beads (Agencourt Bioscience Corp., MA, USA). Samples were 
sequenced at MR DNA (Shallowater, TX) using tag-encoded FLX amplicon 
pyrosequencing on 454/Roche GS FLX Sequencer technology [13, 51]. Data processing 
and analysis followed Hume and colleagues [26]. Rarefaction analysis based on observed 
OTU metrics was performed to assess community coverage using QIIME (v. 1.8.0) [6] 
with default settings. Alpha diversity of the samples was measured based on Simpson and 
Shannon’s coefficients in QIIME [6]. One sample with null diversity (only one OTU 
detected) was removed from analysis. Raw sequences have been deposited in GenBank 
under BioProject PRNJA268649. 
 
Luminex Fungal xTAG ASR Assay 
A multiplex xTAG fungal analyte-specific reagent (ASR) assay consisting of 23 
ASRs developed by Luminex Molecular Diagnostics was used for the simultaneous 
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detection and identification of multiple fungal pathogens in the fecal samples.  The 
following ASRs were used: xTAG Aspergillus flavus, xTAG Aspergillus fumigatus, 
xTAG Aspergillus niger, xTAG Aspergillus terreus, xTAG Blastomyces dermatitidis, 
xTAG Candida albicans, xTAG Candida glabrata, xTAG Candida guilliermondii, 
xTAG Candida krusei, xTAG Candida lusitaniae, xTAG Candida parapsilosis, xTAG 
Candida tropicalis, xTAG Coccidioides immitis, xTAG Cryptococcus neoformans, 
xTAG Fusarium, xTAG Histoplasma capsulatum, xTAG Mucor indicus, xTAG 
Pneumocystis jirovecii, xTAG Rhizopus microsporus, xTAG Rhizopus arrhizus, xTAG 
Scedosporium apiospermum, xTAG Scedosporium prolificans, and xTAG Tremella. 
Multiplex PCR, bead hybridization, and detection were performed on DNA extracted 
from fecal samples above following the protocol of Babady and colleagues [2]. The 
samples were analyzed on the Luminex MAGPIX system (Luminex Corp., Austin, TX) 
and median fluorescence intensity (MFI) values were calculated by the xPONENT 4.2 
software. A threshold value of 225 MFI was set for positive targets, values below 200 
MFI were negative, and 200-224 MFI were equivocal.   
 
2.4 RESULTS 
Sequencing methods 
The gut mycobiota of 16 fecal samples from humans with a vegetarian diet was 
characterized using molecular cloning and 454/Roche amplicon pyrosequencing. Each 
method was able to identify fungi in the samples provided after amplification of the 
fungal ITS genes. The gut mycobiota was first identified using a traditional Sanger 
sequencing-based method via molecular cloning and secondly by 454/Roche 
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pyrosequencing of the ITS1-ITS2 genes. After removing singletons from pyrosequencing 
data, which account for a major source of biases [52], the total number of sequences 
obtained from 16 samples was 186,495 (mean 11,656; median 7,802). The predominant 
fungal taxa identified differed for the two methods. Molecular cloning identified 
Aspergillus as the most abundant genus and 454 pyrosequencing identified Fusarium, 
Malassezia, and Penicillium as the most abundant genera. Pyrosequencing identified 41 
fungal operational taxonomic units (OTUs) that cloning failed to detect. In contrast, 
Leptosphaerulina chartarum was only detected by molecular cloning.  
 
Identification of fungi in fecal samples 
Combining both sequencing methods, two fungal phyla were observed in the 
samples: Ascomycota and Basidiomycota. Ascomycetes were present in all 16 samples 
and basidiomycetes were found in 13 samples. A total of 31 fungal genera were detected 
(mean 7; median 7; range 2-14 per sample). Fourteen genera were present in only one 
sample and four genera were present in only two samples. Malassezia was the most 
commonly detected genus, in 81% of samples (Figure 2.1). Aspergillus and Fusarium 
were the second most commonly detected genera, present in 75% of samples, followed 
by Penicillium (69%), Alternaria (56%), and Candida (50%). Other fungal genera found 
in 25% or more of samples included Agaricus, Cladosporium, and Debaryomyces.  
At the lowest discernible taxonomic level, pyrosequencing and molecular cloning 
identified at least 57 fungal operational taxonomic units (OTUs). The number of OTUs in 
an individual sample ranged from 2-25 (mean 12; median 10.5). Twenty-seven fungal 
OTUs were present in only one sample and 6 OTUs were present in only two samples. 
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The most abundant OTUs included: Malassezia restricta (81%), Fusarium cf. 
graminearum (75%), Aspergillus cf. niger (69%), Penicillium cf. roqueforti (69%), 
Penicillium cf. commune (63%), Alternaria spp. (56%), and Debaryomyces hansenii 
(44%). Other ascomycetes identified included Aspergillus cf. oryzae, Candida albicans, 
Candida tropicalis, Galactomyces sp., Ophiocordyceps sinensis, and Saccharomyces 
cerevisiae. Across all the samples analyzed, no species were common to all individuals. 
The overall distribution of fungi in 16 fecal samples obtained from healthy human 
vegetarians by 454 pyrosequencing is shown in Figure 2.2. Alpha diversity of the fungal 
fecal community was measured with Shannon’s (1.70 +/- 0.86) and Simpson’s (0.53 +/- 
0.25) indices (Figure 2.3). Both indices revealed substantial variation in community 
diversity within individuals, as in some subjects only one fungal OTU was detected (null 
diversity), whereas in others up to 24 distinct OTUs were detected by pyrosequencing. 
Rarefaction analysis revealed that for the majority of samples community coverage 
reached saturation (Figure 2.4). For 75% of the samples, 600 sequences per sample 
covered the fungal diversity of the gastrointestinal tract in humans. 
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Figure 2.1 Detection frequency of fungal genera in 16 fecal samples using molecular 
cloning and 454 pyrosequencing. Only genera present in greater than ten percent of 
samples are shown. Phylum affiliation for each genus is indicated: Ascomycota (orange), 
Basidiomycota (blue). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Overall distribution of gut fungi. Fungi in more than fifteen percent of fecal 
samples from healthy individuals with a vegetarian diet obtained by 454 pyrosequencing 
are shown. 
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Figure 2.3 Alpha diversity of the fungal fecal community. A) Shannon’s diversity 
index, and B) Simpson’s diversity index. 
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Figure 2.4 Rarefaction analysis of ITS pyrosequencing tags in fecal samples from 
adults with a vegetarian diet, showing saturation at approximately 600 sequences. 
 
Fusarium PCR 
 One or more Fusarium species affiliated with F. graminearum was detected in 
many samples. Our lab does ongoing research with Fusarium graminearum Michigan 
field isolate PH-1 (FGSC 9075, NRRL 31084). To determine whether the Fusarium 
detected in the samples was due to lab contamination, several Fusarium-specific PCR 
reactions were performed. Galactose oxidase PCR amplifies a 435 bp fragment of F. 
graminearum while not amplifying related species [10], while the randomly-selected 
OPT18 primers specifically amplify a 470 bp fragment from F. culmorum [46]. Only one 
of the study samples yielded PCR results consistent with strain PH-1, though multiple 
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bands of other sizes amplified (Figure 2.5), suggesting 1) the presence of Fusarium other 
than F. graminearum; 2) that the high level of Fusarium detected by all detection 
methods was not due to contamination with the lab organism; and 3) amplification of 
non-Fusarium species (also present in the DNA) by the PCR primers.  
 
Fungal xTAG ASR Assay 
 A commercially available fungal ASR panel allows for the detection of 23 species 
of fungi: 22 human pathogens and Tremella, which is included as an internal control. Six 
of the fungi detected by the sequencing methods have ASRs available: Aspergillus flavus, 
A. fumigatus, A. niger, Candida albicans, C. tropicalis, and Fusarium. The ASR assay 
detected Fusarium in 10 samples, C. albicans in three, and C. tropicalis in two (Table 
2.2). Despite Aspergillus species being detected in 10 samples by pyrosequencing and 
cloning, the ASR assay only detected A. flavus (= A. oryzae) in a single sample. While we 
performed all 23 ASRs on all samples, the ASR assay did not detect any species that had 
not also been detected by sequencing. 
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Figure 2.5 A) Galactose oxidase and B) Tri3 PCR products from DNA samples 
identified as containing Fusarium. 1KB+: 1 KB Plus ladder (Invitrogen), PH1: 
Fusarium graminearum strain PH-1 (NRRL 31084). The galactose oxidase primers yield 
a product of 435 bp for Fusarium graminearum, present in PH1 and study samples M5 
and (possibly) F3. The multiplexing Tri3 primers yield bands of 243, 610 and 840 bp for 
3-acetyldeoxynivalenol, 15-acetyldeoxynivalenol, and nivalenol, chemotypes, 
respectively. A band of the appropriate size for 15-acetyldeoxynivalenol is present in 
PH1, M5 and F3; other bands are visible, but do not correspond with validated 
trichothecene mycotoxin chemotypes. Clear differences are visible between PH1 and 
study samples. 
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 Table 2.2 Fungi detected in fecal samples from healthy adult vegetarians, by 454 pyrosequencing, cloning, and Luminex ASR 
assays. 
 
OTU M1 M2 M3a M3b M4 M5 M6 F1 F2 F3 F4 F5 F6 F7 F8 F9 
Agaricus bisporus 3781 0 438 12 0 15 0 0 0 0 0 0 0 0 0 0 
Alternaria spp. 704 0 12800 1413 54 1008 0 34497 0 7761 0 0 0 5 0 2433 
Ascocoryne cylichnium 0 0 0 0 0 0 0 0 1340 0 0 0 0 0 0 0 
Ascocoryne sarcoides 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 
Ascomycota sp. 4 2 0 0 0 0 0 0 3 0 0 0 0 0 0 0 
Aspergillus fumigatus 0 548 0 0 74 0 0 0 396 0 0 0 0 0 0 0 
Aspergillus cf. niger 0 0 506 33 0 10862 0 0 0 39 5290 0 0 0 10226 0 
Aspergillus cf. oryzae 0 0 0 0 0 0 0 0 0 590 211 0 0 1373 0 0 
Aspergillus spp. 0 8 4 0 0 74 0 0 0 0 29 0 0 0 240 0 
Candida albicans 2 2197 0 5 0 0 0 0 0 0 0 0 18933 0 371 0 
Candida sp. 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 
Candida tropicalis 562 0 0 292 0 0 5 0 0 0 284 181 2 0 0 0 
Capnodiales sp. 0 0 0 18 0 0 0 0 0 37 0 0 0 0 0 0 
Cladosporium spp. 0 0 0 436 0 0 0 0 0 802 0 0 184 0 0 0 
Cryptococcus amylolyticus 0 0 0 1336 0 0 0 0 0 0 0 0 0 0 0 0 
Cryptococcus tephrensis 0 0 0 0 0 0 0 0 0 1551 0 0 0 0 0 0 
Cyberlindnera jadinii 0 14 0 0 0 0 0 279 0 6 0 0 0 0 0 0 
Debaryomyces hansenii 0 196 0 111 0 0 0 0 0 0 0 0 37 0 2 70 
Diplodia mutila 0 0 0 0 0 295 0 0 0 0 0 0 0 0 0 0 
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 Table 2.2 Continued. 
 
OTU M1 M2 M3a M3b M4 M5 M6 F1 F2 F3 F4 F5 F6 F7 F8 F9 
Epicoccum nigrum 0 0 0 216 0 0 0 0 0 0 0 0 0 0 0 0 
Eurotium niveoglaucum 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 
Eurotium rubrum 0 0 0 0 0 0 0 0 2475 0 0 0 0 0 0 0 
Eurotium sp. 0 0 0 0 0 0 0 0 0 0 890 0 0 0 257 0 
Exophiala heteromorpha 0 0 0 246 0 0 0 0 0 0 0 0 0 0 0 0 
Fusarium cf. graminearum 47 264 0 170 455 710 0 0 890 0 868 883 1026 2513 18 0 
Galactomyces sp. 0 0 2208 0 0 0 0 0 0 0 0 0 0 0 0 0 
Lecythophora spp. 576 0 0 0 250 0 0 0 0 0 0 0 0 0 0 0 
Leptosphaerulina chartarum 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Malassezia globosa 0 0 0 0 11 0 0 0 0 0 0 0 0 0 0 0 
Malassezia pachydermatis 0 0 0 0 0 14 0 0 0 0 0 0 0 0 0 0 
Malassezia restricta 13 179 0 0 8 73 0 671 120 422 30 0 195 2 0 0 
Malassezia slooffiae 0 0 0 171 0 0 0 0 0 0 0 0 0 0 0 0 
Malassezia sp. 5 89 0 0 11 10 0 0 73 345 0 0 0 5 0 0 
Malassezia sympodialis 0 0 0 0 0 450 0 0 0 0 0 0 0 0 0 0 
Mrakia sp. 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 
Mycosphaerellaceae sp. 0 0 0 2 0 0 0 0 0 4 0 0 0 0 0 0 
Neosartorya fischeri 0 4 0 0 6 0 0 0 3 0 0 0 0 0 0 0 
Ophiocordyceps sinensis 0 0 0 0 0 0 0 0 120 0 40 0 0 0 0 0 
Penicillium cf. commune 582 22 0 187 210 0 0 627 4 1398 9 60 4 0 0 0 
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 Table 2.2 Continued. 
 
OTU M1 M2 M3a M3b M4 M5 M6 F1 F2 F3 F4 F5 F6 F7 F8 F9 
Penicillium cf. roqueforti 136 445 0 75 74 0 0 56 802 656 42 39 161 0 0 64 
Penicillium spp. 12 0 0 4 7 0 0 628 2 34 14 0 2 0 0 0 
Penicillium turbatum 0 0 0 0 0 0 0 6 0 0 0 0 0 0 0 0 
Phialocephala lagerbergii 0 0 0 6 0 0 0 0 0 0 0 0 0 0 0 0 
Pholiota sp. 0 0 0 0 0 0 0 0 0 0 36 0 0 0 0 0 
Pichia kudriavzevii 0 0 0 0 0 0 0 22692 0 0 0 0 0 0 0 0 
Pleosporales sp. 6 0 0 9 0 0 0 0 4 73 0 0 0 0 0 3 
Rhodotorula sp. 332 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Saccharomycetales sp. 0 1729 0 8 0 0 0 0 0 0 0 0 0 0 119 2 
Saccharomyces cerevisiae 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Sphaerotheca fusca 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 
Torulaspora sp. 0 0 0 13 0 0 0 0 0 0 0 0 0 0 0 0 
Trichocomaceae spp. 0 0 0 0 0 0 0 0 18 5 0 0 0 0 0 0 
Trichoderma longibrachiatum 0 0 0 0 0 0 0 0 0 0 20 0 0 0 0 0 
Unclassified "Fungus A" 10 0 0 24 0 0 0 0 0 89 0 0 0 0 0 27 
Unclassified "Fungus C" 134 1558 0 308 510 0 0 0 1590 2015 0 1161 0 4438 4 84 
Unclassified "Fungus D" 61 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Wallemia muriae 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 0 
Sum from 454 6970 7255 15956 5099 1670 13518 5 59456 7844 15830 7763 2324 20546 8336 11237 2683 
Numbers = number of 454 sequences. Clones are indicated by a box around the corresponding cell. ASR data is color-coded: green for 
present, red for absent, and yellow for equivocal.
  
83 
 
Temporal analysis of fungal diversity 
The subject who provided fecal samples at two different time points showed little 
similarity and stability over time (Figure 2.2; M3a & M3b). The fecal sample from the 
first time point yielded 15,959 hits from five OTUs and the second fecal sample yielded 
5,099 hits from 24 OTUs. Only three OTUs were common between both time points 
(Agaricus bisporus, Alternaria spp., and Aspergillus cf. niger). Four genera were detected 
in the first time point and 14 genera were detected in the second time point. 
 
2.5 DISCUSSION 
The gut mycobiome of adult vegetarians 
We have demonstrated that the composition of the human gut microbiome is 
diverse among healthy adult humans with a vegetarian diet, identifying a total of at least 
57 different OTUs from two fungal phyla, with a mean of approximately 12 OTUs per 
subject. On average, the vegetarian gut mycobiome does not appear diminished in 
diversity compared to the mycobiome of healthy individuals on a conventional diet and is 
more diverse compared to the mycobiome of an individual with anorexia nervosa [18, 
23]. This study shows that the detectable fungal diversity is not limited to only a few 
fungal genera or species; however, it may be argued that use of the term “mycobiome” 
for all of these species is misleading, as a majority are allochthonous. In addition, we 
have also discovered fungal species previously undescribed in the human gut (Table 2.3). 
Here we report the most commonly detected gut fungus among vegetarians to be 
M. restricta. Other gut fungi studies detect M. restricta and Malassezia species in the gut 
[19, 22]. There is considerable variation among human gut fungal culture-independent 
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studies regarding which fungal species is the most dominant. Gloeotinia/Paecilomyces, 
Galactomyces, Candida, Saccharomyces, and Penicillium have all been documented as 
the most abundant fungi in the GI tract of the studied cohort [7, 23, 33, 41, 45]. 
Abundance discrepancies among studies may be due to differences in in the individuals’ 
diet, environment, host genetics, age, gender, ethnicity, health status or ultimately the 
chosen methodology for detection.
  
8
5
 
 Table 2.3 Unique fungal species from the gastrointestinal tract of vegetarians not previously detected in human gut 
mycobiome studies. 
 
Phylum Class Order Taxa Ecological Niche 
Ascomycota Pezizomycotina Botryosphaeriales Diplodia mutila Causes tree branch cankers; pathogen of apples, pears, grapes 
  
Chaetothyriales Exophiala heteromorpha Environmental fungus; causes phaeohyphomycosis infections 
  
Erysiphales Sphaerotheca fusca  Powdery mildew fungus 
  
Eurotiales Eurotium niveoglaucum Widespread environmental osmophile 
   
Penicillium turbatum Rotten wood 
  
Helotiales Ascocoryne cylichnium Saprobic fungus of hardwoods and conifers 
   
Ascocoryne sarcoides Saprobic jelly fungus 
   
Phialocephala lagerbergii Wood-inhabiting fungus 
  
Hypocreales Ophiocordyceps sinensis Caterpillar fungus; used as herbal supplement  
   
Trichoderma longibrachiatum Common house mold; causes allergic fungal sinusitis 
  
Pleosporales Epicoccum nigrum Common in environment; plant pathogen cereals and nuts, spoilage 
   
Leptosphaerulina chartarum Leaf blight; high-level xylanolytic enzyme production 
  
Sordariales Lecythophora sp.  Dematiaceous mold; isolated from soil and from plant debris 
 
Saccharomycotina Saccharomycetales Pichia kudriavzevii Spoilage yeast; found in soil, fruits; surface biofilms 
Basidiomycota Agaricomycotina Agaricales Pholiota sp.  Wood-rotting saprobic mushroom 
  
Tremellales Cryptococcus amylolyticus Soil organism 
  Ustilaginomycotina Malasseziales Malassezia slooffiae Human skin commensal-external ear canal; dermatitis in goats 
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A previous study in our lab, employing the same DNA extraction, amplification, 
and 454 pyrosequencing methods on fecal samples from adults approximately from the 
same geographical location (upper Midwest) on a conventional diet, identified C. 
tropicalis as the most abundant gut fungus, present in 57% of 69 samples, followed by 
Galactomyces in 49%. [21]. Malassezia, Aspergillus, Fusarium, and Penicillium species 
were identified, but from a much smaller proportion of samples than in this study; 
conversely, only one vegetarian sample contained Galactomyces. Candida tropicalis was 
detected in 25% of the vegetarian samples, and the genus Candida in 50%. 
The relationship between diet and the gut mycobiome remains poorly understood. 
Bacterial microbiome studies have shown that the microbiota of an individual with a 
vegetarian diet is substantially different and shifted in composition in comparison with a 
conventional diet [28, 55]. This suggests that fungal abundance may also be a reflection 
of diet and shifts towards certain populations may occur depending on the chosen dietary 
habits of the individual. Further research is necessary to determine how diet can induce 
significant compositional changes in the gut microbiota. 
 
Identification of fungi using ITS 
The internal transcribed spacers between the nuclear ribosomal RNA genes have 
rightly been selected as fungal barcoding sequences, due to their ease of amplification, 
multicopy nature, and extreme sequence divergence allowing for species-level 
identification in a majority of cases [47]. However, fungal identification is only as good 
as the available databases, and not all species have been sequenced. Additionally, some 
species are so closely related that ITS cannot accurately distinguish between them. In this 
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study, indistinguishable species include Alternaria alternata/A. arborescens/A. 
brassicicola/A. citri/A. mali/A. tenuissima, Aspergillus flavus/A. oryzae, Aspergillus 
niger/A. carbonarius/A. foetidus/A. tubingensis, Cladosporium cladosporioides/C. 
bruhnei/C. colocasiae/C. herbarum/C. macrocarpum/C. oxysporum/C. 
pseudocladosporioides/C. sphaerospermum/C. tenuissimum, Fusarium graminearum/F. 
culmorum/F. asiaticum; Penicillium camemberti/P. allii/P. aurantiogriseum/P. 
chrysogenum/P. commune/P. dipodomyicola/P. freii/P. glandicola/P. italicum/P. solitum, 
and P. roqueforti/P. carneum/P. paneum. We refer to these as Aspergillus cf. niger, 
Fusarium cf. graminearum, etc.; it should be understood that these are not precise species 
identifications. 
 
OTUs of interest 
Among the ascomycetes, members of the genus Aspergillus were commonly 
detected among the samples. Aspergillus species play important roles in industry, the 
environment, and human health. Aspergillus cf. oryzae, found in three samples, 
encompasses A. oryzae, used in soy fermentations, and its wild progenitor, the toxigenic 
A. flavus. Aspergillus fumigatus, detected in three samples, is one of the most ubiquitous 
airborne fungi, and humans will inhale hundreds of Aspergillus conidia per day [17, 24]. 
Consequently, A. fumigatus has become the leading cause of aspergillosis and causes 
fatal invasive infections, resulting in death in 50% of all cases [32]. In addition, our study 
showed 11 samples of Aspergillus cf. niger. A. niger and related species are capable of 
causing human pulmonary infections and contaminating a wide range of food 
commodities [39, 42, 43].  
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Penicillium species were also commonly detected in the GI tract of our study 
cohort. Penicillium is a large, diverse genus of fungi capable of growing in almost any 
environment [43]. Penicillium species are among the main causes of food spoilage 
because of their psychotropic characteristic, allowing them to tolerate refrigeration 
temperatures. Many Penicillium species detected in this study might be a result of 
consuming contaminated foods. In addition, P. camemberti and P. roqueforti are widely 
used in the production of mold-ripened cheeses. 
The frequency of Candida species detected in this study was 50%. Candida 
species, including C. albicans and C. tropicalis, are commensals of the gastrointestinal, 
reproductive, and respiratory tracts and skin. Candida species are of substantial clinical 
significance because of their ability to become opportunistic pathogens responsible for a 
spectrum of diseases, ranging from mucosal, cutaneous, invasive infections when host 
resistance is decreased [27]. Candida species are considered to be the most widely 
distributed and dominant fungi in the human gut mycobiome. In healthy individuals, 
carriage of Candida albicans is estimated to be 30-60% [40].  
Five species of Malassezia were identified from the gut of our cohort: M. globosa, 
M. pachydermatis, M. restricta, M. slooffiae, and M. sympodialis. Malassezia species are 
lipophilic yeasts found naturally on the skin and are associated with a number of skin 
diseases and dandruff [20]. Malassezia has been commonly detected in fecal samples [7, 
18, 22, 33], however, here we report for the first time detection of M. slooffiae. The 
detection of Malassezia species across gut mycobiome studies may suggest a role for its 
presence in the gut due to the favorable lipid-rich environment provided by the host’s 
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diet. Thus, more research is needed to determine if Malassezia species are true gut 
commensals or merely contaminants.  
The introduction of unequivocal food-associated fungi, including dietary 
mushrooms, is not uncommon in the human distal gut [9, 12]. The basidiomycete, 
Agaricus bisporus (white button mushroom, portabello, crimini) was detected in four 
subjects. A. bisporus is the most commonly cultivated edible mushroom worldwide [31] 
and the most widely consumed mushroom in Western countries; its detection in feces is 
almost certainly due to consumption. The yeasts Saccharomyces cerevisiae and 
Debaryomyces hansenii, are used in the production of fermented foods. Ophiocordyceps, 
detected in two individuals, is used as a dietary herbal supplement for a variety of 
therapeutic practices. 
Other fungi detected in this study, such as Epicoccum nigrum, Diplodia mutila, 
Alternaria spp., Podosphaera xanthii, and Fusarium cf. graminearum, are known plant 
pathogens. These fungi may be present in the intestinal tract due to the consumption of 
contaminated foods or consumables requiring the use of fungi for production. Fungi for 
which this study provides the first report in the human gut are shown in Table 2.3, 
together with probable sources. 
 
Transient nature of intestinal fungi  
Our results demonstrate that many fungi present in the gut are of allochthonous 
origin due to their known presence in the environment or foodstuffs. We cannot conclude 
that all of the fungi reported in this study are autochthonous organisms and will remain in 
the gut over time; indeed, the ecology (when known) of the organisms (Table 2.3) 
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suggests a plausible environmental source for most, while several grow poorly if at all at 
human body temperatures. Bacterial gut microbiome studies show bacteria to be 
temporally stable over time [36, 53]. One study documented the transient nature of 
foodborne fungal microbes in the distal gut by sequencing the ITS genes from food and 
fecal samples [9]. A previous study of the micro-eukaryotic diversity in the gut 
demonstrated a temporally stable fungal gut community using a fungal internal 
transcribed spacer-based analysis [45]; conversely, Hallen-Adams et al. [21] observed 
high variability and low persistence of gut fungi from 24 individuals’ samples at two time 
points. The subject in the current study who was sampled at two different time points 
showed little similarity over time. The paucity of data from multiple study subjects limits 
the ability to draw broad conclusions of fungal stability in the gut over time.  
 
Comparison of methods 
Fungi are increasingly being recognized as an important component of the gut 
microbiota. Over the last two decades, cloning and Sanger sequencing have been the 
foundation for microbial sequencing [16]. 454 pyrosequencing represents a method for 
rapidly characterizing microbial communities in a high-throughput, efficient, relatively 
rapid and cost-effective manner [37]. In the current study, we used a combination of two 
different sequencing methods to identify the fungal composition in the gut of humans 
with a vegetarian diet. In some instances one method and not the other detected fungal 
sequences. 454 pyrosequencing identified 41 OTUs that cloning failed to detect. That 
pyrosequencing should detect more OTUs than cloning was not unanticipated; 
pyrosequencing generated several thousands of sequences per sample, while 10 clones 
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from each cloning reaction were selected for further analysis, and only those with distinct 
restriction patterns were sequenced. Tedersoo et al. [52] reported that by combining 
Sanger sequencing and 454 pyrosequencing they were able to identify 141 species of 
ectomycorrhizal fungi in root samples. Approximately 66% of them were common 
between the two methodologies, and they concluded considerable methodology biases 
towards certain lineages existed. These two methods, especially when used in 
conjunction with one another, represent potentially useful methods to characterize the 
mycobiome due to the low abundance and diversity of gut fungi. 
Of more interest is the correlation between the two methods; 55% of the OTUs 
identified by cloning were the same OTUs identified by pyrosequencing, and in 25% of 
the samples, the OTUs pyrosequencing identified as highest abundance (Figure 2.2, Table 
2.2) were present in the clone sequences. Several species detected by cloning were not 
among the tops hits identified by pyrosequencing in their respective sample. For example, 
cloning was able to identify Cyberlindnera jadinii in a sample that only had six 
pyrosequencing hits. Cloning was able to identify six OTUs that had less than 20 hits in 
pyrosequencing, while 16 OTUs identified by cloning never appeared in the 
pyrosequencing data of that sample.  
Of the six taxa found in our samples for which ASRs were available, the ASRs 
showed the highest detection of Fusarium (10 samples), which also represented the most 
commonly detected OTU in the pyrosequencing (11 samples) data. In 3 samples 
Fusarium was detected by all three methods; in 5 samples by ASRs and pyrosequencing; 
in 3 samples by cloning and pyrosequencing; and in 1 sample by cloning alone. In 1 
sample, C. albicans was detected by all three methods, in 2 samples by ASRs alone, and 
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in 2 samples by pyrosequencing alone. The ASR assay detected C. tropicalis from 2 out 
of 4 samples in which it was detected by pyrosequencing. 
The Aspergillus fumigatus and A. niger ASRs failed to detect anything, despite 
high representation of these OTUs in the sequencing data (3 samples with A. fumigatus 
and 6 with A. cf. niger by pyrosequencing, and 10 samples with A. cf. niger clones). As 
our A. cf. niger is imperfectly identified, it is possible that this ASR shows high fidelity 
to A. niger sensu stricto, and is not detecting the OTU(s) in our samples. Babady and 
colleagues [2], evaluating the ASR assay on clinical samples, report that certain isolates 
they had identified as A. niger were not detected by the A. niger ASR and were 
subsequently determined to be A. tubingensis; additionally, Babady and colleagues [2] 
report suboptimal detection of A. fumigatus and A. flavus. 
All methods discussed are limited by dependence on PCR during sample 
preparation, the results of which are influenced by primer choice and template 
characteristics as well as initial template abundance [52]. A serious limitation in 
microbiome studies in general is the difficulty in obtaining reliable measures of OTU 
abundance within sample, let alone making between-sample comparisons. It is tempting 
to conclude that a higher number of 454 sequences or clones, or higher median 
fluorescence in the case of ASRs, equates to greater abundance, but in truth the pool may 
be influenced by PCR biases; the limitations of each technology; and the multicopy 
nature of the nuclear ribosomal region, which differs substantially in copy number 
between organisms (180 copies in the sequenced strain of Fusarium graminearum vs. 55 
copies in Candida albicans; Liti and colleagues [34] report copy numbers ranging from 
54-511 in different strains of Saccharomyces cerevisiae). Amend, Seifert and Bruns [1] 
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report a tenfold difference in 454 read counts between species from samples prepared 
with the same spore counts of each species, and conclude that while read abundance may 
be quantitative within species, between-species comparisons are unreliable. We are not 
confident that any method used in this study provides quantitative data; however, alone 
and in combination, a snapshot of gut fungal diversity is produced. 
 In conclusion, the human gut mycobiome is diverse and dynamic. Many fungi are 
allochthonous due to the high level of exposure to environment or food-associated fungi. 
One must be cautious in drawing conclusions about the role of fungi, as a majority are 
“passing through,” and their contribution to the gut ecology is likely to be minimal. The 
different methodologies displayed differing strengths, weaknesses and biases: notably, 
the ASR assay is limited to detecting species for which there are primers, cloning is 
limited by the number of clones selected for sequencing, and all three methods are 
subject to PCR biases. As gut mycologists continue to expand gut mycobiome studies we 
will begin to understand their beneficial and/or detrimental roles in human health. 
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EPIDEMIOLOGICAL INVESTIGATION OF CANDIDA SPECIES CAUSING 
BLOODSTREAM INFECTION IN PEDIATRIC SMALL BOWEL TRANSPLANT 
RECIPIENTS  
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3.1 ABSTRACT 
Small bowel transplantation (SBT) is a life-saving medical procedure for patients 
with short bowel syndrome; however, these patients remain at high risk for bloodstream 
infections. Gastrointestinal carriage and exogenous acquisition of Candida are potential 
sources of infection. This research aims to characterize the SBT recipient gut microbiota 
over time following transplant and investigate the epidemiology of candidemia in seven 
pediatric SBT recipients at the University of Nebraska Medical Center. Candida species 
from the recipient ileum and bloodstream were identified by ITS sequence and identified 
to strain by multilocus sequence typing and randomly amplified polymorphic DNA. 
Twenty-one ileostomy samples harbored at least one Candida species (C. albicans, C. 
glabrata, C. lusitaniae, C. parapsilosis, C. tropicalis). Bloodstream infections were 
caused by C. parapsilosis (3), C. albicans (2), C. glabrata (1), C. orthopsilosis (1), and 
Wickerhamomyces anomalus (1). Two transplant patients were confirmed to harbor the 
same strain of Candida in the ileum and bloodstream while a third patient had distinct 
ileal and bloodstream Candida strains. Results are congruent with at least two infections 
arising from the recipient GI tract (C. albicans, C. glabrata) and one infection arising 
from Candida other than that colonizing the recipient GI tract (C. parapsilosis). Results 
also suggest two patients were infected by the same strain of C. parapsilosis. Antifungal 
susceptibility testing revealed that all isolates, with the exception of three, showed 
susceptibility to all the antifungals tested. One C. glabrata isolate showed multidrug 
resistance to itraconazole, amphotericin B, and posaconazole and was classified as 
susceptible dose-dependent to fluconazole and voriconazole. 
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3.2 INTRODUCTION 
 Short bowel syndrome (SBS) is a fatal gastrointestinal disorder characterized by 
the inability to absorb enough nutrients and fluids to sustain life [86]. The most common 
cause of pediatric SBS is extensive loss of the small bowel due to congenital birth defects 
(e.g. midgut volvulus, gastroschisis, intestinal atresia) or surgical removal to treat 
intestinal diseases (e.g. necrotizing enterocolitis). Pediatric SBS is defined as the loss of 
≥70% of small intestinal length (either congenital or acquired), equating to no more than 
75 cm of the small intestine remaining in a full-term neonate [69]. One population-based 
estimate of neonatal SBS reports 24.5 cases per 100,000 live births [91] and mortality 
rates of SBS are consistently reported at 20-40% [78, 85, 91].  
Despite high mortality rates, major advances have been made to increase the 
lifespan of those suffering from SBS. Introduction of parenteral nutrition (PN) is 
important for survival and has transformed the management of pediatric SBS [75]. PN 
bypasses gastric digestion and provides a complete source of nutrients, vitamins, and 
electrolytes intravenously. PN support allows time for intestinal adaptation of the residual 
bowel to occur [66]. However, the process of intestinal adaptation is unpredictable and 
pediatric patients receiving long-term PN often face life-threatening complications, 
including PN-associated liver disease and catheter-related sepsis.  
Small bowel transplantation (SBT) is considered a last-resort treatment option for 
pediatric patients with extreme SBS or those suffering life-threatening complications 
from PN [42]. Since 1990, when the first successful intestinal transplant was documented 
[30], intestinal transplants have been successfully employed and survival rates have 
steadily increased [86]. Small bowel transplants have a one-year graft and recipient 
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survival rate of 62-86% in pediatric patients [58]. Additionally, SBT is a cost-effective 
treatment option. Beyond the first year, average costs associated with SBT can be less 
than the average costs of prolonged PN [33, 75, 80]. 
However, two important factors exist when patients are selected to receive a SBT: 
1) increased immunosuppressive therapy to preclude immune rejection of the 
transplanted tissue and 2) microbial colonization of the recipient and/or donor allograft 
[86]. SBT recipients have a higher incidence of allograft rejection than other solid-organ 
transplants, due to the high immunogenicity of the bowel, and therefore require more 
potent immunosuppression therapy [64]. Breakdown and loss of the mucosal barrier 
during episodes of allograft rejection or breach of the gastrointestinal tract during surgery 
can translocate enteric organisms from the recipient or donor bowel into circulation, 
consequently causing bloodstream infections. Bloodstream infections are common 
complications after intestinal transplant and represent a major cause of morbidity and 
mortality among SBT recipients. In one study, 70% of pediatric SBT recipients 
developed a bloodstream infection within one year after transplantation [24]. 
Enterococcus, Klebsiella, and Candida were the main causes of infection. Prevention of 
translocation-associated infections remains a significant challenge, despite improvements 
in antirejection and antimicrobial therapy.  
Candida species are the fourth most common cause of hospital-acquired 
bloodstream infections in the United States [95]. Candida species including C. albicans, 
C. dubliniensis, C. glabrata, C. krusei, C. metapsilosis, C. parapsilosis, and C. tropicalis 
are normal, asymptomatic residents of the gastrointestinal and reproductive tract and skin 
of most individuals. In healthy individuals, carriage of C. albicans is estimated to be 30-
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60% [52]. However, Candida species can also act as opportunistic pathogens that are 
capable of infecting a broad range of body sites when host resistance is decreased. 
Candida species are responsible for a spectrum of diseases, including mucosal, 
cutaneous, and invasive infections.  
Of particular concern is when Candida crosses the epithelial barrier and gains 
access to the bloodstream, causing candidemia and potentially spreading throughout the 
body, causing infections of other organs termed invasive candidiasis (IC). The overall 
incidence of IC is estimated at 63,000 cases/year in the United States [63]. This life-
threatening infection is responsible for mortality rates reaching 49% [32] and medical 
care costs of an estimated $1.7 billion per year [94]. IC continues to be a persistent public 
health problem and infections due to Candida are the most common and fatal fungal 
bloodstream infections among pediatric SBT recipients [23]. 
Patients receiving solid organ transplantations present a unique combination of 
risk factors that predispose them to develop fungal bloodstream infections with Candida. 
In particular, pediatric SBT recipients constitute a population with an increased incidence 
for IC, with up to 25% of recipients developing invasive candidiasis [23]. Risk factors for 
candidemia among SBT recipients include immunosuppressive therapies, broad-spectrum 
antibiotics, use of central venous catheters, invasive abdominal surgery, environmental 
hospital exposures, and repeated endoscopy surveillance [25, 71, 76]. In addition, these 
patients experience disruption of the gastrointestinal barrier during surgery and the 
introduction of a foreign microbiota with the donor allograft.  
The Candida implicated in candidemia may be of endogenous or exogenous 
origin [31]. Candidemia is often believed to derive from an endogenous source, as many 
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individuals harbor Candida species in their gastrointestinal tract. The carriage of Candida 
in the donor or remnant recipient organ may act as a reservoir for pathogenic fungi and an 
endogenous source of IC [76]. Donor organs can also carry commensal Candida or may 
become infected during hospitalization of the donor or during procurement and 
preservation of the organ [31, 39]. Transplantation of an infected organ can serve as 
another possible source of infection.  
There is now increasing evidence for exogenous sources of Candida originating 
from the hospital environment, contaminated implanted medical devices, or from the 
skin. Infection with C. parapsilosis is often linked to an exogenous source because of its 
ubiquity in the environment and its presence on the skin of healthy humans. Carriage of 
C. parapsilosis on the hands of health care workers has long been recognized [38] and 
plays an important role in the transmission of opportunistic yeasts to hospitalized 
patients. Horizontal spread of C. parapsilosis infections from nurses to infants has been 
documented [37, 47]. In addition, nosocomial infections with C. parapsilosis are related 
to the contamination of indwelling central venous catheters used for the administration of 
PN [55]. The ability of C. parapsilosis to produce biofilms on catheter instruments is a 
common cause of IC because it gives the yeast direct access into the bloodstream upon 
insertion [13, 45].   
Molecular typing methods have proven to be valuable to analyze strain 
relatedness in order to perform epidemiological assessment of candidiasis outbreaks. Two 
classes of typing methods exist for molecular characterization of Candida species—non-
DNA-based and DNA-based [73]. The first class, non-DNA-based, includes strain typing 
that indirectly assays the genotype by multilocus enzyme electrophoresis (MLEE). 
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MLEE is a method that assesses and compares multiple core metabolic enzyme 
fingerprints by analyzing their electrophoretic mobilities on a gel. While MLEE has 
shown to be highly discriminatory and reproducible, this method assays the genome 
indirectly, may take several days to complete, and is difficult to master [10, 15, 73].  
The second class of molecular typing methods for Candida species is DNA-based. 
Conventional DNA-based techniques used to genotype Candida in epidemiological 
studies include electrophoretic karyotyping with pulsed-field gel electrophoresis (PFGE), 
restriction enzyme analysis (REA) with Southern blotting, random amplified 
polymorphic DNA (RAPD), and amplified fragment length polymorphism (AFLP) [3, 5, 
9, 49, 65]. These methods have the potential to discriminate at the strain level, but 
potential drawbacks associated with these methods include low reproducibility, low 
discriminatory power, and the need for trained personnel [73]. 
 The conventional DNA-based techniques described above allow for easy strain 
differentiation within a laboratory; however, comparison of data between laboratories is 
nearly impossible. Therefore, exact DNA-based methods that are more unambiguous and 
reproducible, such as multilocus sequence typing (MLST), offer the best way at present 
to strain-type Candida [11]. MLST has been successfully applied to several Candida 
species including C. albicans, C. glabrata, C. krusei, and C. tropicalis, but not C. 
parapsilosis [12, 22, 40, 81, 82]. MLST protocols are based on the analysis of nucleotide 
sequence polymorphisms in 400- to 500-bp internal fragments of 6-8 independent 
housekeeping genes. MLST is a robust typing technique because of the highly 
reproducible nature of the data generated and allows for laboratories to easily compare 
and exchange data. Internet databases have been constructed for a number of organisms, 
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including multiple Candida species, and allow for the sharing of global epidemiological 
data (http://www.mlst.net/databases/). Many Candida epidemiological studies using 
MLST have been reported and show the method to be highly discriminating and stable 
[70, 90]. Ultimately, it is recommended to employ at least two independent techniques to 
verify the results for a set of given isolates [87].  
The prevention and treatment of candidemia among SBT recipients is 
controversial [31]. Antifungal prophylaxis is appealing for recipients of organ transplants 
due to the high mortality rate of invasive fungal bloodstream infections post-transplant. 
However, extensive use of antifungal prophylaxis selects for resistant Candida species. 
The recent emergence of azole-resistant species (C. glabrata and C. krusei) is likely due 
to widespread use of fluconazole and other antifungal agents [77]. Additionally, a shift 
towards non-albicans Candida species causing fungemia has been observed [79].  
Fluconazole is routinely used for antifungal prophylaxis; however, choice of drug, 
who should receive it, and when to initiate/discontinue prophylaxis is not well 
understood, therefore, universal use cannot be justified to all transplant recipients [77]. 
Antifungal prophylaxis should ideally be based on institutional trends. Established 
candidiasis infections are routinely treated with amphotericin B, azoles, and 
echinocandins [59]. Problems associated with antifungal treatments include potential 
toxicity, drug interactions with immunosuppressant agents, high costs, and patient 
compliance. Also, poor compliance with current antifungal management guidelines by 
transplant physicians has been documented [53].  
Small bowel transplantation is a life-preserving treatment for pediatric short 
bowel syndrome patients facing intestinal failure or life-threatening complications from 
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parenteral nutrition. Recipients of SBT represent a population of patients with a 
combination of unique risk factors, making them highly susceptible to fungal 
bloodstream infections, mainly caused by Candida species. Thus, it is essential to 
identify exogenous or endogenous Candida yeasts implicated in infection and understand 
their origin in order to improve survival rates and prevent fungal infections for recipients 
of small bowel transplants. Clinicians must understand the epidemiology of Candida in 
their institution and know which Candida species are implicated in infection in order to 
select appropriate treatment options for their patients. 
To our knowledge, no studies have investigated the intestinal microbiota or origin 
of Candida causing candidemia in SBT recipients. In the present work, we defined the 
gut mycobiota of SBT recipients and genotyped ileum and bloodstream isolates to infer 
origin of infection. We also assessed isolates to determine if patients shared the same 
strains of Candida. The data obtained in this study will contribute to the knowledge base 
of Candida epidemiology and infections acquired by SBT recipients at the University of 
Nebraska Medical Center.   
 
3.3 MATERIALS AND METHODS  
Sample collection 
A total of seven pediatric short bowel syndrome patients who received small 
bowel transplantations and later developed candidemia at the University of Nebraska 
Medical Center were included in this study. The patient cohort comprised 3 females and 
4 males with a mean age of 23.1 months (median: 20 months; range: 16-37 months). The 
University of Nebraska Medical Center is a premier facility for SBT, conducting ~20 
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transplants per year. Ileostomy and blood samples were collected from recipients under 
UNMC Institutional Review Board protocol #417-02, and informed consent was received 
from the caregivers of all patients. Candidemia was diagnosed on the basis of symptoms 
and a positive blood culture identified using the API 20C test (BioMérieux, Marcy 
l’Etoile, France). Ileostomy samples prior to and concurrent with infection (up to nine) 
were collected post-transplantation during hospitalization and stored at -80°C until 
processing (Table 3.1). Culture positive bloodstream isolates from each recipient 
following infection were isolated and maintained on Sabouraud dextrose agar.   
 
Extraction of DNA from Ileostomy Samples 
DNA was extracted from ileostomy samples following the protocol of Oh and 
colleagues [57]. Briefly, 300 μl of ileal effluent was centrifuged at 10,000 x g for 5 
minutes. Cell pellets were resuspended with 750 μl lysis buffer (200 mM NaCl, 100 mM 
Tris [pH=8.0], 20 mM EDTA, 20 mg/mL lysozyme) and transferred to a 2 ml tube 
containing 300 mg of 0.1-mm zirconium beads (BioSpec Products). Cell suspensions 
were incubated at 37°C for 45 minutes and 85 μl of 10% sodium dodecyl sulfate and 40 
μl of proteinase K (15 mg/ml) was added. Samples were then incubated for 45 minutes at 
60°C. After the second incubation, 500 μl of phenol-chloroform-isoamyl alcohol 
(25:24:1) was added, and the samples were bead beaten at maximum speed for 2 minutes 
and immediately cooled on ice. Samples were centrifuged at 13,500 x g for 5 minutes and 
the top aqueous layer was extracted once with phenol-chloroform-isoamyl alcohol  
(25:24:1) and twice with chloroform-isoamyl alcohol. DNA was precipitated by the 
addition of 2.5 volumes of 100% ethanol, 1/10 volume of 3M sodium acetate (pH 5.2) 
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and 50 μg/ml GlycoBlue (Ambion) at -20°C overnight. The samples were centrifuged at 
full speed for 25 minutes and the resulting DNA pellets were washed with 70% ethanol, 
air-dried, and dissolved in 50 μl sterile water.  
 
Isolation of yeasts from ileostomy samples  
To obtain pure culture isolates from ileostomy samples, approximately 250 μl of 
ileal effluent was grown overnight at 37°C with shaking (200 rpm) in yeast nitrogen 
broth (YNB; 6.7 g/L yeast nitrogen base, 10 g/L glucose, 0.76 g L-asparagine, 50 mg/L 
chloramphenicol, 20 mg/L gentamicin sulfate, sterilized by filtration) and yeast extract 
peptone dextrose broth (YPD; 10 g/L yeast extract, 20 g/L peptone, 20 g/L glucose, 50 
mg/L chloramphenicol, pH 5.6). Volumes of 100 μl were plated after 24, 48, and 72 
hours on YPD (supplemented with 50 mg/L chloramphenicol), CHROMagar Candida 
(Paris, France), potato dextrose agar (PDA, Oxoid; supplemented with 50 mg/L 
chloramphenicol), and dichloran rose bengal chloramphenicol (DRBC; 10 g/L glucose, 5 
g/L peptone, 1 g/L monopotassium phosphate, 0.5 g/L magnesium sulfate, rose bengal 
0.025 g/L, dichloran 0.002 g/L chloramphenicol 0.10 g/L). Plates were incubated at 37°C 
and monitored daily for 2 weeks. Multiple colonies from each plate were further isolated 
on the basis of color and morphology and maintained at 4°C. 
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Table 3.1 Outline of patients and sample collection. 
 
Patient Age Sex Sample Name Date of Collection Source of Sample 
P32 28 mo. F 
32_I_1 18 Mar 2005 Ileostomy 
32_B_1 28 Mar 2005 Blood 
P33 37 mo. F 
33_I_1 15 Aug 2005 Ileostomy 
33_I_2 29 Sept 2005 Ileostomy 
33_B_1 7 Oct 2005 Blood 
33_I_3 24 Mar 2006 Ileostomy 
P39 23 mo. M 
39_I_1 7 June 2004 Ileostomy 
39_B_1 8 Oct 2004 Blood 
39_I_2 22 Oct 2004 Ileostomy 
P47 20 mo. F 
47_I_1 13 Sept 2004 Ileostomy 
47_I_2 24 Sept 2004 Ileostomy 
47_I_3 28 Sept 2004 Ileostomy 
47_B_1 30 Sept 2004 Blood 
47_I_4 1 Oct 2004 Ileostomy 
47_I_5 5 Oct 2004 Ileostomy 
47_B_2 6 Oct 2004 Blood 
47_I_6 12 Oct 2004 Ileostomy 
47_I_7 19 Oct 2004 Ileostomy 
47_I_8 27 Oct 2004 Ileostomy 
47_I_9 1 Nov 2004 Ileostomy 
P62 16 mo. M 
62_I_1 14 July 2005 Ileostomy 
62_I_2 22 July 2005 Ileostomy 
62_B_1 30 July 2005 Blood 
62_I_3 2 Aug 2005 Ileostomy 
62_I_4 2 Sept 2005 Ileostomy 
62_I_5 7 Oct 2005 Ileostomy 
P74 20 mo. M 
74_I_1 22 June 2006 Ileostomy 
74_I_2 12 July 2006  Ileostomy 
74_B_1 20 July 2006 Blood 
74_I_3 3 Oct 2006 Ileostomy 
74_I_4 27 Oct 2006 Ileostomy 
74_B_2 7 Nov 2006 Blood 
74_I_5 15 Nov 2006 Ileostomy 
74_I_6 17 Nov 2006 Ileostomy 
P88 18 mo. M 
88_B_1 3 Jan 2007 Blood 
88_I_1 4 Jan 2007 Ileostomy 
88_I_2 16 Jan 2007 Ileostomy 
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 Extraction of DNA from pure culture bloodstream and ileal Isolates 
DNA was extracted from ileal and bloodstream isolates following the protocol of 
Harju et al. [34]. Yeast colonies were grown overnight at 37°C in YPD medium (1% 
yeast extract, 2% peptone, 2% glucose) with 200 rpm shaking and pelleted by 
centrifugation at 20,000 x g for 2 minutes. Pellets were resuspended in 200 μl of Harju 
lysis buffer (2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris-HCl [pH 8.0], 1 
mM EDTA [pH 8.0]). The samples were frozen at -80°C for 10 minutes and then 
immersed into a 95°C water bath for 1 minute. The freeze/thaw process was repeated. 
Sterile pestles were used to disrupt cell walls, and then samples were vortexed vigorously 
for 30 seconds. After the addition of 200 μl of chloroform and 2 minutes of vortexing, 
samples were centrifuged at 20,000 x g for 3 minutes. The upper aqueous layer was 
transferred into a microcentrifuge tube containing 400 μl of ice-cold 100% ethanol, 
mixed with inversion, and incubated at -20°C for at least 10 minutes. The samples were 
centrifuged again at 20,000 x g for 5 minutes. DNA pellets were washed with 500 μl ice-
cold 70% ethanol followed by air-drying at room temperature. DNA was dissolved in 50 
μl sterile water. 
 
Genomic amplification 
The extracted DNA from each ileostomy sample and isolate was selectively 
amplified by PCR using fungal‐specific primers ITS1-F (5’-CTTGGTCATTTAGA 
GGAAGTAA-3’) and ITS4 (5’-TCCTCCGCTTATTGATATGC-3’) [27, 93]. PCR 
reaction mixtures consisted of 1.25 U of TaKaRa Ex Taq (Shiga, Japan), 5 μl of 10X Ex 
Taq buffer, 4 μl of dNTP mixture (2.5 mM each), 20 pmol of each primer, and 1 μl of 
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genomic DNA. Amplifications were performed with the following PCR cycling 
conditions: initial denaturation at 94°C for 4 minutes, followed by 30 cycles of 
denaturation at 94°C for 30 seconds, annealing at 52°C for 1 minute, elongation at 72°C 
for 1.5 minutes and a final extension step at 72°C for 10 minutes. PCR amplicons were 
separated using a 0.7% agarose gel in 1 x TAE buffer and visualized with 0.5 μg/ml 
ethidium bromide staining.   
 
Cloning and sequencing 
PCR products from ileostomy samples were cloned using the pGEM® -T Easy 
Vector System Kit (Promega, Lyon, France) following the manufacturers instructions to 
obtain a profile of the intestinal fungi. For each sample, 25 colonies negative for β-
galactosidase activity were chosen and those with distinct EcoR1 patterns were 
sequenced on an ABI 3730xl platform at Michigan State University’s Research 
Technology Support Facility (East Lansing, MI). Fungal sequences were identified by 
sequence homology using nucleotide BLAST against the UNITE curated fungal ITS 
sequence database [44] and the curated FUNCBS database, as accessed through the 
Centraalbureau voor Schimmelcultures 
(www.cbs.knaw.nl/Collections/BioloMICSSequences.aspx?file=all; accessed September 
2014).  
 
Multilocus sequence typing  
All C. albicans and C. glabrata ileostomy and bloodstream isolates were typed by 
MLST as described previously [12, 22] (Table 3.2). MLST protocols are not currently 
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available for C. parapsilosis. For C. albicans, seven housekeeping gene fragments were 
sequenced (AAT1a, ACC1, ADP1, MPIb, SYA1, VPS13, ZWF1b). For C. glabrata, six 
housekeeping gene fragments were sequenced (FKS, LEU2, NMT1, TRP1, UGP1, 
URA3). Each gene fragment was amplified using 50 μl PCR reactions containing 100 ng 
of genomic DNA, 1.25 U of TaKaRa Ex Taq (Shiga, Japan), 5 μl of 10X Ex Taq buffer, 4 
μl of dNTP mixture (2.5 mM each), and 25 pmol of each primer (Table 3.2). PCR 
conditions for C. albicans MLST reactions were as follows: 94°C for 5 minutes, followed 
by 30 cycles of 94°C for 1 minute, relevant annealing temperature (Table 3.2) for 1 
minute, and 72°C for 1 minute, with a final extension period of 10 minutes at 72°C. PCR 
conditions for C. glabrata MLST reactions were as follows: 94°C for 7 minutes, followed 
by 30 cycles of 94°C for 1 minute, relevant annealing temperature (Table 3.2), and 74°C 
for 1 minute, with a final extension period of 10 minutes at 74°C. 
All PCR products were purified using the Wizard SV Gel and PCR Clean-up Kit 
(Promega, Madison, WI). Following cleanup, amplicons were sequenced in both 
directions using the same primers used for PCR. Sequences were aligned and assembled 
using ClustalW implemented in BioEdit Sequence Alignment Editor version 7.3.2. For C. 
albicans, heterozygosities were assessed by visual inspection of the chromatograms and 
designated using the International Union of Pure and Applied Chemistry nomenclature 
[12]. Sequences were entered into the MLST databases (http://pubmlst.org/calbicans/ & 
http://cglabrata.mlst.net/) and assigned an allele profile for each locus and an overall 
sequence type (ST).  
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Table 3.2 C. albicans and C. glabrata MLST schemes. 
Locus Gene product Primer sequence (5’-3’) 
Annealing 
Temp (°C) 
No. bp 
sequenced 
C. albicans 
AAT1a Asparate 
aminotransferase 
F: ACTCAAGCTAGATTTTTGGC 52 373 
R: CAGCAACATGATTAGCCC 
ACC1 Acetyl-coenzyme A 
carboxylase 
F: GCAAGAGAAATTTTAATTCAATG 55 407 
R: TTCATCAACATCATCCAAGTG 
ADP1 ATP-dependent 
permease 
F: GAGCCAAGTATGAATGATTTG 55 443 
R: TTGATCAACAAACCCGATAAT 
MPIb Mannose phosphate 
isomerase 
F: ACCAGAAATGGCCATTGC 52 375 
R: GCAGCCATGCATTCAATTAT 
SYA1 Alanyl-RNA synthetase F: AGAAGAATTGTTGCTGTTACTG 55 391 
R: GTTACCTTTACCACCAGCTTT 
VPS13 Vacuolar protein sorting 
protein 
F: TCGTTGAGAGATATTCGACTT 55 403 
R: ACGGATGGATCTCCAGTCC 
ZWF1b Glucose-6-phosphate 
dehydrogenase 
F: GTTTCATTTGATCCTGAAGC 52 491 
R: GCCATTGATAAGTACCTGGAT 
C. glabrata 
FKS 1,3-Beta-glucan synthase F: GTCAAATGCCACAACAACAACCT 55 589 
R: GCACTTCAGCAGCGTCTTCAG 
LEU2 3-Isoprpylmalate 
dehydrogenase 
F: TTTCTTGTATCCTCCCATTGTTCA 54 512 
R: ATAGGTAAAGGTGGGTTGTGTTGC 
NMT1 Myristoyl-CoA, protein 
N-myristoyltransferase 
CoA 
F: GCCGGTGTGGTGTTGCCTGCTC  59 607 
R: CGTTACTGCGGTGCTCGGTGTCG 
TRP1 Phosphoribosyl-
anthranilate isomerase 
F: AATTGTTCCAGCGTTTTTGT 50 419 
R: GACCAGTCCAGCTCTTTCAC 
UGP1 UTP-glucose-1-
phosphate 
uridylyltransferase 
F: TTTCAACACCGACAAGGACACAGA 57 616 
R: TCGGACTTCACTAGCAGCAAATCA 
URA3 
 
 
Orotidine-5’phosphate 
decarboxylase 
F: AGCGAATTGTTGAAGTTGGTTGA 53 602 
R: AATTCGGTTGTAAGATGATGTTGC 
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Random amplified polymorphic DNA  
C. albicans, C. glabrata, and C. parapsilosis isolates were also typed by RAPD 
using the primer Oligo 2 (5’-TCACGATGCA-3’) as described previously [9]. C. 
parapsilosis isolates were further typed with the primer OPE-04 (5’-GTGACATG-3’) 
[8]. Additional control Candida strains were added to each RAPD reaction to test 
discriminatory power. Amplification reactions were performed as described above for 
PCR with 10 ng of genomic DNA. PCR was performed as follows: 94°C for 5 minutes, 
followed by 40 cycles of 94°C for 30 seconds, 36°C for 30 seconds, and 72°C for 2 
minutes, with a final extension period of 10 minutes at 72°C. PCR amplicons were 
separated using a 1.5% agarose gel in 1x TAE buffer at 80 V for 90 min and visualized 
with 0.5 g/ml ethidium bromide staining. Isolates were considered distinct if banding 
patterns differed.  
 
Antifungal susceptibility test  
 Antifungal susceptibility was assessed using a commercially available 
colorimetric microdilution panel Sensititre YeastOne YO-9 (TREK Diagnostic Systems). 
The Sensititre YeastOne system provides antifungal susceptibility testing and minimum 
inhibitory concentration (MIC) determination against nine antifungals: amphotericin B 
(0.12 – 8 µg/ml), 5-flucytosine (0.06 – 64 µg/ml), anidulafungin (0.015 – 8 µg/ml), 
caspofungin (0.008 – 8 µg/ml), micafungin (0.008 – 8 µg/ml), fluconazole (0.12 – 256 
µg/ml), itraconazole (0.015 – 16 µg/ml), posaconazole (0.008 – 8 µg/ml), and 
voriconazole (0.008 – 8 µg/ml). Testing was carried out following the manufacturers 
instructions. After 24-48 hours of incubation, panels were observed and MIC end points 
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were determined as evidenced by a color change from blue to red. Isolates were 
categorized according to the CLSI breakpoints (CLSI) reported by the manufacturer. 
Breakpoints were not available for posaconazole and amphotericin B, therefore, isolates 
inhibited by >1 mg/ml of amphotericin B and >1 mg/ml of posaconazole were considered 
resistant [26, 61]. 
 
3.4 RESULTS 
Prevalence of Candida in ileal effluent from SBT recipients 
Profiling fungi of the ileum revealed that SBT recipients harbored several 
Candida and non-Candida species (Table 3.3). C. albicans was the most predominant 
species, detected in the ileum of four patients (57%) and 11 out of 28 ileostomy samples 
(40%). C. glabrata was identified in three patients and 10 samples (35%). C. parapsilosis 
was obtained from two patients and six samples (21%). C. tropicalis was detected in two 
samples (7%) from two patients (28%) and C. lusitaniae (also known as Clavispora 
lusitaniae) was detected in one patient (14%), one sample (3.5%). Two patients (P33 and 
P62) harbored three species of Candida in the ileum and two patients (P47 and P74) 
harbored 2 species of Candida in the ileum. P32 and P39 each harbored one species of 
Candida. No Candida was detected in the ileum of P88.  
 
 
Yeasts causing bloodstream infection in SBT recipients  
Species taxonomic classification was determined for each blood culture and the 
results are shown in Table 3.3. With the exception of P62, all bloodstream infections 
were caused by Candida. C. parapsilosis was the most predominant species isolated from 
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the bloodstream of the patient group (3 patients). C. albicans was the second most-
isolated species from the bloodstream, in two patients, while C. glabrata, C. 
orthopsilosis, and Wickerhamomyces anomalus (formerly Pichia anomala) were each 
isolated from one patient. P74 showed positive blood cultures of two different yeasts (C. 
parapsilosis and C. albicans). 
 
Table 3.3 Identification of fungi in ileostomy and blood samples.  
Sample Candida ileal species Non-Candida ileal species Blood isolate 
32_I_1 C. albicans Epicoccum nigrum, Penicillium 
cf. roqueforti, Acremonium sp. 
 
32_B_1   C. parapsilosis* 
33_I_1 C. albicans Penicillium cf. roqueforti, 
Cladosporium sp., Pichia 
kudriavzevii 
 
33_I_2 C. albicans* Pichia kudriavzevii  
33_B_1   C. albicans* 
33_I_3 C. albicans, C. glabrata. 
C. tropicalis* 
Pichia kudriavzevii *  
39_I_1 C. glabrata*   
39_B_1   C. glabrata* 
39_I_2 C. glabrata*   
47_I_1  Epicoccum nigrum, Penicillium 
cf. roqueforti 
 
47_I_2 C. parapsilosis Debaryomyces sp., Trichoderma 
sp., Penicillium cf. roqueforti 
 
47_I_3 C. parapsilosis, 
C. glabrata* 
C. glabrata  
47_B_1   C. parapsilosis* 
47_I_4 C. parapsilosis* 
C. glabrata* 
Penicillium cf. roqueforti  
47_I_5 C. parapsilosis, 
C. glabrata* 
Penicillium cf. roqueforti  
47_B_2   C. parapsilosis* 
47_I_6 C. glabrata   
  
118 
 
Table 3.3 Continued. 
Sample Candida ileal species Non-Candida ileal species Blood isolate 
47_I_7 C. glabrata*   
47_I_8 C. glabrata   
47_I_9 C. parapsilosis, 
C. glabrata* 
  
62_I_1  Penicillium cf. roqueforti  
62_I_2 C. albicans Fusarium sp., Penicillium cf. 
roqueforti 
 
62_B_1   W. anomalus* 
62_I_3 C. albicans, C. tropicalis Penicillium cf. roqueforti, 
Fusarium sp., Debaryomyces 
hansenii, Pichia fermentens 
 
62_I_4 C. albicans, C. parapsilosis*   
62_I_5 C. albicans Penicillium cf. roqueforti  
74_I_1 C. albicans Penicillium cf. roqueforti  
74_I_2  Penicillium cf. roqueforti  
74_B_1   C. parapsilosis* 
74_I_3 C. albicans, C. lusitaniae   
74_I_4 C. albicans Epicoccum nigrum, Penicillium 
cf. roqueforti 
 
74_B_2   C. albicans* 
74_I_5  Aureobasidium pullulans  
74_I_6  Saccharomyces cerevisiae  
88_B_1   C. orthopsilosis* 
88_I_1  Penicillium cf. roqueforti  
88_I_2 
 
Epicoccum nigrum, Penicillium 
cf. roqueforti, Saccharomyces 
cerevisiae, Pichia kudriavzevii 
 
*Obtained in culture 
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MLST analysis of isolates 
All C. albicans (n=3) and C. glabrata (n=8) isolates were subjected to MLST and 
results are shown in Table 3.4 and Table 3.5. Two sequence types were identified for 
each species. Twelve alleles were identified among the seven loci of C. albicans isolates, 
including two new alleles, which generated a new, unique diploid sequence type. 
Fourteen polymorphic nucleotide sites were found between the two C. albicans sequence 
types. Both C. albicans sequence types detected in this study (ST2854 & ST2855) are 
novel isolates and have been deposited in the MLST database. Additionally, two 
sequence types (ST2 & ST3), consisting of 12 alleles and 23 variable nucleotide sites 
were identified among the six loci of C. glabrata isolates.  
For P33, ileostomy and blood C. albicans isolates yielded one sequence type 
(ST2854). C. albicans causing bloodstream infection in P74 was sequence type 2855, 
distinct from P33. C. glabrata ileostomy and bloodstream isolates from P39 shared 
sequence type 3. P47, who developed candidemia by C. parapsilosis, had gastrointestinal 
colonization by C. glabrata. However, the C. glabrata isolated from this individual had a 
sequence type 2, which was a distinct genotype from P39. In both species for which 
MLST was possible, sequence type and thus strain was consistent within a patient over 
time, but differed between patients. 
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Table 3.4 MLST genotypes of C. albicans isolates studied. 
Sample 
Allele number MLST 
Genotype AAT1a ACC1 ADP1 MPIb SYA1 VPS13 ZWF1b 
33_I_2 156 4 4 4 204 4 4 2854 
33_B_1 156 4 4 4 204 4 4 2854 
74_B_2 35 7 6 4 4 4 239 2855 
 
Table 3.5 MLST genotypes of C. glabrata isolates studied. 
Sample 
Allele number MLST 
Genotype FKS LEU2 NMT1 TRP1 UGP1 URA3 
39_I_1 5 7 8 7 3 6 3 
39_B_1 5 7 8 7 3 6 3 
39_I_2 5 7 8 7 3 6 3 
47_I_3 1 2 2 1 1 1 2 
47_I_4 1 2 2 1 1 1 2 
47_I_5 1 2 2 1 1 1 2 
47_I_7 1 2 2 1 1 1 2 
47_I_9 1 2 2 1 1 1 2 
 
 
RAPD analysis of isolates 
RAPD fingerprinting with primer Oligo 2 was performed on all cultured C. 
albicans and C. glabrata isolates (Figure 3.1 and Figure 3.2). Four C. albicans isolates 
generated three different RAPD profiles. C. albicans isolates recovered from the 
ileostomy and bloodstream of P33 had the same RAPD profile, A. The bloodstream 
isolate from P74 gave a distinct RAPD profile, B (C. albicans was detected in ileostomy 
samples from P74 but could not be cultured). The common laboratory strain C. albicans 
SC5314 also gave a distinct pattern, C. Nine C. glabrata isolates generated three different 
RAPD profiles. C. glabrata isolates obtained from the ileostomy and bloodstream of P39 
  
121 
 
all had same RAPD profile D. C. glabrata ileostomy isolates from five consecutive 
ileostomy samples over a one month period in P47 generated RAPD profile E, while 
control strain C. glabrata NRRL Y-65 gave a distinct RAPD pattern F. The RAPD results 
obtained from C. albicans and C. glabrata isolates are congruent with strain typing data 
by MLST (Table 3.6). No RAPD patterns for C. albicans or C. glabrata were shared 
across individuals. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 RAPD fingerprint patterns of C. albicans isolates obtained with primer 
Oligo 2. Fingerprints indicated with the same letter have equal genotypes. Arrows 
indicate fragments found in any profiles of the strains. First lane 1 KB+ molecular size 
marker. Laboratory strain C. albicans SC5314 included with isolates.   
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Figure 3.2 RAPD fingerprint patterns of C. glabrata isolates obtained with primer 
Oligo 2. Fingerprints indicated with the same letter have equal genotypes. Arrows 
indicate fragments found in any profiles of the strains. First lane 1 KB+ molecular size 
marker. C. glabrata NRRL Y-65 included with isolates.   
 
In addition, RAPD was performed on C. parapsilosis isolates with primer Oligo 2 
(Figure 3.3). Seven C. parapsilosis isolates generated two different RAPD profiles. P47 
C. parapsilosis isolates showed two distinct RAPD patterns between ileostomy and 
bloodstream. The two C. parapsilosis blood cultures were collected from this patient 
before and after the ileostomy sample. Both blood cultures generated the same RAPD 
pattern H. However, the ileostomy isolate showed RAPD pattern G. Interestingly, the two 
ileostomy samples prior to the first bloodstream collection harbored C. parapsilosis, but 
viable organisms could not be cultured. Three C. parapsilosis isolates, collected from the 
ileostomy of P62 and the blood of P32 and P74, gave the same RAPD pattern G. Control 
C. parapsilosis 232, isolated from cheese, also gave the RAPD pattern G. Since a C. 
parapsilosis MLST scheme does not exist, primer OPE-04 was also used for RAPD to 
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confirm or contradict results obtained by primer Oligo 2. Primer OPE-04 likewise yielded 
two different patterns among the seven isolates, in agreement with primer Oligo 2 (Figure 
3.4). 
 
 
 
 
 
 
 
Figure 3.3 RAPD fingerprint patterns of C. parapsilosis isolates obtained with 
primer Oligo 2. Fingerprints indicated with the same letter have equal genotypes. 
Arrows indicate fragments found in any profiles of the strains. First lane 1 KB+ 
molecular size marker. C. parapsilosis 232 isolated from cheese included with isolates.   
 
 
 
 
 
 
 
 
Figure 3.4 RAPD fingerprint patterns of C. parapsilosis isolates obtained with 
primer OPE-04. Fingerprints indicated with the same shape have equal genotypes. 
Arrows indicate fragments found in any profiles of the strains. First lane 1 KB+ 
molecular size marker. C. parapsilosis 232 isolated from cheese included with isolates.   
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Table 3.6 Genotype of cultured ileal (I) and bloodstream (B) isolates. 
Sample Culture RAPD genotype MLST genotype 
32_B_1 C. parapsilosis G n/a 
33_I_2 C. albicans A 2854 
33_B_1 C. albicans A 2854 
39_I_1 C. glabrata D 3 
39_B_1 C. glabrata D 3 
39_I_2 C. glabrata D 3 
47_I_3 C. glabrata E 2 
47_B_1 C. parapsilosis H n/a 
47_I_4 C. parapsilosis 
C. glabrata 
G 
E 
n/a 
2 
47_I_5 C. glabrata E 2 
47_I_7 C. glabrata E 2 
47_B_2 C. parapsilosis H n/a 
47_I_9 C. glabrata E 2 
62_I_4 C. parapsilosis G n/a 
74_B_1 C. parapsilosis G n/a 
74_B_2 C. albicans B 2855 
Control C. albicans C n/a 
Control C. glabrata F n/a 
Control C. parapsilosis G n/a 
 
The chronological carriage of Candida genotyping patterns is reported in Figure 
3.5. At two points, samples were collected from multiple patients during the same time 
period. In both cases, patients carried distinct strains from one another. C. parapsilosis 
isolates of RAPD profile G were detected consistently over time in four patients. Isolates 
of all other MLST and RAPD profiles were each restricted to a single patient, in our 
sampling. No one genotype dominated the patient population.  
  
1
2
5
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Chronological outline of patient sample collection. The MLST sequence types and RAPD profiles are indicated for each 
patient. 
1
2
5
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Antifungal susceptibility 
The antifungal susceptibilities and MICs for the yeast isolates against nine 
antifungals using the YeastOne system are shown in Table 3.7. C. glabrata isolate 
39_B_1 was classified as susceptible dose-dependent to fluconazole and voriconazole 
based on MIC interpretative criteria from the manufacturer. This isolate showed 
multidrug resistance against amphotericin B, itraconazole, and posaconazole. C. 
parapsilosis isolates 47_B_1 and 47_B_2 were resistant to amphotericin B. C. albicans, 
C. orthopsilosis, and W. anomalus isolates were uniformly susceptible to all antifungals. 
For all isolates, the range of MICs were: amphotericin B (0.25-2 μg/ml), itraconazole 
(0.06-2 μg/ml), posaconazole (0.03-2 μg/ml), and voriconazole (0.03-2 μg/ml). 
Fluconazole showed a wide range of MICs among the isolates (0.5-32 μg/ml), as well as 
micafungin (<0.008-2 μg/ml), anidulafungin (0.015-2 μg/ml), and caspofungin (0.015-2 
μg/ml). 5-flucytosine showed a narrow range of MICs among the isolates (<0.06-0.25 
μg/ml). 
 
 
 
  
1
2
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 Table 3.7 Summary of MIC values and antifungal susceptibility of bloodstream isolates determined by YeastOne. 
Isolate 
MIC
1
 (μg/ml) & Susceptibility2 
AB AND CAS FC FZ IZ MF PZ VOR 
MIC S MIC S MIC S MIC S MIC S MIC S MIC S MIC S MIC S 
C. albicans                   
     33_B_1 1 S 0.03 S 0.03 S 0.12 S 0.5 S 0.06 S 0.008 S 0.03 S 0.03 S 
     74_B_2 1 S 0.03 S 0.03 S 0.12 S 4 S 0.12 S <0.008 S 0.06 S 0.12 S 
C. glabrata                   
     39_B_1 2 R 0.06 S 0.25 S <0.06 S 32 S-DD 2 R 0.015 S 2 R 2 S-DD 
C. orthopsilosis                   
     88_B_1 1 S 1 S 0.5 S 0.12 S 1 S 0.12 S 0.5 S 0.12 S 0.12 S 
C. parapsilosis                   
     32_B_1 1 S 2 S 0.25 S 0.25 S 1 S 0.12 S 1 S 0.06 S 0.03 S 
     47_B_1 2 R 2 S 2 S 0.12 S 2 S 0.06 S 2 S 0.06 S 0.06 S 
     47_B_2 2 R 2 S 2 S 0.12 S 2 S 0.06 S 2 S 0.06 S 0.06 S 
     74_B_1 0.25 S 1 S 0.25 S 0.06 S 1 S 0.06 S 1 S 0.03 S 0.15 S 
W. anomalus                   
     62_B_1 0.5 S 0.015 S 0.015 S <0.06 S 2 S 0.06 S 0.015 S 0.12 S 0.06 S 
1 AMB, amphotericin B; AND, anidulafungin; CSP, caspofungin; FC, 5-flucytosine;  FZ, fluconazole; ITC, itraconazole; MF, 
micafungin; PSC, posaconazole; VOC, voriconazole. 
2
 S, susceptible; S-DD, susceptible dose-dependent; I, intermediate; R, resistant. 
1
2
7
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3.5 DISCUSSION 
 Small bowel transplantation is a life-preserving treatment for pediatric short 
bowel syndrome patients facing intestinal failure or life-threatening complications from 
parenteral nutrition. The increasing incidence of Candida infections and the high 
mortality rates post-transplant warrant further research into the epidemiology of 
nosocomial fungal infections. The present study describes a cohort of small bowel 
transplant patients who developed bloodstream infection post-transplant at the University 
of Nebraska Medical Center from 2004-2007. We employed two molecular typing 
methods to determine the potential source of nosocomial candidemia infections in SBT 
recipients.  
Bloodstream infections in this study were mainly caused by C. parapsilosis 
(43%). Prior to 1990, the predominant species causing Candida infections was C. 
albicans [62]. In recent years there has been an emergence of infections caused by non-
albicans species [1, 6, 36]. C. albicans was isolated from the bloodstream in only two out 
of the seven patients. Non-albicans species caused the majority of infections. C. 
orthopsilosis, recently separated from the C. parapsilosis complex with C. metapsilosis 
[81], was identified in the bloodstream of one patient. C. orthopsilosis is known to be 
responsible for bloodstream infections, however, documented cases are limited [28, 83, 
84]. 
One bloodstream infection was caused by Wickerhamomyces anomalus (formerly 
Hansenula anomala and Pichia anomala; teleomorph Candida pelliculosa, current 
teleomorph name Candida beverwijkiae). W. anomalus is a ubiquitous yeast found 
naturally in the environment and various fermentations. This yeast transiently colonizes 
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the oropharyngeal and gastrointestinal tract of humans [16, 54]. W. anomalus is rarely 
found as a cause of infection; however, it has been implicated in a few hospital outbreaks 
in neonatal and pediatric intensive care units [2, 16, 41, 60]. W. anomalus was not 
identified in the intestine of P62 from whom it was isolated from the blood. Therefore, it 
is possible that this patient acquired W. anomalus from an exogenous source. Exogenous 
acquisition of W. anomalus infection is the suggested route of transmission [2].    
This study shows that various species of Candida are present in the 
gastrointestinal tract of SBT patients. This is not surprising, as the human gut is known to 
harbor multiple Candida species [35]. At least one fungal taxon was found in every 
ileostomy sample. Ileostomy samples contained an average of two fungal species and up 
to six species in one sample. This is the first study characterizing the fungal intestinal 
microbiota of small bowel transplant recipients. It is possible that the cloning method 
used to characterize the intestinal mycobiota did not obtain a complete comprehensive 
survey of fungi in the ileostomy samples. The number of clones selected for sequencing 
and the failure to sequence every clone is a limitation of cloning that may result in 
defining a limited diversity. Fungi of low abundance may have not been detected in 
ileostomy samples. Moreover, of interest is the fact that all cultured organisms were 
detected by molecular cloning, but not vice versa. While next-generation sequencing 
methods may describe the complete mycobiota in full, cloning may be the most cost-
efficient and practical way to determine the mycobiota in these patients due to the limited 
diversity of gut fungi expected.  
We detected previous digestive tract colonization with Candida in six of the 
patients with candidemia. Our findings suggest that at least two bloodstream infections 
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(P33 and P39) originated from Candida colonizing the gastrointestinal tract. This is in 
keeping with the findings of other studies that identified the same strain in the intestine 
and blood [19, 43, 51, 67]. Gastrointestinal colonization is an important source of 
candidemia, although only a few studies using molecular typing methods exist and 
sample numbers are small [55]. Many studies only report an association between 
anatomic site of Candida colonization as a risk factor for subsequent candidemia and 
invasive candidiasis in hospitalized and critically ill patients [17, 48]. The epidemiology 
of candidemia in small bowel transplant recipients has not been previously investigated. 
However, it is not surprising that patients in our study were infected by endogenous 
Candida due to the invasive nature of this procedure that disrupts the integrity of the 
gastrointestinal barrier and allows translocation of microorganisms into the bloodstream.  
P47 had different strains of C. parapsilosis colonizing the intestine and infecting 
the bloodstream, suggesting that candidemia derived from an exogenous source of C. 
parapsilosis. While the possibility of hospital transmission cannot be discounted, other 
possibilities exist and include mutation within the patient and increase in prevalence of a 
previously-undetectable strain. Microvariation, small detectable changes in DNA 
sequence among serial isolates or as separate clones from individual patients, is a known 
phenomenon for strains of C. albicans [46, 56]. The majority of documented C. 
parapsilosis infections are of exogenous origin. C. parapsilosis is the most common 
fungus recovered from the hands and studies have implicated health care workers’ hands 
as the source of nosocomial candidemia [50, 88]. Using PFGE and RAPD, Lupetti et al. 
[47] demonstrated horizontal transmission of C. parapsilosis infection from the hands of 
a health care worker to a newborn. Another study showed dissemination of C. 
  
131 
 
parapsilosis between patients and hospital staff, but was unable to determine whether the 
initial infection originated in patient or staff [45]. Another possible route of C. 
parapsilosis transmission could be contaminated parenteral nutrition and intravascular 
devices [18, 21, 92].  
C. parapsilosis was not detected in ileostomy samples from P32 and P74, who 
developed bloodstream infection with C. parapsilosis. It is possible that these two 
individuals exogenously acquired C. parapsilosis. Endogenous C. parapsilosis infections 
are rarely seen [51]. P74 was co-infected by two Candida species. C. parapsilosis was 
the first organism recovered from the blood, but ileostomy samples show an absence of 
C. parapsilosis in the gut prior to infection. Interestingly, C. albicans was present in three 
ileostomy samples prior to C. albicans detection in the blood. It is possible that this 
patient was infected exogenously by C. parapsilosis and endogenously by the patient’s 
own intestinal C. albicans. The inability to culture C. albicans from the patient’s ileum 
precluded strain typing and thus confirmation of a possible endogenous source. 
Additionally P88, who had no gastrointestinal colonization with C. orthopsilosis, may 
have acquired candidemia exogenously.  
Studies have documented the ability of Candida isolates to persist in hospital 
settings and cause temporally-associated infections [4, 90]. In our study, temporal 
analysis revealed multiple species were responsible for causing bloodstream infections 
during this time period. At two different time points, samples collected from two patients 
overlapped, but the patients did not carry the same genotype. However, the same C. 
parapsilosis genotype G in four patients was documented at multiple time points. 
Therefore, there is potential evidence that C. parapsilosis strains had a common source. 
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Dissemination could have been due to health care workers, although they are required to 
wash hands before and after patient contact as well as wear gloves. Samples from health 
care workers or the environment were not taken; however, of potential significance is that 
C. parapsilosis isolates of genotype G were detected throughout this study. 
Methods used to strain-type Candida species have greatly advanced our 
knowledge of fungal epidemiology. MLST and RAPD were applied in this study to help 
elucidate the origin of candidemia. MLST has been shown to be more discriminating than 
RAPD for C. albicans [70]. In our study, MLST identified distinct isolates between 
patients, but did not distinguish between isolates within a patient, whether ileostomy or 
bloodstream. This suggests independent, endogenous acquisition of candidemia. Strain-
typing with RAPD was used as a complement to MLST. RAPD is known to have low 
reproducibility but is useful in strain differentiation due to its speed and cost-efficiency. 
The fingerprints of the RAPD patterns yielded the same conclusions as MLST for C. 
albicans and C. glabrata isolates. Primer Oligo 2 was sufficient to strain-type C. albicans 
and C. glabrata.  
Since a C. parapsilosis MLST scheme does not exist [81], RAPD was necessary 
in order to obtain epidemiological information. RAPD fingerprints generated by both 
primer Oligo 2 and OPE-4 gave the same results: one RAPD fingerprint detected in 
samples from four patients (as well as a control isolate from cheese), and a distinct 
fingerprint in two bloodstream samples from P47, whose ileostomy C. parapsilosis 
yielded the other fingerprint. It is possible that other RAPD primers would further 
differentiate between our isolates; conversely, genetic variation in C. parapsilosis may be 
minimal.  
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There is increasing concern regarding antifungal resistance in Candida, especially 
C. parapsilosis. A study of a neonatal intensive care unit during a 12-year period showed 
that an outbreak of candidemia was caused by a C. parapsilosis strain with fluconazole 
resistance due to the long-term use of fluconazole prophylaxis in this institute [74]. In our 
study, two C. parapsilosis isolates from the same patient showed resistance to 
amphotericin B. MICs reported for C. parapsilosis isolates were within the MIC ranges 
in other studies [14, 29]. Usually, C. albicans is susceptible to azoles, echinocandins, and 
polyenes [68]; our C. albicans isolates were susceptible to all antifungal agents. 
Wickerhamomyces anomalus was susceptible to all antifungals in this study. W. anomalus 
does not show intrinsic resistance to any antifungals; however, susceptibility to 
itraconazole has been reported to be poor [20]. 
 One of the limitations of this study was the lack of environmental isolates. It was 
not possible to determine the exact exogenous source of candidemia in any of the 
patients. Also, this study is unable to determine whether the donor bowel was colonized 
by Candida and consequently, the source of infection. Donor-derived Candida infections 
have been documented in kidney transplant recipients [7, 89]. To date, no efforts have 
been made to identify Candida species and/or strains from the donor small bowel to 
investigate the origin of candidemia in SBT recipients. 
In this study, C. parapsilosis isolates were only typed using RAPD. RAPD is 
known to have low reproducibility and may not be the best method for epidemiological 
studies. The isolates could not be typed by MLST because attempts to construct a C. 
parapsilosis MLST scheme have been unsuccessful thus far due to the lack of sequence 
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variation [81]. Other methods such as PFGE-based typing and microsatellite markers may 
be more discriminatory for epidemiological investigations of C. parapsilosis [45, 72].  
Another limitation of this study was the inability to culture viable organisms from 
several ileostomy samples. In some instances a species could be identified by PCR and 
sequencing from an ileostomy sample but a subsequent isolate could not be obtained. 
Techniques to detect species in mixed matrices are possible with the use of universal or 
species-specific primers. Conversely, strain typing aims to differentiate specific strains 
and requires pure culture of each isolate [87]. Thus, while we know an ileostomy sample 
harbored a specific species, determining intestinal origin could not be elucidated because 
of the inability to strain type. However, it must be noted that the samples we used were 
collected nearly a decade ago and no special steps had been taken to ensure long-term 
survival of microorganisms. The fact that we were able to culture as many isolates as we 
were bodes well for future studies with newly-collected material. 
In conclusion, these findings highlight the possibility of hospitalized SBT patients 
acquiring candidemia both endogenously and exogenously. Although the exact route of 
infection in these transplant patients is not clear, our results suggest that cross infection 
with C. parapsilosis may have occurred and C. parapsilosis strains of profile G are 
frequent and may represent an endemic strain. Attempts need to be aimed at reducing 
Candida gut colonization with the use of antimicrobials and antifungals. Also, focused 
efforts should be made to ensure proper sterilization of equipment and intravenous 
devices. Implementing surveillance programs to ensure correct use of gloves and proper 
hand washing is important to prevent spread of infection. Ultimately, these results 
underline the importance of Candida surveillance in small bowel transplant institutes and 
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knowing the source of Candida implicated in infection (recipient, donor, or hospital 
acquired) to inform pre-transplant interventions and future treatment will improve 
outcomes for SBT patients.  
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4.1 OUTLOOK ON THE ROLE OF THE GUT MYCOBIOME  
 Fungi undoubtedly reside in the human gastrointestinal tract and form a small but 
persistent part of the gastrointestinal microbiota. So why is it important to understand 
their contribution to the gut microbiota as a whole and the human host? Gut mycologists 
have only begun to answer this question and have conducted preliminary studies on many 
aspects of fungal existence in the gut. Like the bacterial microbiota, there is now 
increasing evidence that fungi play a role in the human gut ecology and health. Efforts 
need to continue focusing on the function of fungi in the human gastrointestinal tract, as a 
myriad of questions remain and the field lags immensely behind bacterial gut microbiota 
research. It is gratifying that studies are beginning to question the interactions of fungi 
with diet, immune responses, other microbial communities, and diseased states. As the 
field advances, studies will unveil the importance of the mycobiome and specific fungal 
members as a factor of human health.  
 
4.2 CONCLUSIONS  
In Chapter 2, our goal was to help advance and stimulate the relatively new field 
of gut mycobiome research. To date, most research has focused on characterizing the 
bacterial members of the gastrointestinal tract and the human mycobiome is years behind 
the state of the art represented by bacterial microbiome studies. The human gut 
mycobiome is diverse and relatively unstable, and the search for a “core mycobiome” 
(with the exception of a very few species of human-associated yeasts) may prove futile 
due to high level of exposure to environment or food-associated fungi. To date, next-
generation sequencing platforms show the greatest diversity in gut fungi; however, as so 
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many fungi are allochthonous, this high diversity may be misleading and targeted 
approaches to identify specific organisms from a limited pool of species of interest may 
prove more meaningful. As gut mycologists continue to expand gut mycobiome studies 
using larger sample sizes, geographic distribution sampling, dietary influences, and 
diseased states we will begin to understand their beneficial and/or detrimental roles in 
human health. 
 In Chapter 3, we surveyed the full gut fungal microbiota of small bowel transplant 
patients to determine the source of Candida implicated in candidemia. Using genotyping 
methods, we were able to determine endogenous and exogenous sources of Candida 
causing candidemia. Although this study has only a limited number of isolates, we were 
able to hypothesize that C. albicans and C. glabrata infections were caused by 
endogenous sources of Candida and infection with C. parapsilosis was caused from an 
exogenous source. The proposed work highlights the wide spread nature of Candida 
causing endogenous and exogenous candidemia infections in hospital settings.  
 
4.3 FUTURE DIRECTIONS 
Chapter 2 provides a framework for future studies interested in characterizing the 
fungi of the gastrointestinal tract. Future studies will need to use larger sample sizes in 
order to understand variation of fungal communities between individuals. In addition, 
serial samples from individuals need to be collected over time to gain a better 
understanding of the stability of gut fungi over time. Culture-dependent and -independent 
methods need to be performed in conjunction with one another due to the methodology 
biases. Encompassing samples from multiple individuals with different lifestyles, dietary 
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habits, and geographic locations will allow researchers to better understand gut mycology 
around the world.  
Chapter 3 provides baseline data on the gut ecology of Candida yeasts after small 
bowel transplantation. In this study it was possible to determine if the gastrointestinal 
tract was a potential source of infection. However, due to the limited samples available, 
we were unable to determine if the Candida causing infection was from donor or 
recipient origin. Donor organs could serve as a source of infection. Collecting, 
identifying, and strain-typing Candida yeasts from the donor small bowel at the time of 
transplant and the recipient small bowel prior to transplant would allow us to differentiate 
between a donor or recipient endogenous source of candidemia.  
Collecting donor-recipient ileostomy sample pairs, tracking Candida strain 
presence or absence over time for each donor-recipient pair would provide data on which 
strains seem to have competitive advantages, and information on the Candida strains 
likely to cause candidemia. It would be possible to determine whether strains of Candida 
were present in the patient’s microbiota at the time of transplant or were donor-derived. 
Also, use of sequencing and strain-typing would: 1) show whether single or multiple 
Candida species/strains are present at a given time point, 2) track Candida populations 
and prevalence over time and observe whether donor and recipient strains coexist or if 
one predominates. 
Small bowel transplantation presents a unique opportunity to directly study the 
merging of two distinct microbial populations in humans. The use of next generation 
sequencing to conduct a comprehensive survey of the gastrointestinal microbiota 
(bacteria and fungi) would allow us to evaluate the interactions of two gut microbial 
  
149 
 
populations after merging donor and recipient gut microbiomes via transplant. Collecting 
samples from both the donor and recipient at the time of transplant would be necessary to 
study this. Observing gut microbiota populations over time would allow us to view 
ecological processes, such as competition or synergy. Studying the merging of two 
microbial communities will allow us to study if donor microbes establish themselves or if 
the recipient microbiota is resilient to disturbance. Also, are particular microbes 
consistently dominant, regardless of source? And does the abundance of particular 
bacterial taxa correlate with Candida abundance or infection? 
 
 
 
 
